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Abstract 
Our understanding of adipose tissue as an endocrine organ has been transformed over the last 
twenty years. During this time a number of adipocyte-derived factors or adipokines have been 
identified. This paper will review evidence for how adipokines acting via the central nervous 
system (CNS) regulate normal physiology and disease pathology. The reported CNS-mediated 
effects of adipokines are varied and include the regulation of energy homeostasis, autonomic 
nervous system activity, the reproductive axis, neurodevelopment, cardiovascular function, and 
cognition. Due to the wealth of information available and the diversity of their known functions, the 
archetypal adipokines leptin and adiponectin will be the focused on extensively. Other adipokines 
with established CNS actions will also be discussed. Due to the difficulties associated with 
studying CNS function on a molecular level in humans, the majority of our knowledge, and as 
such the studies described in this paper, comes from work in experimental animal models; 
however, where possible the relevant data from human studies are also highlighted. 
Didactic Synopsis 
Major Teaching Points: 
1. In addition to storing excess energy as triglyceride, adipose tissue is an important 
endocrine organ secreting factors called adipokines into the circulation that act on their 
receptor targets in distant tissues, including the CNS. 
 
2. Leptin is a key adipokine which acts on target receptors throughout the brain to signal 
how much energy the body has stored. 
 
a. Obesity (excess adipose tissue) is associated with high levels of circulating 
leptin. 
b. Reduced circulating leptin is a key signal for the activation of CNS pathways 
which promote weight gain, including increased food intake and reduced energy 
expenditure. 
c. Leptin acting in the brain also regulates the activity of other neuroendocrine axes 
including the reproductive axis and the thyroid hormone axis, and can also 
regulate cardiovascular function. 
 
3. Other adipokines that act in the CNS to modulate physiological processes include 
adiponectin, resistin, apelin, visfatin and adipocyte-derived cytokines. 
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Introduction 
In the past twenty years there has been a transformation in our understanding of adipose tissue 
as an endocrine organ. Numerous adipocyte-derived cell signaling proteins, or adipokines, have 
been identified that have critical functions in normal physiology and pathophysiology. The goal of 
this paper is to provide an overview of the site and mechanism of action of some of the key 
adipokines in the central nervous system (CNS), focusing on those with the most well defined and 
widespread CNS actions. The sheer diversity and number of adipokines that have been identified 
means that it would be beyond the scope of this review to feature them all, and any omissions 
should not be taken as indication that these factors are not considered important but as a 
reflection of a desire to provide a comprehensive overview of the adipokines that have the most 
diverse and currently well-characterized CNS actions, specifically leptin and adiponectin. Due to 
the difficulties associated with studying CNS function on a molecular level in humans, the majority 
of our knowledge, and as such the studies described in this paper, comes from work in 
experimental animal models; however, where possible the relevant data from human studies are 
also highlighted. 
A list of abbreviations used in this paper can be found in table 1. 
Leptin 
Leptin is arguably the prototypical adipokine. Originally identified in 1994 as the product of the 
obese (ob) gene, leptin is evolutionarily conserved across mammalian and non-mammalian 
species (637). The white adipose tissue (WAT) expression of the ob gene is regulated by energy 
status, being upregulated by increased adiposity associated with obesity (positive energy 
balance) (195, 240, 366, 376) and decreased by negative energy balance associated with fasting 
(195, 569). There is also evidence that leptin (ob) gene expression in WAT is diurnally regulated 
(498). Leptin is secreted into the blood where, in mammals, circulating levels are a reflection of 
the amount of WAT stored (377): the more WAT stores, the more circulating leptin. Indeed, 
reduced levels of circulating leptin associated with weight-loss is a key signal for the activation of 
CNS pathways which promote weight gain, including increased food intake and reduced energy 
expenditure (313, 475, 489). The discovery of leptin gave great hope for the development of a 
potential specific therapeutic target for obesity. Indeed, early promising studies demonstrated that 
exogenous administration of leptin into lean and diet-induced obese (DIO) rodents reduces food 
intake and body weight (83, 235, 452). However, evidence rapidly emerged that the high 
circulating levels of leptin associated with obesity were both a cause and consequence of 
resistance to the effects of the hormone on appetite and metabolism (195).  
Even before the cloning of leptin evidence suggested the existence of an adipose-derived 
circulating factor that could regulate feeding behavior by acting in the brain (121, 278). After the 
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cloning of leptin, this was supported by data indicating that radiolabeled leptin bound at high-
levels in the hypothalamus of the rodent brain and that exogenous leptin treatment normalized 
the elevated hypothalamic neuropeptide Y (NPY) gene expression in leptin-deficient obese ob/ob 
mice (539). The importance of the hypothalamus as a key site of leptin action was confirmed 
when the leptin receptor was identified and cloned in 1995 (555).  
Due to the critical importance of adequate energy reserves for numerous physiologic processes 
one of the key integrative roles of leptin, which will be described in more detail in the sections 
below, is as an indicator of sufficient energy availability/reserves, as the circulating levels of this 
hormone drop rapidly during fasting which in turn modulates the activity of a number of 
neuroendocrine axes (8). 
 
Leptin receptor signaling 
There are six alternatively spliced forms of the leptin receptor (Ob-Ra-f) that have been identified 
(345, 592). These are all single transmembrane spanning proteins, with the exception of Ob-Re 
which is predicted to be a soluble protein (345). Of these the full-length or long-form receptor (Ob-
Rb), the only variant with a long intracellular domain sufficient for downstream signaling, is 
believed to be the principal signaling form (41, 214, 345). Ob-Rb is a type 1 cytokine receptor. 
Upon leptin binding to the extracellular domain of the receptor dimer, Janus kinase (JAK) 2 is 
activated, resulting in phosphorylation of the intracellular domain of receptor at three tyrosine 
residues – Tyr985, Tyr1077 and Tyr1138, each of which mediate distinct downstream signaling 
events (figure 1): 1) Phosphorylation of Tyr985 resulting in recruitment of Src-homology 2 
domain-containing phosphatase 2 (SHP2/PTPN1) leading to activation of the extracellular signal-
regulated kinases (ERK) signaling cascade (27, 89, 357); 2) Phosphorylation of Tyr1077 resulting 
in recruitment of the transcription factor signal transducer and activator of transcription (STAT) 5 
(219) and 3) Phosphorylation of Tyr1138 resulting in recruitment of the transcription factor STAT3 
(27, 357, 579). Indeed, activation/phosphorylation of STAT3 (pSTAT3) is a commonly used 
experimental marker of leptin receptor activation/activity in vivo and in vitro (579). Activation of 
leptin receptor signaling also can result in activation of the phosphatidylinositol 3-kinase (PI3K) 
pathway via insulin receptor substrate (IRS) proteins (160, 480). In the course of normal 
homeostasis, negative feedback inhibition of Ob-Rb signaling is provided by suppressor of 
cytokine signaling (SOCS) 3 (53, 55, 164) binding at Try985 and PTP1B acting at JAK2 (106, 
628). Genetic technologies have enabled determination of the relative physiological significance 
of activation of different signaling pathways downstream of the leptin receptor. These will be 
addressed in each of the relevant sections below. 
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In the rest of the document any reference to “leptin receptor is signaling” typically is relating to the 
full-length or long-form receptor (Ob-Rb) unless stated otherwise. 
 
Leptin receptor expression in the CNS 
Within the rodent brain early in situ hybridization studies revealed that Ob-Rb mRNA is highly 
expressed in the hypothalamus (398) and that this receptor is activated by exogenous leptin 
treatment (579, 609). Subsequent studies have revealed a more widespread distribution of leptin 
receptors across the CNS (180) fitting with its diverse functions (table 2). In situ hybridization 
studies have revealed a distinct CNS distribution of the different leptin receptor isoforms, with Ob-
Ra and Ob-Rb being the principal forms expressed in the hypothalamus and OB-Ra, OB-Rc and 
OB-Rf predominating in the choroid plexus (226). The use of transgenic technologies has 
enabled animals with fluorescently tagged leptin receptors to be created, which has facilitated 
detailed studies mapping CNS sites of leptin receptor expression and their downstream targets to 
be mapped (449, 508).  
Although outside of the CNS, of relevance to topics to be discussed later in this review, leptin 
receptors are also expressed on the nodose (inferior) ganglion of the vagus nerve (76, 79). 
Leptin receptors are found on a variety of different neuronal populations in the brain (table 2). 
This widespread distribution contributes to its role as a neuromodulator of numerous 
neuroendocrine and non-neuroendocrine pathways, which will be described in more detail later in 
this review. Specific deletion of leptin receptors from different neuronal populations has 
differential effects on physiology which will be described in the relevant sections below. While the 
majority of work on CNS targets of leptin has focused on neurons, leptin receptors are also found 
on non-neuronal cells in the CNS including astrocytes (110, 272, 442), microglia (455), tanycytes 
(23), endothelial cells (54, 217), and choroid plexus epithelial cells (146, 398). 
  
Leptin entry into the brain 
In order to mediate its effects via the centrally expressed receptors leptin needs to enter the CNS. 
The blood-brain barrier (BBB) functions to protect the brain from fluctuations in the body and 
helps to maintain the microenvironment in the CNS. Made up of endothelial cells which line the 
cerebral microvessels, the function of the BBB is regulated by the interaction of endothelial cells 
with other cellular components of the ‘neurovascular unit’ including astrocytes and neurons (1). 
The BBB regulates movement of substances including nutrients and hormones, including leptin, 
in and out of the brain.   
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Proximal to the cerebral ventricles are circumventricular organs within the brain. Whist there is 
some debate surrounding the number of circumventricular regions in the mammalian brain, major 
sites include the median eminence (ME) and adjacent neurohypophysis, organum vasculosum 
lamina terminalis, subfornical organ (SFO) and the area postrema (AP) (167). In these small 
regions of the brain, the BBB of cerebral microvessels is more readily permeable, facilitating 
communication between the brain and cerebrospinal fluid (CSF), and factors circulating in the 
blood. Evidence suggests that portions of the ME within the hypothalamus lack the normal protein 
components of the BBB, suggesting an absence of the normal barrier in this area (71, 426). Of 
significance to the CNS actions of leptin, data indicates that a population of hypothalamic arcuate 
(ARC) neurons adjacent to the ME project outside of the BBB and are able to rapidly respond to 
peripherally administered leptin, as assessed by expression of pSTAT3 (185). As such, 
circumventricular organs are critical sites of entry for adipokines in the brain and are important for 
their centrally mediated effects (199).  
Understandably, due to the importance of the hypothalamus in the regulation of energy 
homeostasis, the ME has been the focus of most studies examining the entry of leptin into the 
brain. However, it is important to note that the choroid plexus (146), SFO (528) and AP (250, 400) 
are also sites at the blood-brain and/or brain-CSF interface that are also directly responsive to 
leptin and may mediate some of its CNS effects. 
The CNS is the principal site of action of leptin mediating many of its known physiological effects. 
Early studies, shortly after its cloning, tracing the entry of radiolabeled leptin into the brain 
indicated that 75% of circulating 
125
I labelled leptin enters the brain (32). Major sites of entry of 
leptin in to the CNS include the choroid plexus and ME (32, 146). Leptin receptors are expressed 
on cerebral endothelial cells of both rodents and humans (54, 217). While obesity is associated 
with increased circulating leptin, leptin transport into the brain and subsequent CSF levels of 
leptin are not concomitantly increased, suggesting that leptin transport into the brain is saturable 
(77, 87). This saturable transport mechanism is one proposed cause of leptin-resistance 
associated with obesity, which will be discussed in greater detail later in this review. In addition to 
obesity, a number of factors and physiological states have been shown to influence leptin 
transport into the CNS, shown in table 3. 
 
CNS Leptin Resistance 
CNS leptin-resistance is characterized by a loss of physiological responsiveness to leptin despite 
the high circulating levels seen in both obese individuals and animals (without congenital leptin 
deficiency), and was recognized early after the leptin gene was first cloned (195). While obesity is 
associated with chronic elevations in circulating leptin (235), it is debated whether leptin 
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resistance is a cause or consequence of obesity (416), or quite likely both. Within the 
hypothalamus, there is evidence to suggest that leptin-resistance associated with diet-induced 
obesity is more pervasive in the ARC than other nuclei, including the ventromedial hypothalamus 
(VMH), dorsomedial hypothalamus (DMH) and lateral hypothalamic area (LHA) (387, 413), likely 
due to its proximity to the ME causing this region to be readily exposed to the high circulating 
levels of leptin and proinflammatory cytokines derived from WAT of obese animals. Interestingly, 
the ventral tegmental area (VTA), which is a key component of the dopaminergic reward pathway, 
also shows leptin-resistance in response to diet-induced obesity in rats (387). Improving CNS 
leptin sensitivity is seen as a potential therapeutic target for metabolic disease, and as such there 
is extensive interest in understanding the molecular mechanisms behind this phenomenon. A 
combination of defective leptin signaling and impaired entry of leptin into the CNS are both 
thought to be contributing factors (170).  
Recent evidence suggests that mimicking obesity-associated elevations in circulating leptin by 
chronically infusing leptin into wild-type lean mice is not sufficient to induce leptin resistance 
regardless of the nutritional state of the animal (fed/fasting) (476). This indicates that other 
pathophysiological changes associated with obesity are likely contributing to the development of 
leptin-resistance. Candidates include inflammation and endoplasmic reticulum (ER) stress. 
Diet-induced obesity causes inflammation and ER stress in the brain, with the hypothalamus 
being the predominantly studied region in this regard (143, 438, 561, 635). Supporting a potential 
role of ER stress as a causative factor in the development of central leptin-resistance, induction of 
ER stress using genetic and pharmacologic tools is sufficient to induce leptin-resistance in vitro 
(438) and in vivo within the hypothalamus (438, 608) as assessed by a reduction in leptin induced 
phosphorylation of STAT3. This is supported by the finding that treatment with compounds that 
enhance ER function, 4-phenyl butyrate (PBA) and tauroursodeoxycholic acid (TUDCA), 
improves leptin-sensitivity in genetic (ob/ob) (438) and diet-induced (608) mouse models of 
obesity. 
In common with inflammatory signaling, induction of hypothalamic ER stress activates the nuclear 
factor-kappa B (NFκB) signaling pathway and pharmacological inhibition of ER stress reduces 
high-fat diet-induced hypothalamic activation of the NFκB signaling cascade (635). This suggests 
that activation of NFκB signaling is an important downstream mediator of ER stress in this 
context. In the same study, virally mediated activation of NFκB signaling in the hypothalamus was 
sufficient to induce leptin-resistance in lean mice while inhibition of NFκB signaling, specifically in 
agouti-related protein (AgRP) neurons of the medial basal hypothalamus, reduced high-fat diet 
induced weight gain and leptin-resistance (635). Interestingly, in contrast, chronic activation c-Jun 
N-terminal kinases (JNKs) but not NFκB signaling specifically in AgRP neurons is sufficient to 
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stimulate obesity and leptin resistance (572), indicating that different hypothalamic neuronal 
populations may have distinct roles in the response to inflammation. Upstream of NFκB signaling, 
the adaptor protein MyD88 and its associated receptor toll-like receptor 4 (TLR4) are important 
for mediating leptin-resistance associated with high-fat feeding by direct central administration of 
saturated fatty-acids (18, 317). 
As described above, in the course of normal homeostatic leptin signaling, negative feedback 
inhibition of Ob-Rb signaling is provided by SOCS3 (53, 55, 164) and PTP1B binding (106, 628). 
Obesity is associated with elevated hypothalamic expression of both SOCS3 (53) and PTP1B 
(629) and genetic deletion of SOCS3 and PTP1B binding from the CNS or specifically from 
proopiomelanocortin (POMC) neurons in the hypothalamus protects against high-fat diet-induced 
leptin-resistance (44, 307, 405). Together these findings suggest that SOCS3 and PTP1B may 
also play a role in the development of obesity associated leptin-resistance. Expression of SOCS3 
(536) is induced via transcriptional activation of STAT signaling; however, in the case of obesity 
leptin induced phosphorylation of STAT3 is decreased (170), which suggests that alternative 
(non-STAT3 mediated) pathways are likely to be contributing to the upregulation of SOCS3 in this 
context. Additionally, expression of PTP1B is increased by inflammation (629) and ER stress 
(443) via the activation of NFκB signaling suggesting a potential mechanistic link between 
inflammatory signaling and ER stress and the development of CNS leptin-resistance. The 
potential molecular signaling mechanisms underlying the development of CNS leptin-resistance 
are summarized in figure 1. 
One of the challenges in studying mechanisms of leptin-resistance in experimental animal models 
is that intervention (genetic or pharmacological) associated improvements in leptin resistance are 
typically associated with weight-loss or a failure to gain weight when exposed to an obesogenic 
diet; thus, it often is difficult to differentiate whether the reduced leptin-resistance is due to the 
reduced weight gain or vice versa. These challenges are elegantly discussed in a 2010 review by 
Myers and colleagues (416). 
Impaired entry into the brain has been proposed as another potential mechanism underlying CNS 
leptin resistance (170). As described above, a recent study by Balland and colleagues (23) has 
demonstrated that intact leptin receptor signaling in tanycytes is critical for leptin entry into the 
CNS and that this is defective in obese animals (both diet-induced and genetic). This provides a 
molecular basis linking both underlying tenets of CNS leptin resistance: defective leptin signaling 
and impaired entry of leptin into the CNS. Whether similar pathological stimuli, namely 
inflammation and ER stress, impair tanycyte mediated leptin transport into the CNS remains to be 
fully determined. 
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Importance of leptin in development of neural circuitry 
A number of pieces of evidence support an important role for leptin in the development of neural 
circuitry. Early studies in obese mice with congenital leptin deficiency (ob/ob mice) showed that 
these animals have fundamental differences in the macrostructure of their brains, including 
decreased brain weight and volume, and impaired organization of dendrites within the 
hypothalamus (48, 49). The reduction in brain weight in ob/ob mice can be reversed by leptin 
treatment from 4-weeks (5, 541), suggesting a key role for leptin in brain development. Although 
rare in humans, congenital leptin deficiency is associated with changes in brain size and structure 
which can be reversed, at least, in part by leptin treatment (365, 389).  
Leptin receptors are expressed in the brain (leptomeninges and choroid plexus) from early in 
embryonic development [E13.5 in the mouse (262)]. There is a post-natal surge in leptin levels in 
rodents, independent of adipose mass, starting at post-natal day 4 and peaking at post-natal day 
10, which does not concomitantly impact energy homeostasis but is believed to act as a 
developmental cue (7). In mice, hypothalamic circuitry key for the regulation of energy 
homeostasis is not fully developed at birth but the intra-hypothalamic and extra-hypothalamic 
projection develops rapidly becoming mature by around post-natal day 16-18 (65, 66). The 
development of the intra-hypothalamic projections from the ARC to the paraventricular nucleus of 
the hypothalamus (PVH) are attenuated in mice with defective leptin signaling [leptin-deficient 
ob/ob mice (66) and db/db mice with dysfunctional leptin receptors (65)], which may provide a 
neuroanatomic basis for many of the neuroendocrine abnormalities seen in these animals. 
Mimicking the post-natal leptin surge by leptin injection into the leptin-deficient ob/ob mice was 
sufficient to partially restore the ARC to PVH neuronal projections supporting a critical role for the 
post-natal leptin surge in the development of hypothalamic neuroendocrine circuitry (66). Indeed, 
in vitro experiments in organotypic hypothalamic slices from post-natal brains demonstrated leptin 
to be a potent neurotrophic factor (66). Administration of leptin in adult animals was not able to 
restore these critical projections, emphasizing the importance of leptin during this key stage in 
CNS development.  This is further strengthened by data indicating that inhibiting the neonatal 
leptin surge using a leptin antagonist in wild-type rats alters hypothalamic gene expression of 
neurotrophic factors and intermediate filament proteins (nestin and vimentin) (367, 395), 
implicated in growth and survival of neural cells. Interestingly, these effects appear to be sexually 
dimorphic during the neonatal period and also with respect to their phenotypic manifestations in 
the adult animal (367, 395). 
POMC and AgRP neurons of the ARC, which are critical for the regulation of energy homeostasis 
(530), send projections to the PVH. In line with previous studies, leptin deficient ob/ob mice show 
reduced AgRP and POMC fiber density (as assessed by α-melanocyte stimulating hormone 
[αMSH] immunoreactivity) in regions of the PVH containing both neurosecretory and pre-
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autonomic neurons (68).  Significantly, post-natal leptin treatment in leptin-deficient ob/ob mice 
partially restores ARC to PVH projections of AgRP but not POMC neurons in regions of the PVH 
containing pre-autonomic neurons (68), pointing to a differential regulation of the development of 
these important neuronal pathways by leptin. In contrast, perhaps surprisingly, leptin treatment 
was not able to regulate either POMC or AgRP inputs on to PVH neurosecretory neurons in ob/ob 
mice, indicating a differential role of leptin in the development of hypothalamic autonomic 
compared with neurosecretory circuitry. Indeed, these anatomical findings are supported by 
physiological data indicating that ob/ob mice treated with leptin from post-natal day 4-14 show a 
modest improvement in the phenotypic manifestations of their autonomic deficits including a 
modest reduction in food intake, body weight, adipocyte size and thermogenic response to cold 
exposure (68).  In addition to impacting neurons, recent data suggests that post-natal leptin 
treatment can also impact the proliferation of hypothalamic astrocytes, which may in turn 
influence synaptic function and connectivity within the hypothalamus during this critical 
developmental stage (491). 
In the absence of congenital alterations in leptin-signaling, acquired early disruptions in leptin 
signaling associated with leptin-resistance caused by post-natal over-nutrition [small litter size] 
(67, 215), or neonatal exposure to obesity or diabetes (537) also impacts development of the 
hypothalamic circuitry regulating energy homeostasis. 
The development of mice with defects in specific signaling pathways downstream of leptin 
receptor activation has enabled genetic dissection of the leptin receptor signaling pathways 
mediating the actions of leptin on hypothalamic development. Leptin-induced activation of STAT3 
and ERK signaling appear to be important for control of projections from ARC neurons to the PVH 
(64).  
In addition to hypothalamic development there is evidence to suggest that leptin signaling may 
also be important for the development of other key circuits in the brain including those regulating 
cognition and emotion. Absence of leptin-signaling in db/db or ob/ob mice is associated with 
complex changes in response to neurobehavioral testing characteristic of memory deficits, 
depression and an altered anxiety profile (361, 516, 616). Alterations in these behavioral 
paradigms can be representative of alterations in hippocampal function. Indeed, further 
examination has revealed that db/db mice have reduced dendritic spine density in dentate gyrus 
(544), CA1 and CA3 neurons (147) within the hippocampus which may account for the 
neurobehavioral deficits seen in these animal models. Furthermore, congenital defects in leptin 
receptor signaling in both db/db mice and Zucker rats cause impaired hippocampal long-term 
potentiation (LTP) (212, 361). Together these data suggest an important role for leptin in synapse 
development in the hippocampus which impacts its function. A role for leptin in modulating 
hippocampal function will be discussed further later in this review. 
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Effects of leptin on energy and glucose homeostasis 
The most well described physiologic roles of leptin are in the regulation of energy homeostasis. 
Leptin impacts energy homeostasis on multiple levels including regulating food intake, energy 
expenditure, thermogenesis and glucose homeostasis. Loss of leptin-signaling in rodents (122, 
211, 285, 570, 571) and humans (404) results in profound dysregulation of energy homeostasis 
characterized by obesity, increased food intake, insulin resistance and altered energy expenditure 
including impaired thermoregulation. Genetic dissection of the leptin-signaling pathways critical 
for glucose and energy homeostasis has revealed a key role for a number of proteins including 
STAT3 (37-39), STAT5 (450), PI3K (423, 638). Moreover, loss of inhibition of leptin signaling 
through modulation of SOCS3 binding site (Tyr985) results in mice which are leaner than their 
wild-type littermates (56).  
AMP-activated protein kinase (AMPK) is key cellular mediator of energy homeostasis found in 
both neurons and glia in the CNS (for review see (385)). AMPK activity is increased in times of 
energy deficit, acting to conserve cellular energy by switching off unnecessary energy consuming 
pathways and promote ATP production (244). In vivo leptin treatment decreases AMPK activity in 
both the hypothalamus (403) and caudal brainstem (249). Furthermore, genetic or 
pharmacological stimulation of AMPK activity in the hypothalamus or brainstem is sufficient to 
attenuate the inhibitory effects of leptin on food intake (249, 403, 554) suggesting that 
suppression of AMPK activity is a key downstream cellular mediator of leptin-signaling in the 
CNS. In addition to modulating food intake, AMPK has also been implicated in mediating leptin-
induced sympathetic nerve activation (554) suggesting that AMPK action may also impact the 
effects of leptin on thermogenesis, cardiovascular and renal function. 
The roles of different discrete neuropeptides in mediating the downstream effect of leptin on 
energy homeostasis have been studied extensively using both genetic and pharmacologic studies 
in rodents, and will be discussed further below. However, as these neuropeptides typically have 
restricted distribution these studies have resulted in elucidation of discrete leptin-regulated 
circuits in the CNS and the potentially functional overlap/redundancy between these circuits is not 
always clear. Other studies have taken a different approach and have sought to determine the 
broader common critical downstream consequences of leptin signaling that are critical for the 
regulation of energy homeostasis. Taking a wider overview, the work of Vong and colleagues 
examined the role of excitatory compared with inhibitory neurotransmission in mediating the 
effects of leptin on energy homeostasis (587). To do this they created transgenic mice with loss of 
leptin-signaling in glutamatergic (VGlut2; excitatory) or GABAergic (VGat; inhibitory) neurons. 
They found that predominantly inhibitory GABAergic signaling was important for mediating the 
downstream effects of leptin on energy homeostasis, while the contribution of excitatory 
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glutamatergic neurons was relatively small. GABAergic neurons that are directly responsive to 
leptin (as indicated by leptin-induced pSTAT3 immunoreactivity) were found in the ARC, DMH 
and LHA. 
While the hypothalamus has been the main area of the brain that has been studied with respect 
to the role of leptin in the regulation of energy homeostasis, other brain regions including nuclei of 
the hindbrain and components of the mesolimbic dopamine system have also been investigated 
(see figure 2). 
 
Leptin-mediated effects on energy homeostasis via the hypothalamus 
Perhaps the best known and well characterized CNS targets of leptin are the hypothalamic 
neurons involved in the modulation of energy homeostasis. Early studies indicated that in addition 
to reducing food intake, hyperglycemia and hyperinsulinemia, chronic leptin treatment in mice 
reduced hypothalamic NPY mRNA in ob/ob mice, suggesting that NPY neurons of the 
hypothalamus were key mediators of the effects of leptin on food intake and glucose homeostasis 
(539). Importantly, the effects of leptin on regulating hypothalamic NPY mRNA levels in this 
model are a direct consequence of leptin treatment and not merely a side effect of weight-loss, as 
vehicle-treated ob/ob animals which were pair-fed to the leptin-treated ob/ob group showed a 
similar degree of weight-loss with no associated reduction in hypothalamic NPY mRNA levels 
(506). Another key observation in this important study was the finding that leptin-treated ob/ob 
mice showed a greater reduction in serum glucose and insulin than pair-fed vehicle-treated ob/ob 
mice, which lost similar amounts of body weight, providing an early indication of a key role of 
leptin in regulating glucose homeostasis independent of its impact on body weight (506).  The 
ability of leptin to regulate hypothalamic NPY mRNA was also replicated in wild-type animals 
where leptin treatment can reverse fasting-induced reductions in expression of this gene (506). A 
key role for NPY in mediating the effects on leptin on energy homeostasis was reinforced by 
additional studies demonstrating that leptin receptors are localized in NPY neurons of the rodent 
brain (397) and these neurons express SOCS3 and STAT3 after peripheral administration of 
leptin (174, 234). Furthermore, genetic deletion of NPY in ob/ob mice partially reverses their 
obesity phenotype (183).  
The finding that loss of NPY-signaling attenuated but did not completely reverse the obesity 
phenotype in ob/ob mice (183) suggested there were other important downstream targets of 
leptin’s effects on energy homeostasis that remained to be discovered. Like the ob/ob mouse, the 
phenotype of the obese yellow (A
y
) mouse had been described in the 1940’s (150) but in the late 
1990’s when the mechanisms of leptin’s actions on energy homeostasis were beginning to be 
elucidated the underlying molecular basis of the obesity in this model was also undetermined. It 
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was known that genetic mutations in the A
y 
mouse and the phenotypically-related viable-yellow 
(Av
y
) mouse both resulted in ectopic over-expression of the agouti protein which was known to be 
important in regulating pigmentation in hair follicles via its action on melanocortin-1 receptors 
(MC1R) (369). As mice that lack MC1R are not obese (484) the obesity phenotype of the A
y
 
mouse could only be due to the action of agouti at an alternative receptor. Being expressed in a 
number of key hypothalamic sites important for the regulation of energy homeostasis (and other 
neuroendocrine and autonomic functions) (412) the melanocortin-4 receptor (MC4R) was a key 
candidate. In 1997 the MC4R-null mouse was generated and found to have an obesity syndrome 
highly similar to that of the A
y
 mouse, but without the associated coat color phenotype (284). 
Shortly thereafter, leptin receptors were found to be expressed on ARC POMC-neurons (the 
major source of endogenous melanocortin receptor agonists in the brain) (108) and 
administration of a synthetic antagonist for the MC3R and MC4R (SHU9119) into the brain was 
able to attenuate the ability of peripherally administered leptin to reduce food intake (510). These 
studies indicated an important role for the central melanocortin system in mediating the 
downstream effects of leptin on energy homeostasis. However, crossing A
y
 and ob/ob mouse 
strains together indicates that while central melanocortin signaling is important for mediating the 
effects of leptin, it can also exert effects on energy homeostasis (and indeed other 
neuroendocrine pathways) independent of leptin signaling (61).  
In 1997, a homologue of agouti was cloned and discovered to be a selective endogenous 
antagonist of the melanocortin receptors expressed in the brain (MC3R and MC4R) (433). Named 
AgRP, its mRNA was found to be expressed in the ARC and ME and to be down regulated in 
obese ob/ob mice but highly upregulated by fasting (233, 433, 520). Transgenic overexpression 
of AgRP under the control of the β-actin promotor resulted in a similar phenotype to the mice with 
transgenic overexpression of Agouti, however, without the alterations in pigmentation (433). A 
single injection of AgRP directly into the brain robustly increases food intake (169) an effect that 
persists for several days (232). Soon after its discovery, AgRP was shown to co-localize with NPY 
in the ARC in neurons with close proximity to POMC neurons (233) and suggested that a 
presence of a critical leptin-sensitive neuronal circuit regulating energy homeostasis within the 
hypothalamus. ARC POMC neurons have also been shown to co-express cocaine- and 
amphetamine-regulated transcript (CART), another neuropeptide which reduces food intake and 
whose expression is regulated by nutritional status and leptin (330). The leptin-sensitive 
melanocortin circuit in the ARC made up of anorexigenic POMC/CART neurons and orexigenic 
NPY/AgRP neurons, which inhibit and stimulate food intake respectively, plays a pivotal role in 
energy homeostasis via MC4R expressed at downstream sites, including the PVH, has been 
extensively studied and recently comprehensively reviewed elsewhere (547) (summarized in inset 
box of figure 2). This central melanocortin circuit has also been shown to be critical for mediating 
the effects of other key hormones involved in regulating energy homeostasis including 
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adiponectin (464), ghrelin (573, 593) and insulin (45), and as such the modulatory activation of 
leptin on this circuit can in turn modulate the efficacy of these key metabolic hormones (113, 256, 
564). 
The importance of ARC leptin signaling in the regulation of energy homeostasis is indicated by a 
study showing that introduction of functional leptin receptors in the ARC of Koletsky rats, which 
have defective leptin-signaling, using an adenoviral mediated gene delivery approach attenuates 
the obesity phenotype in this model (409). In genetically modified mice which are obese due to 
the presence of a transcriptional blocker inhibiting leptin receptor expression, site-specific 
reactivation of leptin receptor expression in ARC neurons alone is sufficient to improve the 
obesity, hyperinsulinemia, hyperglycemia and hypoactivity (129). Modulations in energy 
homeostasis are also seen in a number of other studies in mice looking at modulating leptin-
signaling specifically in POMC (24, 152, 257, 307, 459, 581) and AgRP neurons (581). 
Collectively these studies reveal subtle differences in the role of different elements of ARC leptin 
signaling in regulating body weight and glucose homeostasis, but importantly demonstrate that 
the ARC is not the sole site mediating the effects of leptin on energy balance. 
Detailed mapping studies indicate that while the ARC is one of the hypothalamic sites with the 
highest level of cell bodies expressing leptin receptor significant numbers were also found in the 
ventral premammillary nucleus (vPMN) and the DMH, while neuronal projections of leptin 
receptor expressing neurons were enriched in the PVH, anteroventral periventricular nucleus and 
the central nucleus of the amygdala (449). These findings are supported by studies mapping of 
pSTAT3 immunoreactivity after peripheral leptin-treatment (413). The widespread expression of 
leptin receptors/leptin-responsive neurons in different hypothalamic nuclei highlights that the 
modulatory actions of leptin on energy homeostasis circuits are complex and diverse and extend 
far beyond the ARC (417). 
The LHA is important for regulating feeding behavior, wakefulness and arousal (59). Importantly, 
the LHA is also critical for mediating reward behavior and is a key gateway between the 
hypothalamus and the mesolimbic dopamine system (151, 246, 305). Neurons of the LHA 
express leptin receptors (180, 352) and are directly responsive to leptin as indicated by leptin-
induced expression on pSTAT3 immunoreactivity and changes in electrical activity (352). Indeed, 
different populations of LHA neurons were either depolarized or hyperpolarized by leptin 
suggesting that leptin may exert differential effects via the modulation of neuronal activity in this 
brain region. In addition to direct regulation, the LHA can also be indirectly regulated by leptin via 
ARC NPY and POMC neurons which project to the LHA (174, 177). Direct administration of leptin 
into the LHA decreases food intake and body weight in rats (352) supporting a role for the LHA in 
mediating the homeostatic effects of leptin. This is further supported by data indicating that 
disruption of leptin-signaling in the LHA increases food intake and body weight (139).  
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Within the LHA leptin receptor neurons are GABAergic (352, 587) and a subpopulation(s) of 
these also express the neuropeptides neurotensin (353) and galanin (339). Interestingly, despite 
their known role in regulating energy homeostasis (497, 518) - both are implicated in stimulating 
feeding - neither orexin nor melanin concentrating hormone (MCH) neurons in the LHA contain 
leptin receptors (352). However, leptin can exert an indirect inhibitory effect on LHA orexin (but 
not MCH) neurons via adjacent neurotensin (216, 368) and galanin neurons (338). Genetic-
deletion of leptin receptors from neurotensin neurons results in animals with early-onset obesity 
associated with elevated food intake and reduced locomotor activity (353). In contrast, leptin 
receptor deletion from galanin neurons results in late onset obesity and an increased preference 
for sucrose over fat (338). Although galanin and neurotensin extensively colocalize in the LHA 
(339), the differential effects of loss of leptin-signaling in galanin compared with neurotensin 
neurons may potentially be explained by the fact that while both neuronal populations innervate 
orexin neurons within the LHA, galanin neurons in this region project to the locus coeruleus (338) 
and neurotensin neurons project to the VTA (353). The differences in phenotype between the two 
models may also be explained by the fact that both neurotensin and galanin are expressed in 
neurons at sites outside of the LHA (321, 525). Myers and colleagues have proposed a model in 
which leptin receptor expressing neurons in the LHA tonically inhibit local orexin neurons and that 
reductions in leptin-signaling, associated with negative energy balance e.g. fasting or starvation, 
remove this inhibition leading to increased activity of orexin neurons resulting in increased food 
intake, arousal, and locomotor activity (216).  
The DMH is another key hypothalamic site mediating the effects of leptin on energy homeostasis. 
Indeed, diet-induced obesity in rodents is associated with induction of NPY expression in this 
region, which is not evident under normal weight animals (227). These diet-induced obesity 
associated DMH NPY neurons coexpress CART, and leptin directly induces depolarization and 
increased firing activity in these cells (348) indicating a potential role for leptin in regulating their 
activity. Leptin-action in the DMH has been shown in a series of independent studies to be critical 
for the regulation of energy expenditure/thermogenesis. Leptin-deficient ob/ob mice have 
profound deficits in their ability to regulate brown adipose tissue (BAT) activity and adjust to cold 
temperatures (260, 570, 571) indicating a key role for leptin in regulating this key physiological 
adaptation. Furthermore, the ability of leptin to reduce body weight in mice is partially dependent 
on thermogenesis in BAT (126).  
A central circuit encompassing projections between the median preoptic area (mPOA), DMH and 
rostral raphe pallidus (rPA) (84, 623) regulates sympathetic output to BAT during cold exposure. 
Retrograde labeling studies in mice have demonstrated that a subpopulation leptin receptor 
expressing neurons in the DMH project to BAT and are activated (as assessed by expression of 
c-FOS immunoreactivity) by cold-exposure (636). These anatomical findings were supported by 
physiological studies published around the same time by an independent group which indicate 
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that intra-DMH administration of a leptin receptor antagonist in mice was sufficient to attenuate 
the thermogenic effect of peripherally administered leptin (182). Intra-DMH leptin administration 
can also reverse the low body temperature (hypothermia) that is a physiological characteristic of 
leptin-deficient ob/ob mice (483). Interestingly, the hyperthermic effect of leptin is intact in diet-
induced obese mice, which is in contrast to leptin’s effects on food intake which are attenuated by 
obesity (182). 
Activation of DMH leptin receptor cells using Designer Receptors Exclusively Activated by 
Designer Drugs (DREADDs) induces weight-loss associated with increased energy expenditure 
(BAT thermogenesis and locomotor activity) but not changes in food intake (483). The same 
study indicates that virally mediated genetic deletion of leptin receptors from DMH neurons in 
mice produces the opposite effect, namely increased body weight associated with reduced 
energy expenditure and locomotor activity (483). A complementary study by the same group also 
demonstrated an important role for leptin receptors in the mPOA in mediating body temperature, 
further reinforcing a key role for leptin in modulating the tone of the central circuit regulating 
thermogenesis (625). Within the DMH prolactin-releasing peptide (PrRP) neurons are responsive 
to leptin and deletion of leptin receptors from these cells attenuates the thermogenic effects of 
leptin indicating that DMH PrRP neurons are key mediators of leptin’s effect on thermogenesis 
(155). 
 The VMH has long been known to be a key site in the regulation of energy homeostasis. Early 
studies indicated that lesioning the VMH region in rodents leads to profound obesity (254) and 
furthermore, mice which lack the transcription factor steroidogenic factor-1 (SF-1) have defective 
VMH development and are obese (378). The VMH has populations of glucose-sensing neurons 
(for review see (492)). Critically, VMH neurons also expresses leptin receptors (180) and are 
directly responsive to leptin, as indicated by the expression of  nuclear localization of STAT3 after 
leptin treatment  (275). Direct injection of leptin in to the VMH is sufficient to reduce food intake 
(290, 501) and stimulate sympathetic nervous system activation in rodents (243, 502). 
Interestingly, pregnancy is associated with a reduction in leptin receptor mRNA and a 
concomitant reduction in leptin-induced pSTAT3 in the VMH but not the ARC, suggesting that the 
VMH may be a critical site mediating pregnancy-induced leptin-resistance (336). 
Neurons in the medial VMH send excitatory inputs to ARC POMC neurons (542), providing 
evidence for a functional regulatory interaction between these two leptin-sensitive areas. Loss of 
leptin receptor signaling in SF-1 neurons of the VMH results in obesity and impaired glucose 
tolerance on standard chow and also enhanced weight gain on a high-fat diet (52, 149). In 
support of a potential role for VMH leptin signaling in sympathetic nervous system activation, 
mice with loss of leptin receptor signaling in SF-1 neurons display a defect in diet-induced 
thermogenesis (149). Activation of PI3K signaling is one of the pathways downstream of leptin 
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receptor activation (423, 638). PI3K signaling in VMH SF-1 neurons leads to enhanced diet-
induced obesity and a defect in diet-induced thermogenesis, suggesting the PI3K may be one of 
the key signaling pathways mediating the effects of leptin in VMH neurons (613). Furthermore, 
the effect of VMH leptin signaling on tissue glucose utilization and insulin-sensitivity appear to be 
mediated via ERK signaling (565). Enhancing leptin signaling in VMH SF-1 neurons by specific 
deletion of SOCS3 increased the efficacy of leptin in reducing food intake and also resulted in 
improved glucose homeostasis in both standard chow and high-fat fed mice (634). Preventing 
PTP1B mediated inhibition of leptin signaling in VMH SF-1 neurons (SF-1 PTP1B null mice) also 
enhances leptin-sensitivity but surprisingly resulted in increased body weight in high-fat fed 
female mice, which was associated with reduced energy expenditure and sympathetic nervous 
system activity (111). As PTP1B also regulates insulin signaling, it is has been proposed that 
enhanced insulin signaling in the SF-1 PTP1B null mice counteract the effects of improved leptin-
sensitivity in these animals when exposed to a high-fat obesogenic diet (111).  The 
neurochemical identity of leptin responsive neurons in the VMH remains to be fully determined, 
but candidates include pituitary adenylate cyclase-activating polypeptide (PACAP) (248) and 
dynorphin (175).  
Within the hypothalamus multiple distinct nuclei are sensitive to leptin and have been implicated 
in mediating the effects of the adipokine on energy homeostasis. While some overlapping actions/ 
redundancy exist it is likely that we have yet to uncover the true integrative and coordinated 
action of these site in the regulation of this complex physiologic process. 
 
Extra-hypothalamic effects of leptin on energy homeostasis 
While the hypothalamic effects of leptin in regulating energy homeostasis have been the most 
extensively studied (see preceding section), deletion of leptin receptors from various 
hypothalamic neuronal populations (described above (24, 52, 149, 152, 257, 307, 338, 353, 459, 
581)) does not fully recapitulate the metabolic phenotype of the animals with congenital leptin-
signaling defects (122, 211, 285, 570, 571). This indicates that leptin signaling in extra-
hypothalamic areas is also critical for the normal regulation of energy homeostasis. 
Leptin-mediated effects on energy homeostasis via the hindbrain 
In animal models, leptin receptor expression has been reported in a number of hindbrain sites 
relevant to the regulation of energy homeostasis including the area postrema, nucleus of the 
solitary tract (NTS), dorsomotor nucleus of the vagus (DMX), lateral parabrachial nucleus (lPB), 
and ventrolateral medulla  (VLM) (225, 399, 400). However, variation in distribution and 
abundance has been reported between mammalian species (399, 400). Early studies indicated 
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that administration of leptin in rodents induces c-FOS immunoreactivity in the NTS and  lPB in the 
brainstem (179); yet, subsequent studies reported low levels of activation in the NTS (175, 591), 
suggestive of a failure of leptin to activate neurons in this region. As c-FOS is thought to 
principally be a marker of neuronal activation, the failure of leptin to induce c-FOS in the NTS 
may be explained by the finding that leptin has been found to inhibit excitability of NTS neurons 
(604). Mapping of leptin-induced expression of phosphorylated STAT3 confirms that the NTS, 
DMX and lPB are direct targets for the action of leptin (79, 178, 209, 225, 266, 281).  
Neurochemical characterization indicates that cholecystokinin (CCK) neurons in the lPB and NTS 
are leptin-responsive (175, 209). Additionally, in the NTS preproglucagon (a precursor for 
glucagon like peptide-1 [GLP-1]) and POMC neurons are direct targets for leptin (178, 209, 281), 
while cholinergic neurons are a target of leptin in the DMX (79).  
The functional significance of these anatomical studies has been verified by numerous 
independent groups. Administration of leptin into the fourth ventricle or dorsal vagal complex 
(DVC; a region of the brainstem encompassing the NTS, area postrema and DMX) reduces 24 h 
food intake and induces weight-loss over the same period (225). In a subsequent study the viral-
mediated knock-down of leptin receptor expression in the DVC in rats caused modest but chronic 
hyperphagia leading to body weight gain (250) indicating a role for endogenous leptin signaling in 
the homeostatic regulation of food intake. Loss of leptin receptors from hindbrain 
preproglucagon/GLP-1 neurons in mice led to a similar phenotype of modest hyperphagia and 
weight gain (509) , although phenotypic differences were seen in the animals between the two 
studies which the authors propose may be related to differences in brain stem expression of 
leptin receptors in mice and rats (282).  
One of the mechanisms by which brainstem leptin-signaling has been proposed to modulate 
energy homeostasis is via modulation of gut-brain communication. An early study indicated that 
injection of leptin into the fourth ventricle was sufficient to inhibit gastric emptying (526) 
supporting a role for leptin in modulating gastrointestinal (GI) function, likely via modulation of 
vagal efferent tone. This early work was followed on by subsequent studies indicating that 
peripheral leptin treatment enhanced NTS neuron activity in response to gastric distention (505) 
and nutrient preloading (181), thus providing a neurophysiologic mechanism for how leptin may 
act to reduce meal size.  
Related studies have demonstrated that leptin is able to impact food intake via modulation of the 
action of gut released peptides at hindbrain sites. CCK released from the GI tract acts as a satiety 
factor reducing meal size via its action on receptors located on vagal afferents which are relayed 
to the DVC in the brainstem and also forward on to higher centers regulating food intake (154). 
Multiple independent groups have demonstrated that in rodents the injection of sub-threshold 
doses of leptin and CCK, which alone do not influence feeding behavior, can produce reductions 
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in food intake indicative of a synergistic action of the two peptides (10, 35, 390, 603). This effect 
was seen when leptin was administered peripherally (10, 35) or into brain via cerebroventricular 
injection (390, 603). The inter-relationship between leptin- and CCK-signaling is further 
strengthened by the finding that absence of intact leptin signaling in Koleysky (408) or Zucker 
(401) rats is associated with increased meal-size and relative insensitivity to the effects of CCK 
on food intake, although interpretation of these findings may be complicated by the profound 
obesity in these models that likely impacts numerous parameters. However, the importance of 
leptin in modulating the actions of CCK on food intake in a physiological context are further 
supported by the data indicating that fasting-induced reductions in circulating leptin also impair 
the ability of CCK to reduce food intake, an effect that can be reversed by restoration of leptin 
levels by exogenous administration of leptin (393). Leptin receptors in the NTS are critical for 
mediating the effects of CCK on food intake as adenoviral mediated knockdown of leptin 
receptors in this brain region attenuates the satiating effect of exogenously administered CCK 
and also leads to an increased meal size, indicative of a disruption of the normal satiety pathways 
(250).  
In addition to NTS leptin-signaling forebrain sites have also been implicated as being important in 
mediating the synergetic interaction between leptin and CCK. Co-administration of leptin and 
CCK leads to an amplification of neuronal activation in the PVH, as assessed by c-FOS 
immunoreactivity, compared with that seen following either peptide alone, suggesting that the 
PVH may be an important site of functional convergence of both peptides (35, 181). Indeed, 
surgical transection of the connectivity between forebrain and hindbrain in rats prevented the 
inhibition of food intake associated with co-administration of leptin and CCK, indicating that 
connectivity between the two areas is critical for mediating the synergetic action of these two 
peptides (10). Descending oxytocin pathways from the PVH to the NTS have been implicated as 
potential key mediators (57). Interestingly, in Koletsky rats restoration of leptin-signaling in the 
ARC, a brain region with direct connectivity to the PVH, using viral-mediated gene delivery was 
sufficient to reduce average meal-size to that seen in wild-type animals and also restore 
sensitivity to the satiating effects of exogenously administered CCK (408). Together, these data 
suggest that hypothalamic leptin-signaling can modulate the activity of CCK via descending 
neuronal pathways from the PVH to the NTS. Interestingly, a recent study has demonstrated that 
CCK-neurons of the NTS, that are known to be leptin responsive (209), project to the PVH and 
play an important role in regulating satiety (133). 
In common with CCK, leptin has also been shown to act synergistically with GLP-1 to reduce food 
intake; indeed the interaction between GLP-1 and leptin in the regulation of energy homeostasis 
bears a lot of similarities to the interaction with CCK described above. GLP-1 like CCK is a 
peptide released from the GI tract that has been shown to mediate satiety and is also expressed 
in neurons of the NTS of the brain stem (568). Peripherally secreted GLP-1 is also an incretin 
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hormone. It is not clear whether peripherally derived GLP-1 enters the brain and/or whether the 
interaction between leptin and GLP-1 signaling in the CNS is largely mediated downstream of 
CNS derived GLP-1 (568).  As described above, leptin receptors are found on  GLP-1 neurons in 
the NTS (218) and are directly responsive to leptin-treatment in mice as indicated by expression 
of pSTAT3 immunoreactivity (209, 281). Electrophysiologic studies indicate that GLP-
1/preproglucagon neurons of the NTS are depolarized by leptin and receive direct input from 
vagal afferent fibers (261). Intracerebroventricular administration of a GLP-1 antagonist [extendin 
9-39] at a dose that had no effect when administered alone, is sufficient to attenuate the effect of 
leptin on food intake (218, 639), implicating GLP-1 signaling in mediating some of the 
downstream effects of leptin on food intake. Furthermore, co-administration of leptin and a GLP-1 
agonist [exendin-4] into the fourth cerebroventricle in rats had an additive inhibitory effect on food 
intake.  In rats, peripheral leptin administration can attenuate fasting-induced reductions in NTS 
GLP-1 mRNA (281) an effect that is not seen in mice, indicating that there may be important 
differences between the two species. NTS GLP-1 neurons send projections to the hypothalamus 
as well as a number of other brain sites (340).  As with CCK, intact hypothalamus-brainstem 
connectivity appears to be required for the interaction between leptin and GLP-1 signaling in the 
regulation of energy homeostasis, as the additive effect on food intake is attenuated in midbrain 
transected rats (11). Loss of leptin receptors from GLP-1 neurons in the NTS is sufficient to 
impact food intake and induce a modest increase in body weight in animals fed standard 
laboratory chow indicating that endogenous GLP-1 neurons are important downstream mediators 
of endogenous leptin signaling (509). These animals are, however, capable of reducing their food 
intake and body weight in response to exogenous peripheral leptin infusion over the course of a 
week, indicating that in this context leptin receptors on GLP-1 neurons are not required for the 
effect on food intake and body weight, likely due to a compensation by other leptin activated 
pathways. 
In addition to the caudal brainstem nuclei (NTS, AP, VLM and DMX) another direct target of leptin 
in the hindbrain is the lPB (79, 178, 209, 225, 266, 281). The parabrachial nucleus (PBN) is a key 
intermediary site linking the hypothalamus to the caudal brainstem including the NTS and VLM 
(500). Within the PBN, leptin receptors are expressed in CCK neurons which project to the VMH 
(194). Leptin receptor expressing neurons in the PBN are inhibited by leptin but activated by low 
glucose levels indicating that they may be a key regulatory node for low-glucose sensing linking 
the hypothalamus and brainstem (194). Deletion of leptin receptors from CCK neurons resulted in 
mice with an exaggerated counter-regulatory response (CRR) to low-glucose characterized by a 
reduced glucose infusion rate in a hypoglycemic clamp (194). The same study nicely 
demonstrated using chemogenetic technologies (DREADDs) that inhibition of the activity 
specifically of PBN leptin receptor containing neurons blunted the CRR while activation of these 
neurons enhanced it, in a process that could be inhibited by the CCK-receptor antagonist 
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proglumide. While mice with deletion of leptin receptors from all CCK neurons including those 
found in the PBN show normal food intake and body weight, an independent study demonstrated 
that direct injection of leptin into the PBN reduces food intake and meal size in rats leading to a 
reduction in body weight (13). This suggests that the effect of intra-PBN leptin on food intake is 
mediated by neurons in the PBN that do not contain CCK or alternatively, that other pathways 
adapt to maintain normal energy homeostasis in mice with leptin receptors deleted from their 
CCK neurons. 
  
Role for non-neuronal targets of leptin in the regulation of energy homeostasis 
Within the CNS the majority of work examining the role of leptin in regulating energy homeostasis 
has focused on neuronal signaling; however recent work has begun to explore the contribution of 
non-neuronal cells as targets for leptin’s actions, in particular the potential role of astrocytes. 
Leptin receptors are expressed in astrocytes (110, 271, 272, 442). Indeed, astrocytes have been 
shown to be directly responsive to leptin as indicated by increased translocation of STAT5 to the 
nucleus of astrocytes following systemic leptin treatment in vivo in rats (415). Additionally, studies 
show that leptin treatment can induce both pSTAT3 and pSTAT5 in astrocytes in vitro, with 
pSTAT5 showing more pronounced regulation (60) indicating that it may be the predominant 
signaling pathway downstream of leptin receptor activation in astrocytes; however, further work 
needs to be done in this area. In vitro, leptin induces an increase in intracellular calcium in 
astrocytes, providing further evidence of a functional effect of leptin on downstream signaling in 
astrocytes (272). 
In obese animal models, both monogenic and diet-induced, leptin receptor expression is 
upregulated in hypothalamic astrocytes, suggestive of a potential role of astrocytic leptin-signaling 
in the regulation of energy homeostasis (272, 442). This expression data is supported by 
mechanistic studies indicating that leptin treatment regulates both the structure and function of 
hypothalamic astrocytes; including levels of hypothalamic glial-fibrillary acidic protein (GFAP) and 
vimentin, key structural proteins (207), as well as the expression of glucose and glutamate 
transporters found in astrocytes (202). Conditional deletion of leptin receptors from GFAP-
expressing astrocytes in adult mice reduces astrocytic coverage of melanocortin neurons (POMC 
and AgRP) in the ARC resulting in an increase in synapse number and a change in the 
neurophysiological activity of these neuronal populations (310). While there were no notable 
differences in feeding behavior in these animals under normal husbandry conditions (freely 
available standard chow), the animals’ demonstrated altered physiological responses when 
experimentally challenged. Conditional deletion of leptin receptors from GFAP-expressing 
astrocytes in mice resulted in an enhanced response to manipulations that typically increase food 
intake, fasting or ghrelin treatment, and attenuation of the ability of leptin to reduce food intake 
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(310). Together these data point to a role for leptin in regulating the astrocytic modulation of 
synaptic activity in ARC melanocortin neurons. The importance of astrocytes in mediating the 
effects of leptin on energy homeostasis was supported by a subsequent study demonstrating that 
chemogenetic activation of astrocytes using DREADDs enhanced the reduction in food intake 
associated with leptin-treatment, while inhibition of astrocytes attenuated it (618). Of note, germ-
line deletion of leptin receptors from GFAP-expressing cells does not lead to any overt changes in 
body weight or feeding behavior on standard chow, but a modest and complex difference in their 
response to high-fat feeding that requires further study (293). 
 
Effects of leptin on the modulation of CNS reward pathways 
In addition to increasing food-seeking behavior, negative energy balance associated with food 
restriction/fasting increases other motivated behaviors including drug-seeking and rewarding 
brain self-stimulation via electrodes implanted into the brain (435). As such, food-restriction is 
often used as an experimental context in neurobehavioral studies in rodents as a motivational 
tool. Early functional in vivo studies indicated that intracerebroventricular treatment with leptin can 
attenuate the ability of food-restriction to increase rewarding brain self-stimulation, via electrodes 
implanted in the LHA, providing evidence for a role of leptin in modulating reward pathways (206). 
The dopaminergic reward pathways are critical for the regulation of motivated behaviors including 
food-seeking (606). Leptin receptors are expressed on dopaminergic (191, 264) and GABAergic 
neurons of the VTA which project to the nucleus accumbens (205) suggestive of a role of leptin in 
modulating the critical mesoaccumbens dopamine pathway. Ex vivo, leptin decreases the 
frequency of excitatory postsynaptic currents in VTA dopaminergic neurons, providing a 
neurophysiological evidence for a role of leptin in modulating the activity of this pathway (563). 
This is supported by studies which demonstrate that absence of leptin-signaling in leptin deficient 
ob/ob mice is associated with reduced levels of tyrosine hydroxylase, the rate limiting enzyme in 
dopamine synthesis, in the VTA and a deficit in amphetamine-induced motivated behavior (205), 
both of which can be reversed by systemic leptin treatment. Leptin acting directly in reward 
centers of the brain has also been shown to modulate feeding.  Administration of leptin directly 
into the VTA reduces food intake in rodents while knock-down of leptin receptors in this region 
increases food intake and preference for palatable foods (sucrose and high-fat) (264). The effect 
of intra-VTA administered leptin on food intake appears to be dependent on JAK2 signaling but 
not PI3K or mechanistic target of rapomycin (mTOR), which is in contrast to the effects of intra-
hypothalamic leptin (407).   
In addition to mediating important aspects of the leptin effect on food intake, VTA leptin signaling 
is also important for energy expenditure as loss of STAT3 signaling in dopamine neurons is 
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associated with an increase in the rewarding effect of voluntary activity (running) in mice (189), an 
effect that can be reverse by intra-VTA administration of leptin. Leptin receptor expressing 
neurotensin neurons of the LHA innervate the VTA and intra-LHA administration of leptin into 
leptin deficient ob/ob mice was sufficient to increase VTA tyrosine hydroxylase gene expression 
and nucleus accumbens dopamine levels, indicating a functional anatomic link between LHA and 
the mesoaccumbens dopamine system (352, 353). Like the hypothalamic nuclei, the VTA 
neurons also show cellular leptin resistance in response to diet-induced obesity (387). 
 
Leptin in the modulation of other neuroendocrine axes 
 
Reproduction 
Reproduction is energetically demanding, particularly for female animals. As such, having 
sufficient energy reserves in the form of stored body fat is essential for the health of the mother 
and the offspring. Circulating leptin levels play a key role in communicating information on body 
fat stores to the CNS, with a drop in circulating leptin levels being a key mediator of the 
neuroendocrine deficits triggered by the reduction in energy availability associated with fasting 
(8). Leptin has been shown in numerous studies to have a key role in modulating multiple aspects 
of reproductive function from puberty to lactation (98).  
Before the cloning of leptin it was known that both male and female obese ob/ob mice had severe 
reproductive deficits with the homozygous female animals being sterile and the male animals only 
capable of reproducing when their excess body weight was curtailed by food restriction (127).  
Detailed characterization of these animals revealed an absence of ovulation due to reduced 
levels of reproductive hormones associated with dysfunction at the hypothalamic-pituitary level 
(40, 493-495, 549); ovaries from female ob/ob mice were functional when transplanted into lean 
mice (279). The reduced levels of reproductive hormones in ob/ob mice cause immaturity/atrophy 
of the reproductive organs (550). Breeding of homozygous ob/ob animals is typically achieved 
through pairing heterozygous ob/+ animals. 
After the cloning of the Ob gene and identification of the hormone leptin in 1994, early studies 
explored whether leptin replacement in ob/ob animals was sufficient to reverse the reproductive 
deficits. Continuous peripheral leptin-treatment in adult female ob/ob mice was able to restore the 
ability of the animals to become pregnant, deliver and nurse healthy pups (99). While the leptin-
treatment in female ob/ob mice caused a reduction in body mass, weight-loss in control ob/ob 
mice caused by food restriction alone was not sufficient to restore reproductive capacity indicating 
that the absence of leptin signaling and not just obesity was the principal cause of sterility in the 
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mice. Continuous leptin treatment was required to restore fertility in ob/ob mice as subsequent 
withdrawal of treatment post-partum prevented subsequent pregnancies (99). A complementary 
study of Barash and colleagues, published in the same year, indicated that two-weeks’ of 
peripheral leptin treatment in both male and female ob/ob mice caused an increase in gonad 
weight, and began to normalize some of the notable histologic differences in the seminal vessels 
(males), ovaries and uterus (females), compared with control animals. Serum levels of key 
reproductive hormones were also regulated in ob/ob mice by leptin treatment; females showed 
elevated serum luteinizing hormone (LH) and males elevated serum follicle–stimulating hormone 
(FSH) (33). As with the study of Chehab and colleagues, these effects were found to be 
independent of leptin’s effect on body-weight. Together these early studies pointed to a critical 
role for leptin in the control of the reproductive system. Intriguingly, the genetic background of the 
ob/ob mice is a critical factor determining the severity of the loss of leptin signaling on 
reproductive function, with ob/ob mice on a C57BL6 background being largely sterile while 
animals which carry with the same mutation of the BALB/cJ background are capable of 
reproducing despite profound obesity (184) suggesting the existence a strain dependent genetic 
modifiers of leptin’s effect on reproduction. 
In addition to animal models, intact leptin signaling has also been shown to be critical for 
reproductive function in humans. Although rare in humans, in agreement with the data from mice, 
genetic defects in the ob gene cause severe obesity and individuals do not undergo puberty 
unless treated with leptin (186, 404). However, leptin has also been shown to be critical for 
reproductive function in humans without genetic alterations in leptin signaling. Amenorrhea is 
seen in female patients with very low leptin levels caused by the presence of low body fat 
including athletes (341), patients with anorexia nervosa (252, 324) or lipodystrophy (583). This 
has been shown to be reversible by leptin treatment in athletes and others with hypothalamic 
amenorrhea (114, 599). 
 
Puberty 
Body fat level is associated with the onset of puberty with low levels such as those seen in female 
athletes being associated with delayed onset (197) while high levels of body fat associated with 
obesity are linked to early onset (12, 140). In boys and girls increased serum leptin levels have 
been shown to be associated with the onset of puberty (117, 208, 380). Studies in wild-type 
female mice indicate that peripheral administration of leptin causes earlier onset of puberty and 
maturation of the reproductive tract (6, 100); however other studies suggest that in the rodent the 
role of leptin is more permissive, necessary for the onset of puberty but not sufficient to trigger it 
(109).  
Page 24 of 119Comprehensive Physiology
  25 
  
CNS pathways mediating leptin’s effects on the reproductive axis 
Pulsatile gonadotrophin-releasing hormone (GnRH) secretion and the subsequent surge of LH 
prior to ovulation is critical for reproduction in female mammals. Leptin receptors are expressed in 
the pituitary gland (168, 630) and also hypothalamic neuroendocrine neurons (table 2) which are 
key components of the reproductive axes. Loss of leptin receptors specifically in neurons is 
sufficient to reduce plasma estradiol levels in female mice indicating a key role of centrally acting 
leptin in mediating female sex hormone secretion (120). Interestingly, in the same study, plasma 
testosterone levels were unchanged by neuronal leptin receptor deletion, suggesting sexual 
dimorphism in how leptin impacts reproduction. In a complementary study, reintroduction of 
functional leptin receptors into neurons in db/db mice (which have defective leptin signaling) is 
sufficient to restore fertility in both male and female animals (490) reinforcing the critical role of 
neuronal leptin signaling for fertility. 
In male and female rats, sheep, cows and rhesus monkeys peripheral leptin treatment is sufficient 
to reverse the fasting-induced reduction in pulsatile LH secretion (193, 322, 373, 418, 596) 
providing evidence for a role of leptin in the nutritional regulation of reproductive hormone 
secretion across multiple species. Administration of a leptin anti-serum also decreases LH 
pulsatility in normally fed female rats providing further evidence of a role of leptin in the 
modulation of LH secretion in the absence of a nutritional stress (90). The effects of leptin on LH 
secretion can be prevented by antagonism of central MC4R (596) indicating a potential role of the 
central melanocortin system in mediating the effects of leptin on secretion of reproductive 
hormones. The absence of leptin receptor expression on GnRH neurons (193) indicates an 
indirect effect of leptin in modulating this pathway. An indirect effect of leptin in modulating GnRH 
neurons was supported by a robust study in mice which demonstrated that leptin administration 
into the brain failed to induce STAT3 signaling in GnRH neurons and genetic deletion of leptin 
receptors specifically from GnRH neurons in mice had no impact on fertility (467).  
A number of CNS pathways have been implicated in mediating the effect of leptin on 
reproduction. It has been argued that the redundancy within this pathway is understandable from 
an evolutionary context given the importance of reproduction for survival of a species (98). The 
kisspeptin pathway, peptides encoded by the Kiss1 gene acting via the Kiss1-receptor/GPR54, is 
a key regulator of puberty and reproduction in humans and rodents (142, 513) acting via 
modulation of GnRH neurons. Kiss-1 and GPR54 are nutritionally regulated showing a reduction 
in response to calorie restriction (421) and obesity associated with a high-fat diet or leptin-
deficiency in ob/ob mice (188); all states in which leptin signaling is reduced. Leptin 
administration in leptin-deficient ob/ob mice increases Kiss-1 gene expression and induces 
sexual maturation (527). These findings led to the hypothesis that the kisspeptin pathway may be 
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a key functional link between leptin and the regulation of the reproductive axis. However, in 
common with GnRH neurons, Kiss-1 neurons do not appear to be directly activated by leptin 
(188, 421). There is also conflicting evidence as to whether ARC Kiss-1 neurons express leptin 
receptors, with some studies suggesting up to 40% colocalization (527) and others indicating that 
only a very limited number of kisspeptin neurons (<6% in the ARC and none in the anteroventral 
periventricular nucleus) express leptin receptors (311). Kiss1 expression in the brain is increased 
during pubertal development (512). A detailed analysis in the change in Kiss-1 and leptin receptor 
expression over time (94) indicates that in prepubertal female mice there are low levels of leptin 
receptor expression in Kiss-1 neurons and accordingly at this age few Kiss-1 neurons are 
activated (as assessed by pSTAT3, c-FOS or pSTAT5 immunoreactivity) by leptin treatment. 
After sexual maturation 10-15% of ARC Kiss-1 neurons expressed leptin receptors. This 
anatomic evidence is supported by genetic studies in mice that demonstrate the deletion of leptin 
receptors from hypothalamic Kiss-1 neurons has no impact on puberty (157). Furthermore, re-
expression of endogenous leptin receptors in Kiss-1 neurons of leptin receptor null animals using 
cre-mediated removal of a transcriptional blocking cassette also failed to restore normal 
reproductive function to the leptin receptor null animals (94). Together these studies indicate that 
the kisspeptin pathway is not directly mediating the effects of leptin signaling on the onset of 
puberty. But an indirect/downstream role of kisspeptin in mediating leptin’s effects on 
reproduction and the potential role of leptin in direct modulation of Kiss-1 neurons in adult animals 
has not yet been clarified. 
The central melanocortin system has also been implicated in mediating leptin’s effects on 
reproduction. Melanocortin neurons of the ARC, both POMC and AgRP, express leptin receptors 
(108, 397) and have been shown to innervate both GnRH and Kisspeptin neurons (432, 516, 
607). A subpopulation of Kiss-1 neurons of the mPOA and ARC both express MC4R (516). These 
data provide a potential anatomical basis for a role for the central melanocortin system in 
mediating the effects of leptin on reproduction. Indeed, pharmacologic studies indicate that 
inhibiting MC4R attenuates leptin’s ability to induce LH release in fasted female rats (596). 
However, others have shown that while antagonism of central melanocortin receptors 
(MC3R/MC4R) using SHU9119 attenuates leptin’s ability to reduce food intake in ob/ob mice, it 
does not prevent leptin induced stimulation of reproductive function in these animals (616). While 
leptin receptors in POMC or AgRP neurons are not necessary for the onset of puberty and fertility 
in mice (283, 453), loss of AgRP signaling or heterozygosity of MC4R is sufficient to restore 
reproductive capacity (onset of puberty, fertility and lactation) in female db/db mice without any 
significant changes in body weight (288). Together these data suggest a complex interaction 
between the leptin and melanocortin systems in the regulation of reproductive function, the study 
of which may be complicated by redundancy in the system and developmental compensation in 
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knockout mouse models. Future studies utilizing inducible transgenic models may help to provide 
more clarity. 
Genetic deletion of leptin receptors from GABAergic but not glutamatergic neurons (384) in 
female mice leads to reproductive deficits characterized by a disrupted estrous cycle and reduced 
ovarian and uterine weight. This suggests an important role for inhibitory GABAergic tone in 
mediating leptin’s effects on reproduction. Kiss-1 neurons receive GABAergic inputs which are 
regulated by both time of day and estradiol (144). GABAergic signaling has also been shown to 
regulate GnRH neuron activity (595). This suggests that a leptinGABAKisspeptin/GnRH 
pathway may be one mechanism by which leptin may be able to indirectly modulate the 
reproductive axis. Critically, AgRP neurons in the ARC are GABAergic, whereas POMC neurons 
are both GABAergic and glutamatergic (607) providing a functional anatomical link between the 
leptin and melanocortin systems that may provide further insights into how these systems interact 
in the regulation of reproduction. 
The hypothalamic ventral premammillary nucleus (PMv) has emerged as a key site mediating the 
effects of leptin on the reproductive axis. Anatomical tracing studies in mice reveal that PMv 
neurons, including those known to express leptin receptors, directly innervate GnRH neurons 
(157, 288, 355) and lesioning of the PMv in ob/ob mice attenuates the ability of exogenous leptin 
treatment to induce puberty in these animals (157). Reintroduction of leptin receptors into the 
PMv of leptin receptor null mice was sufficient to induce puberty and positively impact fertility in 
the absence of any notable effect on the body weight of the animals, which remained obese 
(157). These studies revealed an anatomical dissociation between the brain regions mediating 
the effects of leptin on reproduction and energy homeostasis. The neurotransmitter(s) mediating 
the modulation of GnRH neurons downstream of leptin-induced activation of PMv neurons are not 
fully elucidated but glutamate and nitric oxide have been implicated (157, 355, 595). 
In addition to the importance of leptin receptor expression in different brain regions, specific 
modulation of different signaling pathways downstream of the leptin receptor has been shown to 
differentially modulate reproductive function. Genetic modulation of leptin-induced STAT3 
signaling either through specific deletion of STAT3 in leptin receptor expressing cells (213) or by 
genetic introduction of leptin receptors that are unable to couple through STAT3, due to 
replacement of the Tyrosine residue at 1138 (247), is sufficient to cause an increase in body 
weight but has no impact on the onset of puberty or fertility. Specific deletion of STAT5 in leptin 
receptor expressing cells (213) also fails to impact reproductive function. This is perhaps 
surprising given that preventing leptin-induced phosphorylation of the leptin receptor at Tyr1077 
(450), the site that is thought to be important for STAT5 recruitment (219), causes impairments in 
the estrous cycle of female mice. Together these data indicate that another (as yet 
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underdetermined) leptin-induced signaling cascade dependent on phosphorylation of Tyr1077 
may be important for mediating leptin’s effects on reproduction in female mice. 
 
Thyroid hormone axis 
The hypothalamus-pituitary-thyroid (HPT) axis regulates the secretion of thyroid hormone which 
has critical functions including modulation of whole organism and cellular metabolism, 
cardiovascular function, growth, and development. Absence of leptin signaling is associated with 
hypothyroidism in ob/ob and db/db mice (37, 432). In rodents and humans calorie-
restriction/fasting leads to downregulation of the HPT axis as a compensatory mechanism to 
reduce energy expenditure in order to conserve resources during the absence of food (127, 490). 
Following the cloning of leptin, it was found that treatment with peripheral administration of leptin 
was sufficient to partially reverse the starvation/fasting-induced reductions in circulating 
triiodothyronine (T3) and thyroxine (T4) levels in mice, providing evidence of a physiologic role for 
leptin in wild-type animals in the integration of metabolic cues and the function of the thyroid 
hormone axis (8, 349). Leptin treatment could also reverse the fall in circulating T3 and T4 levels 
associated with calorie-restriction induced weight-loss in humans (490). 
Within the brain, leptin treatment in rodents reverses the fasting-induced reduction in pro-
thyrotropin-releasing hormone (proTRH) mRNA levels in neurons of the PVH, which are key 
regulators of thyroid-stimulating hormone (TSH) modulating its release from the pituitary. 
Subsequent studies by multiple independent groups have demonstrated that while leptin can 
directly activate thyroid releasing hormone (TRH) neurons within the PVH (247, 283), an indirect 
pathway via the ARCPVH melanocortin circuitry is also a critical mediator of the effects on 
leptin on nutritional regulation of the HPT axis (188, 247, 311, 421). This has been confirmed by 
electrophysiologic studies indicating that both leptin and α-MSH can induce firing activity of PVH 
TRH neurons (213). In diet-induced obesity it has been proposed that leptin-resistance in the 
ARC leads to underactivity of the indirect melanocortin mediated pathway and that the function of 
the HPT axis in the obese state is maintained principally by the direct action of leptin on PVH 
TRH neurons (453). Mutation of Tyr1138 in the leptin receptor is sufficient to impact the HPT axis 
indicating that activation of STAT3 downstream of the leptin receptor is a key transcriptional event 
in mediating leptin’s effects on the HPT axis (37). 
In addition to modulating the HPT axis at the level of the TRH neurons, leptin can also modulate 
the activity of the enzyme deiodinase type II (D2; the enzyme which converts T4 to T3) within the 
brain (80), including the hypothalamus. D2 has been proposed to play a role in regulating the 
activity of ARC melanocortin neurons via modulation of uncoupling protein 2 (UCP2)(130); as 
such, modulation of hypothalamic D2 activity may represent another mechanism by which leptin 
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exerts its effects on whole organism metabolism, although this is an area that requires further 
study. 
 
CNS mediated effects of leptin on cardiovascular and renal function 
Cardiovascular disease is one of the key comorbidities associated with obesity, with elevations in 
blood pressure believed to be one of the key underlying factors (166, 460). Over the years, 
hyperinsulinemia (236), endothelial dysfunction (511), inflammation (238, 274), alterations in fluid 
homeostasis (237) and changes in sympathetic function (153) have all been implicated in 
mediating obesity-associated cardiovascular pathology. As the focus of this review is CNS targets 
of leptin, we will focus on how centrally acting leptin may modulate cardiovascular function; but 
leptin may also impact cardiovascular function via direct action on the heart and kidney as leptin 
receptors are known to be expressed in these organs (345, 592) . 
Obesity-associated increases in sympathetic nervous system activity in animals and humans has 
been implicated in mediating hypertension (486, 534, 624). The link between the sympathetic 
nervous system and obesity-associated hypertension was further supported by early mechanistic 
studies in animal models indicating that renal denervation prevented high-fat diet induced 
increases in arterial pressure and alterations in sodium retention (299).  
The importance of leptin in modulating sympathetic nervous system activity was discovered soon 
after its initial cloning. In rodents, peripheral administration of leptin increased norepinephrine 
turnover in BAT (123) and sympathetic nerve activity in BAT, kidneys and adrenal glands (251). 
In conscious non-obese rats, chronic peripheral infusion of leptin increases arterial blood 
pressure (517), an effect that can be blocked by administration of adrenergic receptor blockers 
(86). These experiments directly implicated leptin-mediated activation of the sympathetic nervous 
system in the modulation of the cardiovascular system. The effects of leptin on blood pressure in 
non-obese animals can also be seen following direct administration into the CNS via 
cerebroventricular infusion (93, 131, 162); these effects were attenuated by central administration 
of a melanocortin receptor antagonist implicating the central melanocortin system in mediating, at 
least in part, the CNS-mediated cardiovascular effects of leptin (134, 163). 
Despite profound obesity mice with defective leptin signaling, leptin-deficient ob/ob mice and 
db/db mice with defective leptin receptors, fail to show the predicted increase in blood pressure 
seen in diet-induced obese animals with comparable body weight (382, 522). This is in contrast to 
the obese agouti yellow mouse with defects in central melanocortin signaling which has the 
predicted obesity-associated increase in blood pressure (9, 382). This further suggests that leptin 
exerts important effects on cardiovascular function independent of the central melanocortin 
system. Surprisingly, leptin-replacement in ob/ob mice (leading to serum levels comparable to 
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those seen in diet-induced obese mice) causes an increase in heart rate and blood-pressure 
despite a reduction in body weight (522). This was not due to an increase in physical activity as 
the leptin-treated ob/ob animals remained hypoactive compared with their lean and diet-induced 
obese wild-type counterparts. In agreement with what was seen in the animal models, genetically 
mediated loss of leptin-signaling (either lack of leptin or defective receptor function), although rare 
in humans, is also associated with lower blood-pressure compared with age and body-mass 
index (BMI) matched controls (522).  
Within the CNS a number of brain regions have been implicated in mediating the cardiovascular 
effects of leptin. In anaesthetized rats, direct administration of leptin into the hypothalamus, 
specifically the ARC (469) or VMH (383), significantly increased arterial blood pressure and renal 
sympathetic nerve activity but had no impact on heart rate. In contrast, direct injection of leptin 
into the DMH failed to impact renal sympathetic nerve activity while increasing arterial blood 
pressure and heart rate (383). This is further supported by studies indicating that loss of leptin 
signaling specifically in the DMH of mice (via either antibody-mediated or viral-induced 
knockdown of leptin receptors) is sufficient to attenuate diet-induced obesity associated increases 
in heart rate and blood pressure (522).  Perhaps surprisingly given its role in mediating renal 
sympathetic outflow (640), injection of leptin directly into the PVH of the hypothalamus did not 
impact any of the parameters measured (383). Together these data implicate discrete 
hypothalamic nuclei in mediating the cardiovascular effects of leptin.  
The SFO is a circumventricular site which is important in the regulation of autonomic functions 
including those associated with the cardiovascular system. The long-form of the leptin receptor is 
expressed in the SFO (528) and direct inject of leptin into the SFO of lean rats dose dependently 
decreased blood pressure but not heart rate, an effect that is absent in obese animals (529). 
Specific viral-mediated deletion of leptin receptors from the SFO prevents leptin induced 
increases in renal sympathetic nerve activity but has no impact on leptin-induced changes in food 
intake, body weight or sympathetic nerve activity in brown adipose tissue, suggesting that the 
functional role of leptin-signaling in the SFO is highly specialized (528).  
The baroreceptor reflex is a rapid homeostatic mechanism for the maintenance of blood pressure 
via the regulation of cardiac parameters including heart rate. Within the CNS, autonomic 
regulatory neurons in the brainstem found in the NTS and VLM, are key in mediating this critical 
homeostatic feedback loop (137); these are key sites of leptin receptor expression in the rodent 
brainstem (400). Microinjection of leptin in to the NTS of anaesthetized rats attenuates the 
reduction in heart rate associated with increased arterial pressure induced by intravenous 
administration of the α1-adrenergic receptor agonist phenylephrine, indicative of a negative effect 
of leptin on baroreflex sensitivity (15). In contrast, in the same study NTS leptin administration 
failed to impact the compensatory increase in heart rate associated with intravenous sodium 
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nitroprusside-induced decreases in arterial pressure, or acutely impact resting arterial pressure or 
heart rate. Together these data suggest that NTS leptin may specifically modulate the 
parasympathetic arm of the baroreflex (15); however, further data also exist that suggests that 
forebrain and not brainstem sites are important in modulating leptin’s effects on the baroreflex 
(356). In addition to modulating parasympathetic activity, data suggests that administration of 
leptin into the caudal (but not rostral) NTS increases sympathetic nerve activity in the kidney, yet 
not BAT (381) implying regional differences in the actions on leptin on cardiovascular parameters 
within the NTS.  
In addition to the NTS, the RVLM is an important site for regulation of sympathetic nervous 
system control of cardiovascular functions (137). Retrograde tracing studies indicate that leptin 
receptor expressing cells of the RVLM innervate the kidney and microinjection of leptin directly 
into the RVLM increases arterial pressure and renal sympathetic nerve activity in anaesthetized 
rats (34) supporting a role for this brainstem nucleus in mediating the effects of leptin on 
cardiovascular function. 
Leptin receptors utilize a number of different signaling pathways to exert their downstream 
effects. Interestingly, while diet-induced obesity in rodents is associated with an attenuated 
response to the effects of leptin on food intake and sympathetic nerve activity in BAT (indicative 
of leptin resistance) the leptin-induced increase in renal sympathetic nerve activity remains intact 
(470). This suggests that different pathways are responsible for mediating the leptin-mediated 
effects on sympathetic activity to different organs. 
Pharmacological and transgenic technologies have enabled the dissection of the relative 
contribution of different CNS leptin signaling pathways in cardiovascular physiology. Loss of 
endogenous homeostatic modulation of leptin signaling by SOCS3 (which itself inhibits leptin 
signaling) and SHP-2 (which enhances ERK mediated leptin signaling) following genetic mutation 
in Tyrosine985 of leptin receptors in mice   [Lepr
L985
 (l/l) mice] results in animals with elevated 
blood pressure and heart rate compared to littermate controls, without any notable impact on 
body weight (245). Leptin treatment in the l/l mice further elevated their blood pressure, heart rate 
and renal sympathetic activity compared to controls. In contrast, the leptin-induced increase in 
BAT sympathetic nerve activity is attenuated in l/l mice further emphasizing the divergent 
pathways regulating leptin induced control of renal- and BAT-sympathetic nerve activity (245). 
Complementary studies indicate that pharmacological inhibition of CNS ERK1/2 signaling has no 
effect on leptin induced increases in sympathetic activity in the kidney and adrenal gland but 
abolishes the leptin-induced increase in sympathetic activity in BAT (471). Together these studies 
indicate that endogenous negative feedback on the leptin signaling mediated via SOCS3 is 
necessary for normal cardiovascular regulation, while leptin receptor induced activation or 
ERK1/2 signaling is a key pathway regulating BAT but not renal sympathetic nerve activity. 
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Further work in the same area indicates that leptin-induced increases in sympathetic activity in 
the kidney, but not the adrenal gland and BAT, are inhibited by pharmacological CNS blockade of 
PI3K (468, 471), suggesting that this signaling pathway may be more critical in mediating the 
leptin-induced modulation of sympathetic activity which modulates cardiovascular function. 
While less widely studied, in addition to (or likely upstream of) modulation of the autonomic 
nervous system, leptin has also been shown to modulate the activity of neuroendocrine systems 
regulating cardiovascular function (237). The renin-angiotensin system (RAS) has been 
implicated in mediating obesity-associated hypertension (238). Exogenous leptin treatment 
regulates gene expression of key elements of the RAS system in the rodent brain and periphery 
(258, 259). Notably in the CNS, intracerebroventricular administration of leptin increases gene 
expression of angiotensin-receptor 1a (AT1aR) and angiotensin-converting enzyme (ACE) mRNA 
in the SFO and AT1aR mRNA in the ARC (259). Additionally, in the same study it was shown that 
pharmacological inhibition of RAS centrally using intracerebroventricular administration of 
losartan or captopril attenuated leptin induced increases in renal and BAT sympathetic nerve 
activity (259), an effect also seen in AT1aR-deficient mice. Central administration of leptin 
enhances the hypertensive effect of Angiotensin-II treatment, likely through enhancing CNS RAS 
signaling (615), and may represent an underlying mechanism for the enhanced hypertensive 
effect of Angiotensin-II treatment associated with diet-induced obesity in rats (614). 
 
Evidence for a role of leptin in modulating cognitive function 
Obesity is associated with altered cognitive function in both adults and children (for review see 
(543)). Numerous studies have demonstrated a correlative relationship between circulating leptin 
levels and altered cognitive function in humans (69, 263, 335, 553) but this is not consistently the 
case across all studies (431, 553, 560) and causation has yet to be definitively proven. 
The hippocampus is a key site for modulating emotion, learning and memory formation and is 
known to express leptin receptors (398). As discussed earlier in this review, there is evidence for 
changes in hippocampal structure and function in animals with congenital leptin-signaling defects 
(147, 212, 361, 544) providing evidence for a role of leptin in mediating functional hippocampal 
development. However, evidence also indicates a potential role for leptin in enhancing cognition 
via modulation of hippocampal function in animals without congenital leptin-deficiency (287). Both 
in vivo (597) and in vitro experiments (the latter performed in hippocampal slices) showed that 
exogenous leptin induces LTP, likely via glutamatergic [N-methyl-D-aspartate (NMDA)] receptor 
dependent mechanisms (372, 434, 515). Additional modulatory actions of leptin that support a 
role of leptin in modulating hippocampal synaptic plasticity include reversal of evoked LTP (411) 
and induction of long-term depression (LTD) in recording conditions that promote enhanced 
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excitability (165). In vitro, leptin can stimulate filopodial density and motility, and ultimately 
synapse formation in cultured hippocampal neurons (429), providing a mechanistic basis for the 
enhanced LTP seen following leptin administration. At the molecular level, leptin-induced 
dendritic spine formation in the hippocampus appears to require activation of the 
calcium/calmodulin-dependent protein kinase II (CaMKII) signaling cascade and transient 
receptor potential cation (TRPC) channels (147, 434). These molecular and neurophysiologic 
changes are reflected in an ability of peripherally administered leptin to enhance the performance 
of rodents in hippocampal-dependent spatial learning tasks, such as the Morris water maze (434). 
Based on its ability to enhance cognitive function (434) and enhance hippocampal synapse 
formation  in animal models (148, 429, 434), leptin has also been explored as a potential 
therapeutic agent in neurodegenerative diseases such as Alzheimer’s disease (AD) in which loss 
of hippocampal function is a key pathologic feature. In vitro, in neuronal cultures and mouse brain 
extracts, leptin can reduce amyloid-beta (Aβ) secretion (190, 223) and tau-phosphorylation (156, 
222-224), which are believed to play a key role in AD pathogenesis. Functionally, leptin can 
prevent the negative effects of Aβ on LTP in vitro and reduce Aβ-induced neuronal cell death via 
a STAT3 mediated mechanism (156). The functional relevance of these in vitro studies are 
confirmed by in vivo work that demonstrates that chronic exogenous peripheral leptin treatment is 
able to reduce pathologic features and enhance cognitive performance in a transgenic mouse 
model of AD (221, 222). These effects have also been recapitulated in a distinct animal model of 
AD by an independent research team using a viral-gene delivery approach to enhance leptin 
levels directly in the brain (454). In normal rats, chronic intracerebroventricular leptin is able to 
attenuate the impairments in both spatial memory and hippocampal LTP induced by a single 
acute intracerebroventricular injection of Aβ 1-42 peptide (566). These animal studies are 
promising, but further work is needed to determine how these findings may translate to humans. 
 
Adiponectin 
Adiponectin is a 244 amino acid protein secreted by adipose tissue (273) which circulates in 
human plasma at ~1.9-17.0 mg/ml in the form of homomultimers of trimers, hexamers and high 
molecular weight multimers (HMW) (14, 419, 588). The protein has an N-terminal domain 
containing collagen repeats whereas the C-terminal has a globular structure which, when cleaved 
from the mature protein by leukocyte elastase released by monocytes/neutrophils (589), 
produces globular adiponectin (gAd). The gAd has distinct pharmacological properties from the 
HMW (3, 198). Mutations within the gene alter the formation of di-sulfide bonds, which impact the 
ability of adiponectin to form larger HMW. For example, human mutations G90S and G84R 
prevent adiponectin from forming HMW (588) and are associated with diabetes (584). Moreover, 
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adiponectin is also post-translationally modified at a number of leucine residues within the 
globular domain (specifically, residues 68, 71, 80 and 104) and mutation of these residues to 
arginine, prevents hydroxylation and glycosylation, which abrogates the formation of HMW (594). 
Importantly, prevention of lysine modification of adiponectin reduces the ability of adiponectin to 
stimulate AMPK in the liver. Furthermore, treatment of obese db/db mice with non-post-
translationally modifiable adiponectin (at lysine residues 68, 71, 80 and 104) severely diminishes 
the ability of adiponectin to reduce hyperglycemia, hyperlipidemia and insulin resistance, 
suggesting that hydroxylation and glycosylation of adiponectin plays an important role in the 
insulin-sensitizing function of adiponectin (594). Mutations in the gene have also been reported to 
alter adiponectin secretion. A mutation resulting in an isoleucine to threonine change at position 
164 (I164T) alters the secretion of adiponectin from adipocytes and is associated with the 
presence of metabolic syndrome (312).  
Generally, plasma levels of adiponectin are higher in females than males (124, 440) and 
circulating levels are significantly lower in people with type-2 diabetes (T2D) (268) and obesity 
(14), but higher in those with type-1 diabetes (T1D) (379). Adiponectin mRNA expression and 
secretion from mouse 3T3-L1 adipocytes in vitro is downregulated by proinflammatory stimuli 
such as IL-6 and tumor necrosis factor (TNF) α (73, 187) through a mechanism partly dependent 
on intact p42/44 MAPK signaling (187). Adiponectin secretion can be increased following weight 
loss (73), suggesting that changes in adiponectin expression and secretion are sensitive to and 
respond to the inflammatory stimuli associated with diet-induced obesity. Moreover, adiponectin 
expression is enhanced by thiazolidinedione (TZD) treatment, in a peroxisome proliferator-
activated receptor (PPAR) γ2-dependent manner (230, 375) in insulin-resistant humans and 
rodents (375).  
Adiponectin-deficient mice were generated in 2002; heterozygote mice were reported to be mildly 
insulin-resistant, whereas the homozygote knockout animals were moderately insulin resistant 
and glucose intolerant (332, 420), overall, suggesting a critical role for adiponectin in the 
maintenance of glucose homeostasis. The defects in glucose homeostasis in null animals are 
exacerbated by high-fat feeding (420), an effect which may be related to elevated plasma TNFα 
and reduced free fatty acid clearance (374).  Nawrocki et al., (2006) also demonstrated that 
induction of muscle and liver AMPK activity by TZDs was absent in adiponectin null animals, 
indicating that at least in part, the therapeutic benefit of TZDs is dependent on intact adiponectin-
AMPK signaling. This is further strengthened by the observation that pioglitazone-induced 
improvement in hepatic insulin resistance in ob/ob mice is ablated in adiponectin null ob/ob mice 
(331). 
Adiponectin knockout animals are resistant to high-fat diet-induced obesity, primarily mediated by 
increased leptin sensitivity (333). In addition to having alterations in glucose homeostasis, 
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adiponectin-null animals have increased vascular damage following external vascular cuff injury, 
supporting a role for adiponectin in maintaining vascular health (332).  
Adiponectin entry into the brain 
The origin of adiponectin that activates CNS receptors is debated. Adiponectin is found in the 
CSF from humans and mice; however, the CSF:plasma ratio varies between species. For 
example, in mice the CSF concentration of adiponectin is approximately 1-4% of plasma (464) 
whereas in humans, the CSF concentration of adiponectin is lower, at approximately 0.1% of 
plasma (325, 334); although it should be noted that not all studies have detected adiponectin in 
the CSF of humans (535).  
Recent evidence suggests that adiponectin can directly permeate the BBB. In adiponectin null 
animals’ adiponectin was detected in CSF samples taken three hours after injection of trimeric 
adiponectin, indicating that the low molecular weight adiponectin can directly enter into the CNS 
from the circulation (621). 
 
Adiponectin receptors 
Adiponectin has two receptors termed AdipoR1 and AdipoR2, which were cloned in 2003 (588). 
AdipoR1 in humans and mice share 96.8% homology and the AdipoR2 shares 95.2% identity 
(617). While not G-protein coupled, both receptors have 7 transmembrane domains and have 
proteins with predicted molecular masses of 42.4 kDa and 35.4 kDa for mouse AdipoR1 and 
AdipoR2, respectively. AdipoR1 is relatively ubiquitously expressed, with the highest expression 
seen in skeletal muscle, whereas AdipoR2 is most abundantly expressed in mouse liver (617).  
AdipoR1 and R2 can interact with the adaptor protein APPL1 and in neurons adiponectin can 
stimulate a number of signaling pathways (figure 3) including the insulin receptor substrate1/2 
(IRS1/2) pathway leading to increased Akt (serine 473) and ERK (threonine 202/tyrosine 204) 
phosphorylation (128). Adiponectin can also stimulate the JAK2-STAT3 pathway (128), 
increasing tyrosine 705 phosphorylation, which is required for transcriptional activation. The 
adipokine can also activate the AMPK pathway (333), increasing threonine 172 phosphorylation, 
which greatly enhances kinase activity. In some cell types, particularly vascular endothelial cells, 
adiponectin can increase eNOS (serine 1177) phosphorylation via the AMPK pathway (422), 
leading to increased nitric oxide production. This is a neuroprotective pathway and is discussed in 
more detail below. 
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Adiponectin receptors in the CNS 
Within the CNS, both AdipoR1 and AdipoR2 are found in the hypothalamus in post-mortem 
human tissue; although, AdipoR1 is expressed throughout the hypothalamus, whereas AdipoR2 
is restricted to the PVH (325). In mouse, AdipoR1 is found in the cortex, hippocampus, striatum, 
thalamus and hypothalamus (table 4). Within the hypothalamus, AdipoR1 is localized within the 
supraoptic nucleus (SON), PVH and ARC (229). AdipoR2 expression is less widespread, being 
limited to regions of the cortex, hippocampus, amygdala, thalamus and anterior cingulate cortex 
(ACC) (316) (table 5). Within the hypothalamus, AdipoR2-expressing cells are found within the 
anterior hypothalamic area (AHA) and LHA, perifornical region, SON, PVH and ARC. Within the 
mouse hypothalamus, AdipoR1 and AdipoR2 are located on both NPY and POMC neurons (229) 
and on warm-sensitive neurons of the POA, that control the regulation of core body temperature 
(316). 
The expression of both receptor types in the CNS is predominately neuronal although AdipoR1 
and AdipoR2 expression is found on GFAP-positive cells, on ependymal cells and tanycytes 
lining the third ventricle (229). Adiponectin receptors are also expressed within the endothelial 
cells of the BBB (535), suggesting that some of the metabolic effects of adiponectin may be 
mediated by altered signaling in brain microvascular endothelial cells. 
Adiponectin in neurodevelopment and neurogenesis 
High-fat feeding is known to reduce hippocampal neurogenesis in rats (362) and mice (446), with 
neurogenesis within the dentate gyrus being particularly sensitive to alterations in metabolic state. 
Moreover, exercise is a known stimulator of neurogenesis in the dentate gyrus (582). Yau and 
colleagues (2014) investigated whether the exercise-induced changes in hippocampal 
neurogenesis were dependent on intact adiponectin signaling. They found that after running, 
hippocampal levels of adiponectin were significantly elevated, in the absence of any changes in 
AdipoR1, AdipoR2 or the downstream adaptor protein APPL1. Moreover, adiponectin-null 
animals had diminished running-induced hippocampal neurogenesis, in the absence of any 
changes in baseline neurogenesis, suggesting that adiponectin specifically regulates exercise-
induced neural cell proliferation (621). This work was complemented by another study indicating 
that adiponectin application can increase the proliferation of cultured hippocampal neural stem 
cells/progenitors isolated from adult rats. In these cells, adiponectin activated both AMPK and 
p38 MAPK, however, only p38 MAPK signaling was involved in adiponectin-induced proliferation, 
as inhibition of this kinase using SB203580 blocked the effect of adiponectin, whereas inhibition 
of AMPK using compound C was without effect on proliferation (632). 
In addition to neural stem cell proliferation, data suggests that adiponectin may also exert trophic 
effects on neuronal outgrowth. Loss of adiponectin results in decreased dendritic length, reduced 
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branching and spine density in hippocampal dentate gyrus granule neurons, whereas infusion of 
adiponectin increased dendritic spine density (633).  
 
Adiponectin and regulation of food intake 
As described above, AdipoR1 and AdipoR2 are expressed within the hypothalamus. Specifically, 
both receptors are expressed in NPY and POMC neurons within the ARC (229). Intravenous 
administration of adiponectin increases food intake in mice (333) and stimulates the activity of 
hypothalamic AMPK, a known driver to food intake (403). Interestingly, adiponectin-induced 
increases in food intake are dependent on AdipoR1-mediated activation of AMPK. Knockdown of 
AdipoR1 prevents adiponectin-induced increases in hypothalamic AMPK, whereas knockdown of 
AMPK prevents adiponectin-induced increases in food intake (333). Adiponectin-null animals 
have significantly reduced basal AMPK phosphorylation in the hypothalamus, suggesting a 
constitutive role for adiponectin in stimulating hypothalamic AMPK activity. 
In contrast, another study has suggested that adiponectin action in the hypothalamus decreases, 
rather than increases food intake (128). In this study, adiponectin was administered directly into 
the cerebroventricular system in the brain (intracerebroventricular) as opposed to the intravenous 
injection utilized by Kubota and colleagues (333). The central administration study by Coope et al 
(128) went on to demonstrate that adiponectin predominantly utilizes AdipoR1 to alter metabolism 
and that activation of this receptor recapitulated key features of insulin and leptin-induced 
signaling pathways, namely activation of the IRS-Akt-forkhead box protein 01 (FOXO1) pathway 
and the JAK2-STAT3 pathway (128). A 2016 study by Sun et al demonstrated that adiponectin 
and the small molecular AdipoR agonist AdipoRon excited ARC POMC-expressing neurons 
(545). This study also showed that adiponectin could directly inhibit ARC NPY/AgRP neurons via 
the activation of the ATP-sensitive K
+
 channel (KATP). Therefore suggesting that adiponectin could 
inhibit feeding via direct activation of POMC neurons and simultaneous inhibition of NPY/AgRP 
neurons, thus reducing inhibitory synaptic input onto POMC neurons (545). The discrepancies in 
the effect of central compared with peripheral administration of adiponectin on food intake may be 
dependent on ambient glucose concentrations. During fasting, intracerebroventricular injection of 
adiponectin significantly decreases food intake; however, co-injection of glucose with adiponectin 
stimulated food intake (548). This divergence may be explained by differential regulation of ARC 
POMC neurons at differing glucose concentrations. Using ex vivo slice patch clamp experiments 
in POMC-hrGFP mice, application of adiponectin in the presence of high glucose (10 mM) 
induced hyperpolarization of POMC neurons, in an AMPK dependent manner. Whereas, during 
lower glucose (euglycemic; 5 mM), adiponectin depolarized POMC neurons in a PI3K-dependent 
manner. It should also be noted that the study by Sun et al 2016, also noted adiponectin-induced 
depolarization of POMC-expressing neurons, however, further lowering of extracellular glucose 
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over the physiological range (0.5-5 mM) failed to modify the adiponectin response (545). This 
suggests that supraphysiological glucose levels, where AMPK is sufficiently inhibited, may modify 
the adiponectin response. 
Adiponectin may also play a role in treatment-induced changes in body weight in T2D. For 
example, while TZDs are anti-hyperglycemic drugs, they can promote weight gain. One 
mechanism by which this is believed to occur is via the action of TZDs as agonists of PPARγ, 
leading to lipogenesis, fluid retention and increased appetite. TZDs are also known activators of 
AMPK signaling in the periphery (201, 496) and in the brain (466), and recent evidence suggests 
that the TZD pioglitazone (PIO) increases food intake, adiposity, body weight and reduces energy 
expenditure via a mechanism requiring ARC AdipoR1-mediated activation of AMPK (466). 
Following PIO treatment, animals had increased serum levels of adiponectin and, despite weight 
gain observed in PIO-treated animals, hypothalamic leptin and insulin-sensitivity were improved 
as indicated by the restoration of insulin-induced Akt phosphorylation and leptin-induced pSTAT3 
in high-fat fed animals. This improved leptin and insulin sensitivity was also reflected in a 
restoration of leptin and insulin-induced decrease in acute food intake in PIO-treated mice (466).  
 
Adiponectin and thermogenesis 
In addition to impacting energy homeostasis by modulating food intake, recent evidence suggests 
that adiponectin may play a role in modulating energy expenditure/adaptive thermogenesis. Hui 
and colleagues (2015) demonstrated that adiponectin expression is significantly increased in the 
subcutaneous WAT (scWAT) of mice exposed to chronic cold (277). Moreover, this accumulation 
of adiponectin in scWAT was associated with increased browning of WAT, driven by an 
enhancement of anti-inflammatory M2 macrophage accumulation in this tissue. Treatment of 
mature adipocytes with adiponectin increased the expression of uncoupling protein 1 (UCP1), a 
marker of brown adipose tissue, which was blocked by the AMPK inhibitor Compound C. 
Moreover, the accumulation of adiponectin was not dependent on AdipoR1 or AdipoR2, but 
instead the effect was mediated by T-cadherin, which was predominantly expressed on M2 
macrophages (277). Taken together, these data suggest that adiponectin drives browning of 
scWAT.  
Further indirect evidence for a role for adiponectin in regulating thermogenesis comes from the 
study by Kolumam et al (323). This group used an antibody to activate the fibroblast growth factor 
1 (FGF1)/βKlotho complex, which when administered produced a variety of beneficial effects in 
both mice and monkeys, including increased energy expenditure, browning of WAT, weight loss 
and improved glucose and lipid homeostasis. Importantly, the levels of HMW adiponectin were 
significantly increased in animals treated with the FGF1/βKlotho-activating antibody and loss of 
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adiponectin partially reduced the beneficial metabolic effects. The authors propose that the later 
beneficial effects of the antibody are mediated by adiponectin-dependent browning of WAT. In 
this study however, it should be noted that the effect of FGF1/βKlotho antibody on insulin-
sensitization was independent of adiponectin (323).  Further indirect evidence suggests that 
adiponectin may promote thermogenesis as the study by Hou et al (269) determined that 
treatment of mice on a high fat diet with irisin, a myokine released from exercising muscle, 
increased circulating adiponectin and increased markers of browning on WAT, UCP1 and Cidea 
(269). Although this study did not determine whether browning of WAT by irisin required 
adiponectin, but it does suggest that adiponectin may be involved.  A central effect of adiponectin, 
may at least in part, contribute to the regulation of heat production as AdipoR1 and AdipoR2 
expression has been detected on warm-sensitive neurons within the POA of the hypothalamus, 
which is involved in thermoregulation. Moreover, central adiponectin injection into the POA 
increases core body temperature with a concomitant decrease in respiratory exchange ratio 
(RER), indicating increased lipid oxidation (316). This study demonstrated that both AdipoR1 and 
AdipoR2 contributed to heat production as knockout of either receptor blunted the adiponectin-
induced changes in core body temperature. Interestingly, only loss of AdipoR1 altered the 
decrease in RER, suggesting that AdipoR1-expressing POA neurons are involved in regulating 
lipid oxidation/activation of brown adipose tissue, whereas AdipoR2-expressing neurons do not 
(316). 
These studies are in contrast to the study by Qiao and colleagues who demonstrated a 
suppressive role for adiponectin in browning of adipose tissue (465). In this study, adiponectin 
knockout animals displayed a higher core body temperature than wild-type mice suggesting a 
repressive role for adiponectin on browning of adipose tissue during cold exposure. Moreover, 
viral overexpression of adiponectin in wild-type mice suppressed UCP1 expression in brown 
adipose tissue, which occurred without a change in mitochondrial DNA copy number (465). This 
study also demonstrated that adiponectin overexpression reduced β3 adrenergic receptor-
mediated lipolysis and thermogenesis. Clearly, further research is required to determine the role 
of adiponectin in regulating browning of WAT/thermogenesis and under which conditions this 
adipokine may play a positive or negative role in promoting thermogenesis. 
 
Adiponectin and reproduction 
Adiponectin levels increase from birth to adulthood in mice, with the increase larger in female 
than male mice (124). Moreover, during pregnancy the levels of adiponectin decrease from the 
2
nd
 trimester onwards in mice, correlating with the change in circulating prolactin. Direct infusion 
of prolactin in female mice has also been shown to decrease circulating adiponectin levels (124). 
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In humans, adiponectin levels also decline during pregnancy, reaching a nadir during lactation 
(19), moreover, direct application of prolactin to primary cultures of adipocytes decreased 
adiponectin expression and secretion, suggesting that prolactin drives down adiponectin 
expression during lactation to promote the storage of fat.  
Adiponectin and AdipoR2 are expressed in the human placenta, specifically localized to 
cytotrophoblast and syncytiotrophoblast cells (82). Treatment of human placental tissue with gAd 
has been reported to paradoxically increase the release of proinflammatory cytokines IL-1β, IL-6, 
TNFα and prostaglandins E2 and F2α in an ERK1/2 dependent manner (337). Moreover, the 
adiponectin expressed in human placenta is secreted and can stimulate ERK1/2 and p38 MAPK 
signaling when conditioned media from human placental tissue is added to HEK292 cells 
expressing AdipoR1 (102). The placental expression of adiponectin is decreased in gestational 
diabetes (102), correlating with the decreased circulating levels seen in women with gestational 
diabetes (481, 605).  The decreased placental production of adiponectin is likely driven by 
proinflammatory cytokines directly, as application of TNFα, interferon (IFN)-γ and IL-6 all acutely 
decrease adiponectin secretion from this tissue (102). 
In mice, transgenic overexpression of adiponectin produces female mice that are infertile (125). 
Moreover, women with T1D are subfertile compared to the general population (295) and have 
been shown to have higher circulating adiponectin levels (379), including throughout the 
gestational period (474). Importantly, the pituitary gland expresses adiponectin and both AdipoR1 
and AdipoR2 (462), specifically within the growth hormone (GH), FSH-, LH- and TSH-producing 
cells. Using LβT2 pituitary gonadotropic cells, Lu and colleagues demonstrated a functional role 
for adiponectin in regulating LH secretion. This study showed that LβT2 cells expressed both 
AdipoR1 and AdipoR2 and treatment with adiponectin led to increased AMPK activation, which 
was accompanied by decreased LH secretion (which could be mimicked by pharmacological or 
genetic activation of AMPK). This indicates that the suppression of LH is directly mediated 
through activation of the AMPK pathway (370). 
There is also evidence to suggest that adiponectin may influence the hypothalamic-pituitary-
gonadal (HPG) axis at the level of the hypothalamus. Adiponectin has been reported to inhibit 
GnRH release from cultured hypothalamic GT1-7 cells and in primary mouse hypothalamic 
cultures in an AMPK-dependent manner (107, 320, 601).  As described in the section on leptin 
and reproduction above, kisspeptin is the peptide hormone encoded by the Kiss1 gene 
responsible for initiating GnRH release at puberty. Adiponectin inhibits Kiss1 mRNA production in 
GT1-7 cells, also via an AMPK-dependent pathway (600). Together, these data suggest that 
increased adiponectin levels associated with starvation/negative energy balance, decrease 
fertility and puberty via a mechanism involving the suppression of GnRH and LH secretion in the 
Page 40 of 119Comprehensive Physiology
  41 
hypothalamus and pituitary, respectively. Indeed, increased adiponectin levels may explain 
reduced fertility and the delayed onset of puberty seen in T1D (364). 
 
Bone, energy homeostasis and adiponectin 
Osteoblasts and osteoclasts are bone-specific cells that have recently been described as playing 
a role in maintenance of energy metabolism. Interestingly, mice genetically engineered with loss 
of osteotesticular protein tyrosine phosphatase (OST-PTP) specifically in osteoblasts are lean, 
protected from high fat diet-induced obesity and are hypoglycemic (347). This is mediated by 
hyperinsulinemia due to increased β-cell proliferation combined with increase insulin sensitivity. 
These animals also display specific hyperadiponectinemia without changes in other circulating 
adipokines (347). Moreover, co-culture osteoblasts with adipocytes, increased adiponectin 
expression and loss of OST-PTP further enhanced adiponectin expression, suggesting that a 
molecule secreted from osteoblasts mediated this response. Furthermore, the 
hyperinsulinemic/hypoglycemic phenotype of OST-PTP deficient mice could be rescued by 
deletion of a single copy of osteocalcin, a molecule specifically secreted from osteoblasts, 
suggesting that osteocalcin directly regulates adiponectin production and β-cell proliferation 
(347). Interestingly, the link between bone and adiponectin levels may be reciprocal since 
adiponectin knockout mice have a higher than normal bone density at 6 weeks of age, whereas 
adiponectin-overexpressing mice have decreased bone mass (297). However, older adiponectin 
knockout mice develop low bone mass mediated by decreased proliferation of osteoblasts. This 
led Kajimura and colleagues to speculate that perhaps loss of adiponectin at older ages led to 
increased sympathetic nervous system activation, which is a stimulator of bone reabsorption 
(173).  This group partially reduced sympathetic tone by removing one copy of dopamine β-
hydroxylase (an enzyme involved in catecholamine synthesis), in mice and crossed these with 
adiponectin-null mice. The resulting offspring showed maintained bone mass at later stages of 
life, mediated by increased osteoblast proliferation and increased bone mass (297). Taken 
together, these studies suggest a complex interplay between the peripheral and central effects of 
adiponectin on bone formation and metabolism.  
 
Adiponectin and mood disorders 
Adiponectin has been proposed to have anti-depressive/anxiolytic actions in the CNS. For 
example, correlative data indicates that plasma adiponectin levels are decreased in patients with 
major depressive disorder (350, 354) and bipolar depression (280), independently of effects on 
body weight. A potential mechanism of action of the anti-depressive effects of adiponectin is via 
an anti-inflammatory action. For example, direct injection of adiponectin into the CNS decreases 
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pro-inflammatory cytokine expression in microglia from chronically stressed mice (95). 
Furthermore, the ability of environmental enrichment to reduce stress and the elevations in CNS 
proinflammatory cytokines (IL-1β, IL-6 and TNFα) in the hippocampus and hypothalamus 
associated with the chronic administration of corticosterone in mice is lost in adiponectin-null mice 
(95). Together these data suggests that adiponectin signaling may modulate microglial activation 
and neuroinflammation in the CNS, which in turn could influence behavior.  
Patients with schizophrenia treated with antipsychotic drugs have been reported to present with 
low serum adiponectin, due to increased adiposity driven by the drug treatment (318, 319). 
Moreover, the alteration in adiponectin levels is drug specific. In humans, a prospective study 
found that plasma adiponectin levels were decreased in schizophrenic patients treated with 
olanzapine, but not those taking risperidone. Although both patient groups gained weight, the 
decreased adiponectin levels seen in the olanzapine group were associated with the most 
pronounced weight gain; however, the olanzapine-associated decrease in adiponectin levels 
were still significant after adjusting for BMI. Recent data suggests that individuals taking 
clozapine and olanzapine have significantly lower plasma adiponectin that those taking 
risperidone (36) and that low serum adiponectin levels in male patients is a specific marker for 
weight gain on clozapine treatment (319).   These metabolic side-effects of second generation 
anti-psychotics have a significant impact of patient welfare, leading to emotional issues related to 
weight gain and in some cases poor compliance with the treatment (576). 
 
CNS mediated effects of adiponectin on cardiovascular physiology 
A major component of the metabolic syndrome is the increased risk of cardiovascular disease, 
predominately driven by hypertension. Several studies have explored the links between low 
adiponectin levels and hypertension (2, 289, 304). The current data suggests that lower 
adiponectin levels correlate with higher blood pressure in both men and women (2, 304). A 
potential role for adiponectin in modulating cardiovascular physiology is further supported by 
studies which indicate that polymorphisms in adiponectin itself may underlie blood pressure 
responses to dietary salt intake. Single nucleotide polymorphisms (SNPs) at rs16861205 and 
rs822394 in the adiponectin gene were associated with diastolic blood pressure (DBP) response 
to low salt loading, with the latter SNP also being associated with mean arterial pressure in the 
Chinese Han population (115). These same SNPs were also associated with the DBP response 
to high salt loading. 
With the CNS the brainstem is an important integratory site for cardiovascular and autonomic 
sensory afferents, specifically the NTS, which is involved in the baroreceptor reflex which 
maintains blood pressure homeostasis. Neurons in the NTS express both the AdipoR1 and 
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AdipoR2 and infusion of adiponectin directly into the NTS in rodents has been reported to 
decrease blood pressure (270). This is mediated by modulation of the electrical activity of NTS 
neurons, with the majority of NTS neurons being excited by adiponectin and a proportion being 
inhibited. In single cell RT-PCR analysis, the majority of the cells depolarized by adiponectin were 
found to be NPY- and glutamic acid decarboxylase 67 (GAD67)-positive, suggesting that 
adiponectin acts on the AdipoR1 to depolarize NPY-containing neurons, thereby increasing 
GABAergic neurotransmission (270). 
An independent study also demonstrated that the electrical activity of neurons within the AP, 
which project to the NTS, are regulated by adiponectin. Neurons within the AP express both 
AdipoR1 and AdipoR2, and stratifying neuronal responses based on AdipoR expression, 
indicating that only the neurons which expressed both AdipoR1 and AdipoR2 tended to be 
electrically altered by adiponectin. In contrast to the work in the NTS (270), this study, 
demonstrated that adiponectin injection directly into the AP increased, rather than decreased, 
blood pressure (200). This suggests that the downstream regulation of blood pressure may 
require the integration of signals from a number of different brain nuclei and further work remains 
to be done to elucidate the CNS mediated effects of adiponectin signaling on cardiovascular 
physiology. 
 
Neuroprotective actions of adiponectin  
Adiponectin may play a role in protecting neurons during ischemic stroke. Recent data suggests 
that polymorphisms in both AdipoR1 and AdipoR1 are associated with an increased risk of 
ischemic stroke in a Chinese population (241, 626). This is supported by animal studies indicating 
that adiponectin-null animals have a larger infarct area following medial cerebral artery occlusion 
(MCAO) injury (an experimental model of ischemic stroke) compared to wild-type animals (422). 
This study also showed that adiponectin protein was localized to the endothelial compartment 
during transient ischemia, suggesting that adiponectin can accumulate at the site of injury, 
possibly entering via areas where the BBB is damaged. Moreover, administration of adiponectin 
using a viral approach could reduce infarct size in both wild type and adiponectin-null animals, an 
effect that was associated with the increased phosphorylation of endothelial nitric oxide synthase 
(eNOS). In this study, adiponectin-null mice also displayed reduced cerebral blood flow 
suggesting that adiponectin-induced activation of eNOS increases perfusion to reduce neuronal 
damage/death (422). A more recent study found that obesity caused by a Western diet (known to 
reduce circulating plasma adiponectin levels) in rats, increased MCAO injury and symptom 
scores of neurological deficits (610). The cellular damage in the hippocampus, striatum and 
frontal cortex and the neurological deficits could be partially rescued by viral transfer of 
adiponectin (610). 
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In sepsis, endothelial dysfunction is a major factor in organ damage, including damage to the 
brain. Sepsis increases platelet and leukocyte-adhesion in the cerebral microcirculation and this 
is augmented by the loss of adiponectin. These effects were accompanied by increased BBB 
dysfunction in these mice (578). Moreover, in obese mice, sepsis induced neuroinflammation, 
microvascular dysfunction and brain function are impacted more severely than reported in lean 
animals. Given that obesity is associated with lower adiponectin levels and the evidence 
suggesting obese individuals have an increased mortality during sepsis, it is plausible that the 
increased sepsis-associated mortality as seen in obesity may in part, be due to 
hypoadiponectinemia. 
Further evidence for a potential neuroprotective effect of adiponectin comes from animal models 
of epilepsy. In an experimental model of kainic acid (KA)-induced seizure activity, serum 
adiponectin levels decreased following KA treatment. This was accompanied by an increase in 
AdipoR1 expression in the hippocampus, without altering AdipoR2 expression (294). KA also 
significantly increased markers of cell death including TUNEL and caspase-3, which were all 
significantly reduced by pre-treatment with adiponectin for 24 hours (294). This study also 
demonstrated that KA-induced neuroinflammation (as measured by NFκB immunoreactivity) was 
also diminished by adiponectin, further demonstrating an anti-inflammatory role of adiponectin. 
Adiponectin also protects against glutamate-induced excitotoxicity in hippocampal neurons. For 
example, exposure of mouse hippocampal HT22 neurons to glutamate increases cleavage 
caspase-3, Bax/Bcl2 ratio and TUNEL staining, which is reversed by adiponectin treatment. This 
occurs by rescue of glutamate-induced decreases in SIRT1 and PGC1α (627). 
 
Adiponectin and neurodegeneration 
Obesity and diabetes are linked with increased risk for developing dementia (406), including AD 
(351, 371), with people with diabetes having an odds ratio of approximately 1.6 for risk of 
developing dementia. As mentioned above, adiponectin levels are decreased in obesity and 
diabetes and similarly, adiponectin levels have been reported as decreased in elderly people with 
mild cognitive impairment (MCI) and AD when compared to cognitively healthy age-matched 
controls (558). Moreover, in patients with T2D, those with MCI have significantly lower 
adiponectin compared to control individuals (T2D without MCI) (220). As mentioned above in AD, 
a key hallmark is the presence of Aβ-plaques. In a cell based study, adiponectin can protect 
against Aβ-induced cytotoxicity during H2O2-induced oxidative stress (96). Furthermore, osmotin, 
which is a plant-based protein homolog of adiponectin, can improve neurological deficits in a 
mouse and cell model of AD (514). Treatment of Aβ-overproducing SH-SY5Y cells with osmotin 
reduced Aβ production via a mechanism requiring activation of AdipoR1, AMPK, SIRT1 and 
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inhibition of sterol-regulatory element binding protein 2 (SREBP2). The activation of AMPK and 
increased SIRT1 expression following osmotin treatment was also observed in mice with mutant 
amyloid precursor protein/presenilin 1 (APP/PS1) and this correlated with the improved 
performance in hippocampal-dependent memory tests (Morris Water Maze and Y-maze tests) 
(514). 
However, not all studies have found an association between circulating adiponectin levels and 
dementia. For example, in a Japanese population, Kitagawa and colleagues demonstrated that 
serum HMW adiponectin was not changed in patients with AD, vascular dementia (VAD) or other 
types of dementia (314). Similarly, Dukic and colleagues found no association between circulating 
adiponectin levels and AD, VAD or MCI (161). Conversely, two studies have identified positive 
correlations between adiponectin levels and MCI (306, 575).  Clearly the relationship between 
circulating/CSF adiponectin and dementia is complex. This is likely complicated by changes in 
appetite and weight with dementia progression, caused by eating disturbances and altered 
appetitive and swallowing capabilities (296). Indeed, weight-loss per se has been reported to 
increase circulating adiponectin levels (63, 329, 620). 
 
Adiponectin and glia 
Little is known about the role of adiponectin in regulating the function of glial cells within the brain. 
However, both AdipoR1 and AdiporR2 are present on human U373 astrocytoma cells and 
cultured human primary astrocytes (590). Furthermore, AdipoR1 is present on GFAP-positive 
cells within the rat ARC (229), suggesting that adiponectin may play a role in regulating glial cell 
function. In vitro data from human astrocyte cells has shown adiponectin to have a potential 
proinflammatory role, increasing the mRNA expression of IL-6, MCP-1, IL-1β and IL-8 and also 
increasing the secretion of IL-6 and MCP-1 (590). However, another study demonstrated that 
adiponectin injection into the brain promoted an anti-inflammatory phenotype in microglia and 
brain macrophages in a mouse model of depression (induced by chronic corticosterone 
administration) (95). It is not clear whether this anti-inflammatory effect is direct on the microglial 
cells, or by changes in astrocyte-microglia or neuron-microglial signals. Moreover, there is 
currently no data indicating that microglia or oligodendrocytes express adiponectin receptors. 
However, adiponectin-null mice treated with KA in order to induce seizes display microglial 
hypertrophy and clustering in the hippocampus, providing evidence of excessive gliosis, 
compared to wild-type mice (344). The potential role for adiponectin signaling in glial cell 
functions requires further study. 
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Other adipokines 
Excluding leptin and adiponectin, numerous adipokines have been identified that have been 
shown in experimental studies to exert physiologic actions via the CNS. One limitation of many of 
these studies is that some of these “adipokines” have themselves subsequently been found to be 
expressed in the CNS, making it challenging to differentiate the CNS-mediated effects of the 
peripherally-derived protein compared with those of the protein found in the brain. While this does 
not necessarily indicate that when these are proteins secreted from adipocytes they do not exert 
CNS-mediated effects which are functionally relevant, it does however complicate our 
understanding of the underlying mechanisms. Furthermore, while some adipokines have been 
shown to have physiological effects when injected directly into the CNS, evidence for their 
transport across the BBB may not have been conclusively proven making the physiological 
significance of some of the findings unclear; at least under non-pathologic conditions when the 
BBB is fully intact and functioning normally. 
In the following sections we will encounter some of these issues as we review the literature 
around the CNS targets of some other adipokines that have been shown to have CNS-mediated 
effects on physiology. Much of this section will be focused on the CNS-mediated effects of these 
other adipokines on glucose and energy homeostasis, as this has been the main focus of much of 
the published work; however, other important physiological and pathological are also likely to be 
regulated by these proteins. 
 
Resistin 
Resistin, so-called due to its ability to induce insulin resistance, is a 12.5 kDa cysteine-rich 
polypeptide hormone (of the resistin-like molecule family) which was discovered as part of a study 
to identify adipose-derived factors that are regulated by TZD anti-diabetic drugs (540). Resistin is 
synthesized (during adipogenesis) and secreted from white adipocytes in rodents (540); however, 
in humans monocytes and macrophages are believed to be the main source (448, 503), 
highlighting important species differences. Elevated levels of resistin are reported in diet-induced 
and genetically obese mice (540) with insulin and glucose both proposed to mediate the 
nutritional regulation of resistin mRNA in WAT and circulating serum levels in rodents (473). In 
obese humans, resistin serum levels display a positive correlation with alterations in BMI, body 
fat, circulating insulin and mean glucose amongst others (21, 473). However, it should be stated 
that a minority of studies have failed to identify a relationship between resistin and known 
markers of insulin resistance in humans and as such it remains controversial (291, 346, 577). Of 
interest, in rodents resistin mRNA has also been detected in BAT, pancreatic β-cells, skeletal 
muscle tissue, kidney (424) and brain (47, 602). 
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CNS-mediated effects of resistin on glucose and energy homeostasis 
Resistin is hypothesized to play a role in obesity-induced insulin resistance and T2D (119, 519) 
as immunoneutralization of endogenous resistin in vivo enhances insulin-stimulated glucose 
uptake and improves insulin sensitivity in high-fat diet-induced obese mice (540). In contrast, in 
lean mice, intraperitoneal administration of recombinant resistin results in glucose intolerance and 
insulin resistance (540). These findings are further supported by work in mice  indicating that 
genetic deletion of resistin in both wild-type and leptin-deficient ob/ob animals improves glucose 
homeostasis (463), while transgenic overexpression of resistin in adipose tissue induces insulin-
resistance (445). 
How resistin mediates obesity-induced insulin resistance is not well understood, in part due to the 
fact that the target receptor has not yet been identified (22, 113). However, evidence suggests 
that central administration of leptin is sufficient to decrease WAT resistin mRNA levels and 
improve insulin sensitivity in ob/ob mice (20) providing a potential functional link between the two 
adipokines. Resistin-associated impairment in insulin sensitivity occurs primarily in the liver via 
modulation of hepatic gluconeogenesis (26, 472). Evidence suggests that this effect of may be 
mediated, at least in part, via the CNS. Hepatic insulin resistance can be induced by acute central 
infusion of resistin and is linked to glycogenolysis, and induction of cytokine and SOCS3 
expression in the liver. These effects are thought to be mediated via the hypothalamus and 
depend on intact NPY Y1 signaling (414, 523). In rodents, chronic central infusion of resistin 
promotes inflammation and insulin resistance through hypothalamic TLR4 signal transduction in 
vivo, leading to activation of JNK and p38/MAPK signaling pathways, which upregulates IL-6, 
SOCS3 and PTP1B (47). This finding indicates that inflammation is a key mechanistic event 
mediating resistin-induced insulin resistance. Evidence also suggests that chronic central infusion 
of resistin is sufficient to down impair adiponectin and fibroblast growth factor 21 (FGF21) 
signaling in the brain and periphery but this appears to be secondary to the inflammatory effects 
on chronic central infusion of resistin as the effect is lost following inhibition of TL4R signaling 
(46). 
In addition to having an effect on glucose homeostasis, evidence exists for an effect of centrally 
administered resistin on energy homeostasis in rodents. Intracerebroventricular administration of 
10µg resistin acutely suppresses fasting-induced and typical day-time food intake in fed rats (567, 
585). In this study, intracerebroventricular resistin was found to induce c-FOS and SOCS3 in the 
ARC suggesting a hypothalamic site of action. Indeed, centrally administered resistin prevents 
fasting-induced increases in orexigenic AgRP and NPY mRNA expression, whilst also decreasing 
anorexigenic CART mRNA expression in the ARC (585). Interestingly, chronic 
intracerebroventricular infusion of resistin into diabetic rats (that had undergone pancreatectomy) 
has little effect on food intake or body weight; however, resistin is able to attenuate the effects of 
Page 47 of 119 Comprehensive Physiology
  48 
leptin on these parameters when the two were co-infused providing further evidence supporting a 
potential functional interaction between the two peptides (447). Central administration of resistin 
has also been shown to impact energy expenditure via modulation of sympathetic nerve activity: 
increasing skeletal muscle (lumbar) and decreasing brown adipose tissue sympathetic nerve 
activity (as first demonstrated in rats) potentially implicating resistin, via its effects on sympathetic 
nerve activity, in metabolic dysfunction seen in obesity and diabetes (328). 
  
Other CNS-mediated effects of resistin on physiology 
In addition to impacting glucose and energy homeostasis, other CNS-mediated effects of resistin 
have also been reported in animal models. These include a role for resistin in regulating pituitary 
somatotrope cell functions (487), and obesity-induced hypertension, as central resistin was found 
to enhance renal sympathetic nerve activity (327); thus, impacting salt and water balance (22).  
Intriguingly, in contrast to mice, in human-derived adipocytes resistin is barely detectable, with 
mRNA levels actually reported to be higher in monocytes and macrophages (448, 503). Of note, 
high concentrations of leptin and insulin upregulate resistin mRNA and protein secretion in 
human-derived peripheral blood monocyte-enriched mononuclear cells in vitro (574). In human 
obesity, the main source of resistin appears to originate from infiltrating macrophages found in 
visceral WAT (132). Indeed, a role for resistin in inflammation in immune cells has been 
proposed, as resistin stimulates proinflammatory TNFα and IL-6 expression in human blood 
monocyte-enriched mononuclear cells and in both human and mouse macrophages, the latter via 
NFκB signaling (58, 521, 574). 
Resistin has also been implicated in the pathology of a number of conditions characterized by 
inflammation. For example, people suffering from acute inflammatory disease display higher 
serum resistin levels (538) and others have suggested a pathological role of resistin in traumatic 
brain injury (72). Resistin could also potentially be an etiological factor in cardiovascular disease 
(78, 479), as exogenous resistin has been demonstrated to activate vascular endothelial cells 
(586) and promote the proliferation of smooth muscle cells (81). 
 
Challenges in understanding the biology of resistin 
Overall, our current understanding of the role of resistin in glucose homeostasis, inflammation 
and vascular disease is complicated by several findings: 1) resistin mRNA levels do not always 
complement the changes observed in serum resistin levels in models of obesity/T2D; 2) the 
expression of resistin appears to be differentially regulated both between species (humans vs. 
rodents) and within tissues (with respect to distribution profiles) (448, 503, 540), and 3) the 
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receptor mediating the physiological effects of resistin remains to be determined. Studies on 
resistin demonstrate its ability to activate a variety of signaling cascades; thus, it may potentially 
interact with one than one receptor, depending on target tissue and cell type (47, 81, 326, 327, 
487). 
Resistin mRNA is detected in rodent brain, in hypothalamic nuclei such as the ARC, which could 
be a site of endogenous resistin production (47, 602). In humans resistin has been detected in 
CSF (325), which may originate from within the brain or from peripheral resistin crossing the 
through the BBB. The finding of a CNS source of resistin means that many of the CNS-mediated 
effects of resistin described above could be as a result of the centrally-derived and not WAT-
derived peptide pool. This further complicates our current understanding of the physiological role 
of this adipokine. Further studies examining the effect of selective loss of CNS compared with 
peripheral resistin pools could help elucidate this.  
 
Apelin 
The peptide apelin is an endogenous ligand of the class A G protein-coupled APJ receptor (556), 
which is reported to share most homology (~30-40%) with the angiotensin II receptor (428). 
Apelin and the APJ receptor are widely expressed both in the periphery and CNS in humans and 
rodents (342, 392, 394, 461), including in adipocytes (62).  Apelin is obtained from a 77 amino 
acid preproprotein (preproapelin), enzymatically cleaved to produce bio-active endogenous C-
terminal fragments including, apelin-13 (and its pyroglutamylated form, pGlu-apelin-13), apelin-
17, apelin-36 and “synthetic” apelin-12 (141, 172, 231). The species-specific distribution of long 
(apelin-36) and short (for example, apelin-13) forms of apelin has been shown to vary in different 
tissues ((303), for review see (457)). Recently, another endogenous peptide, Toddler/ELABELA, 
was also found to activate the APJ receptor and was shown to be important for embryonic 
development in zebrafish (112, 451). Collectively, apelin-APJ signaling is relatively diverse, as 
various molecular forms of apelin can bind to and activate APJ receptors, recruiting different G 
proteins associated with a variety of intracellular cascades in a tissue- and cell-specific manner 
(427). Masri et al., (386) have demonstrated that the APJ receptor is differentially desensitized as 
a result of preferential G-protein coupling by apelin fragments. 
 
CNS-mediated physiologic effects of apelin on energy homeostasis 
Due to the widespread mRNA expression of mammalian apelin and the APJ receptor, associated 
functional effects have been demonstrated in the periphery and CNS (88). In 2005, apelin was 
identified as an adipokine, shown to be expressed and secreted from human and mouse cultured 
adipocytes, with increased expression seen during adipocyte differentiation (62). Nutritional 
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status exerts an important influence on apelin expression in adipocytes, with fasting resulting in a 
strong inhibition, whilst refeeding reversed this effect in vivo; in fact, apelin expression is directly 
regulated by insulin through PI3K, protein kinase C (PKC) and MAPK stimulation, with elevated 
apelin plasma levels and increased apelin mRNA expression reported in adipocytes from obese 
hyperinsulinemic mice (62). Importantly, upregulation of  adipocyte apelin levels in obesity is only 
seen when the obesity is associated with hyperinsulinemia, indicative of insulin, rather than 
obesity per se, being a potent regulator of apelin expression (62, 92). Of interest, TNFα has also 
been shown to induce the expression of apelin in adipose tissue via PI3K, JNK and MAPK1/2 
signaling (138). Overall, apelin appears to exert a direct anti-diabetic effect, playing an important 
role in glucose homeostasis (91, 97). In humans, elevated levels of plasma apelin were reported 
in morbidly obese and/or in type 2 diabetic subjects (253, 360), although not all studies report a 
positive correlation between circulating levels of apelin and BMI, highlighting once more that 
obesity alone does not determine circulating apelin levels (51, 91). More recently, it was shown 
that the intracerebroventricular injection of a high dose of pGlu-apelin-13 was capable of 
controlling hepatic glucose metabolism via activation of the sympathetic nervous system, the 
effect of which was dependent on the elevated production of hypothalamic reactive oxygen 
species (ROS) by apelin (158). Importantly, these authors concluded that increased levels of 
central apelin in obese/diabetic mice appears to actually contribute to a type 2 diabetic state, as 
chronic blockade of central apelin with the APJ receptor antagonist F13A, resulted in an 
improvement in the regulation of glucose homeostasis during the diabetic state in high-fat fed 
mice.  
A controversial role of apelin and the APJ receptor in the central regulation of food intake exists. 
The intracerebroventricular administration of pGlu-apelin-13 in fed rats was shown to have no 
effect on food intake, with a significant increase in food intake seen during the subjective day in 
fasted rats only at the highest dose tested (551). In another study, it was reported that 
intravenous injection of apelin-13 did not alter food intake in fed or fasted rats; however, a 
decrease in food intake was shown after intracerebroventricular infusion of apelin-13 in fed and 
fasted rats (546). In addition, the central administration of apelin-12 was found to reduce food 
intake during the subjective night period in rats (2-4 hours post-infusion) and actually stimulated 
feeding in fed rats during the subjective day, but only at the highest dose and only in some rats 
(430). Thus, the effectiveness of apelin may depend on the level of satiety of the animal, the time 
of day, the dose and route of administration, and the apelin form used. The link between body 
weight and responsiveness to apelin was explored by Clark et al., (116), who showed that 
intracerebroventricular infusion of apelin-13 (at the end of the subjective day) decreased food 
intake in diet-induced obese rats fed a control diet, but this effect was absent in diet-induced 
obese rats fed a high-fat diet. This insensitivity to apelin was associated with the downregulated 
mRNA expression of hypothalamic APJ receptors by apelin in specifically the diet-induced obese 
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rats fed a high-fat diet. Of interest, the chronic (10 day) infusion of apelin-13 into the third 
ventricle in mice resulted in an increase in several parameters measured, including food intake 
and body weight (these effects were indistinguishable from saline-treated controls after day 8), 
with secondary effects noted such as increased locomotor activity, especially during the animal’s 
active phase, which was accompanied by an increase in body temperature during this period 
(580). Higuchi et al., (255) demonstrated that chronic (14 day) intraperitoneal injection of apelin-
13 in normal and high-fat fed mice resulted in a decrease in weight of white adipose tissue, with 
no apparent effect on food intake. This apelin-induced decrease in body adiposity was proposed 
to be mediated by an increase in energy expenditure, as apelin treatment was associated with the 
increased mRNA and protein expression of UCP1 and UCP3 in brown adipose tissue and 
skeletal muscle respectively (255). Furthermore, it is hard to exclude central regulation of energy 
expenditure by apelin as brain areas, such as the hypothalamus and sympathetic nerve activity 
are known to regulate UCP1 in brown adipose tissue (25, 504). Indeed, recent evidence has 
implicated apelin-APJ signaling in the enhancement of brown adipogenesis and adipose tissue 
browning, involving PI3K/Akt and AMPK signaling and relief from the known inhibitory effects of 
TNFα on brown adipogenesis (562). The recent report by Drougard et al., (159) showed that 
chronic intracerebroventricular injection of a high dose of apelin-13 in normal mice was enough to 
induce the hypothalamic upregulation of proinflammatory markers, in accordance with the 
previously reported effect of apelin in vitro, in microglial BV2 cells (103). In addition, this treatment 
in mice was associated with no change in either body weight or food intake, yet a decrease in 
thermogenic capacity and energy expenditure was reported and found to be associated with the 
decreased mRNA expression of peroxisome proliferator-activated receptor 1 alpha (PGC1α), PR 
domain containing 16 (Prdm16) and UCP1 in brown adipose tissue (159). These latter findings 
are suggestive of decreased mitochondrial biogenesis and attenuated activity and function of 
brown adipose tissue. Of note, the application of apelin-13 in hypothalamic slices was found to 
stimulate hypothalamic POMC-positive neurons in vitro (159), Intriguingly, within the arcuate 
nucleus of the hypothalamus, ~90% of apelin-positive neurons appear to be POMC-positive, with 
APJ receptors found to be expressed in ~50% of POMC-positive neurons (477). In line with these 
findings, Lee et al., (343) previously demonstrated that the application of apelin-13 in 
hypothalamic slices containing the arcuate nucleus enhanced the intrinsic excitability of identified 
POMC-EGFP neurons through Gβγ activation of phospholipase C (PLC) -β signaling and 
inhibition of M-currents via the downstream inactivation of KCNQ channels. It is interesting that 
Drougard et al., (159) saw no effect of apelin on food intake, yet also reported an enhancement of 
POMC activity by apelin. Such findings highlight the proposed functional heterogeneity of 
hypothalamic POMC neurons, with distinct subpopulations responsible for different aspects 
related to the regulation of food intake and energy metabolism (531). 
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Apelin and cognitive function 
A role for apelin-13 in anxiety (559) and cognition has recently been addressed. With respect to 
cognition, post-training intracerebroventricular infusion of apelin-13 in mice trained in the novel 
object recognition memory task was shown to induce impairments in both the formation of short-
term memory and consolidation of long-term memory, with no apparent impairment seen in 
acquisition of the memory per se (242). Such findings are in line with the known expression of 
apelin and the APJ receptor in brain regions associated with learning and memory processing 
(394). However, apelin and the APJ receptor are also expressed in brain areas related to the 
stress response (427). Indeed, apelin plays a role in the regulation of the hypothalamic-pituitary-
adrenal (HPA) axis, as central administration of pGlu-apelin-13 increased plasma 
adrenocorticotropic hormone (ACTH) and corticosterone levels, with findings from hypothalamic 
extracts demonstrating that this effect of apelin could be mediated through apelin stimulated 
release of arginine vasopressin (AVP) and corticotrophin releasing hormone (CRH) (551). 
Furthermore, the recent report by Li et al., (358) demonstrated that in stressed rats which 
displayed depressive-like and cognitive impairments, the repeated intracerebroventricular infusion 
of apelin-13 resulted in an anti-depressant-like phenotype, as evaluated in the forced swim and 
learned helplessness tests. In addition to this, apelin-13 was able to reverse the memory 
impairment seen in the novel object recognition test in stressed rats, the mechanism of which 
involved PI3K and MAPK1/2 activation. Thus, apelin-APJ signaling may prove to be a useful 
target for the treatment of depression.    
 
Other CNS mediated effects of apelin 
Functionally, apelin has been shown to be important in cardiovascular functions, regulating both 
blood pressure and vascular tone via nitric oxide signaling (292, 342, 557) and it also displays 
angiogenic properties (298). A pathophysiological role of apelin-APJ signaling has been 
described in human cardiovascular disease (458); however, neuroprotective effects of apelin-APJ 
have also been described in a model of ischemic/reperfusion injury in rats (631). In line with this, 
in the CNS, the intracerebroventricular infusion of apelin-13 was found to be neuroprotective 
suppressing neuroinflammation in an experimental rat model of ischemic stroke (612). In addition, 
apelin has been shown to play a role in the central control of body fluid homeostasis, involving 
modulation of AVP release by apelin at the level of the hypothalamus (141, 478, 485).  
 
Does adipocyte-derived apelin exert physiological effects via the CNS? 
Although, peripheral administration of apelin-12 increased c-FOS immunoreactivity in a number of 
brain areas including the PVH, LHA, LPB, NTS and DMX (552), it should, however, be noted that 
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apelin transport across the BBB has not as of yet been conclusively demonstrated (619). As 
such, it is unclear whether adipocyte-derived apelin exerts any CNS mediated effects on 
physiological processes, particularly in the context of obesity /hyperinsulinemia when adipose 
tissue levels are elevated (62).  Further study examining the relative impact of CNS compared 




Visfatin, a 52 kDa protein, first identified as an adipokine in 2005 was shown to be predominately 
produced and secreted by human and mouse abdominal visceral fat, with plasma levels positively 
correlating with both the amount of visceral (but not subcutaneous) fat in humans and the 
development of obesity in mice (204). Visfatin was found to correspond to pre-B-cell colony-
enhancing factor (PBEF) (204), a protein with cytokine activity mainly expressed in lymphocytes 
and other cells found in human bone marrow, muscle and liver (499), also recognized for its 
nicotinamide phosphoribosyltransferase (NAMPT) activity (488). For clarity, visfatin, PBEF and 
NAMPT are acknowledged as the same protein (135, 276, 532). Visfatin/NAMPT exists in 2 forms 
in mammals: the intracellular form which is accepted to have nicotinamide adenine dinucleotide 
(NAD
+
) biosynthetic enzyme function in cellular redox reactions, and an extracellular form the 
function of which remains controversial, with various attributed roles including as an insulin-
mimetic adipokine, proinflammatory cytokine and NAD biosynthetic enzyme (210), all of which will 
be discussed below. A potentially important role of visfatin in physiology and/or development is 
supported by the finding that germ-line deletion of the visfatin gene results in embryonic lethality 
in homozygous deficient animals (204). 
Effects of visfatin on glucose and energy homeostasis 
Initial findings by Fukuhara et al., (204) demonstrated a glucose-lowering (insulin-mimetic) effect 
of visfatin through the acute intravenous injection of recombinant visfatin in wild type mice, 
insulin-resistant obese (KKAy) mice and in streptozotocin-induced models of diabetes in mice. 
Indeed, chronic administration of recombinant visfatin via adenoviral vector delivery in wild type 
and KKAy mice also resulted in a lowering of plasma glucose (and insulin) levels. Although 
animals homozygous for a deletion in visfatin (visfatin
-/-
 mice) died during embryogenesis, 
animals heterozygous for the deletion (visfatin
+/-
 mice) showed a seemingly normal metabolic 
phenotype (including body weight and growth rate) except for mild elevations in circulating 
glucose and slightly impaired glucose clearance in a glucose tolerance test (204).  Furthermore, 
in in vitro studies in 3T3-L1 adipocytes and L6 myocytes, visfatin (like insulin) was found to 
stimulate glucose uptake, whilst also suppressing glucose release in H4IIEC3 hepatocytes (204). 
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Visfatin was found to bind the insulin receptor (at a different site to that of insulin) and activate 
downstream insulin signaling, involving the phosphorylation of the insulin receptor, IRS-1 and 
IRS-2 and activation of PI3K/Akt and MAPK signaling in cultured adipocytes, myocytes and 
hepatocytes (204). Yet, the binding of visfatin to the insulin receptor was later discovered to be 
batch-dependent (of purified recombinant visfatin protein preparation), resulting in the subsequent 
retraction of the original article (203). Nonetheless, findings from other groups reported similar 
insulin mimetic effects of visfatin in cultured osteoblasts (611) and a possible interaction between 
visfatin and the insulin receptor to induce glucose uptake in cultured kidney mesangial cells (533). 
In contrast, a study by Revollo et al., (482) provide strong evidence against an insulin-mimetic 
action of visfatin instead proposing that the effects of visfatin on glucose homeostasis are 
mediated by impacting NAD
+
 biosynthesis and subsequent regulation of insulin secretion from 
pancreatic β-cells.  
Elevated plasma visfatin levels have been reported in obese and non-obese patients with T2D 
(104, 171) and in both overweight and obese patients associated with MetS (192). However, the 
relationship between visfatin and metabolic disorders remains controversial (50, 286, 439), for 
review see (210)). A potential role for visfatin in the pathogenesis of cardiovascular disease 
associated with obesity and T2D has been proposed based on evidence of effects of visfatin on 
vascular inflammation (4, 136). Indeed, visfatin levels and/or mRNA expression in humans 
appear to be elevated in several other inflammation-associated conditions including, chronic 
obstructive pulmonary disease (363), rheumatoid arthritis (70, 391, 436) and osteoarthritis (105, 
391).  
The presence of visfatin in the CNS of rats was first demonstrated in 2003 (315) and some years 
later visfatin was also identified in human CSF (239). First, the previous observation that elevated 
plasma visfatin levels were associated with increasing BMI and body fat mass in human subjects 
was also confirmed by Hallschmid et al., (239); second, they reported the presence of visfatin in 
human CSF (at ~10% to that of plasma levels); third, a decrease in CSF visfatin levels was found 
to be related to the incremental rise in several factors including, plasma visfatin levels, BMI, body 
fat mass and insulin resistance in humans subjects. The authors concluded that since only body 
fat mass (adiposity) was independently associated with CSF visfatin levels, the decrease in CSF 
visfatin levels observed may reflect an impaired transport of visfatin across the BBB in obesity 
and/or may contribute to obesity-related pathologies (239). To date, the direct action of visfatin at 
the level of the BBB has not yet been explored yet given its impact of vascular endothelial cells 
(described above) (4, 136) a potential proinflammatory effect on BBB endothelial cells could 
reasonably be postulated. 
It is currently unknown whether circulating visfatin can enter the CNS and moreover, whether or 
not it can be directly secreted from specialized CNS sites. Nevertheless, a possible role for 
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visfatin in the central regulation of food intake has been indicated by a study performed in chicks. 
Intracerebroventricular infusion of recombinant human visfatin in chicks induced an increase in 
food intake, with associated changes in neuronal activity (as reflected by increased c-FOS 
expression) in the lateral hypothalamus (118). Recent work in mammals has demonstrated that 
chronic central infusion of visfatin in diabetic rats improves hypothalamic insulin (but not leptin) 
signaling through Akt phosphorylation, with no other long-term effects observed with regards to 
body weight, visceral fat accumulation or energy expenditure (309). This improvement in glucose 
homeostasis in diabetic rats was found to involve the potentiation of glucose-stimulated insulin 
secretion, rather than an improvement in insulin sensitivity per se and was associated with 
increased pancreatic β-cell mass (309). The authors proposed a CNS-to-periphery signaling 
mechanism of visfatin, transmitted via the autonomic nervous system, since the chronic infusion 
of central visfatin did not alter serum visfatin levels. Recently, it was demonstrated that the NAD
+
-
dependent deacetylase sirtuin-1 (SIRT1) could promote the release of the extracellular form of 
NAMPT (visfatin) by deacetylating intracellular NAMPT at lysine 53 in adipocytes, in turn, 
enhancing the activity of extracellular NAMPT (622). In addition, this peripherally-derived NAMPT 
was shown to influence hypothalamic NAD
+
-SIRT1 signaling and physical activity in mice, 
suggestive of the important role of adipose tissue in modulating systemic NAD
+
 biosynthesis 
which may be key in the maintenance of metabolic homeostasis (622).  
 
Adipocyte-derived cytokines 
As adipocyte-derived cytokines may not be adipokines in the purest sense of the definition, a 
conscious decision has been made to keep this section brief. Additionally, due to the highly 
heterogeneous nature of adipose tissue: a mixture of adipocytes, preadipocytes, mesenchymal 
stem cells, fibroblasts, endothelial and immune cells; it can be experimentally challenging to 
accurately identify which cell type(s) within adipose tissue are producing cytokines (and in what 
proportions) under basal and pathological conditions. However, as adipocytes produce cytokines 
which undoubtedly have critical roles in physiology and pathology, it was felt that they should not 
be completely omitted.  
 
Proinflammatory cytokines and CNS regulation of energy homeostasis  
Obesity is now well accepted to be a state of chronic low-grade inflammation, characterized by 
the synthesis of proinflammatory cytokines, such as TNFα and IL-6, from both adipocytes and 
immune cells found within adipose tissue (196, 267, 598). The immunological changes in adipose 
tissue associated with obesity are diverse and wide-ranging with changes in immune cell 
populations in adipose tissue from both the innate and adaptive branches of the immune system 
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(388). The dysregulation of pro- versus anti-inflammatory cytokine production in obese adipose 
tissue contributes to various aspects of the metabolic syndrome (145, 437). Indeed, obesity-
related inflammation is associated with both peripheral and central leptin and insulin resistance 
(43, 196).  
In addition to inducing inflammation in adipose tissue, obesity also leads to elevations in 
proinflammatory cytokines (143, 561) and activation of glial cells (75, 265, 561) in the CNS. While 
the hypothalamus is the area of the brain predominantly studied in this regard (75, 265, 561) 
evidence also indicates that other brain sites including the hippocampus are impacted (75, 228, 
456). Indeed, in neurons and astrocytes the NFκB pathway, which is known to be critical in 
mediating inflammatory signaling, is important for the central regulation of energy homeostasis 
(74, 635). Furthermore, in a rodent model of obesity, inhibition of TNFα signaling in the 
hypothalamus by infusion of a neutralizing antibody is sufficient to improve peripheral insulin 
sensitivity (17, 402) and the thermogenic capacity of BAT (17); thus, demonstrating that 
modulation of inflammatory signaling in the CNS can induce changes in the function of peripheral 
organs and potentially contribute to the pathology of the disease. It is important to note that in 
these studies it is not known whether inhibiting inflammatory signalling in the CNS alters 
physiology solely by impacting obesity-associated CNS-derived inflammation, CNS-actions of 
adipocyte/adipose tissue-derived cytokines or a combination of both. 
The cellular origin of the proinflammatory cytokines produced in the CNS associated with obesity 
remains to be fully determined, but is likely to be a combination of glial (astrocytes, tanycytes, and 
microglia) and neuronal sources. Regardless of the cell(s) producing them, proinflammatory 
cytokines likely mediate their downstream effects via autocrine and paracrine actions on different 
cell types. CNS-derived cytokines have extensive roles in modulation of physiology and 
pathophysiology but as the focus of this article is the CNS actions of adipokines (which may 
include cytokines derived from adipocytes) we feel a discussion of this is beyond the remit of this 
article and has recently been extensively reviewed elsewhere (42).  
The dissection of central versus peripheral actions of adipocyte-derived cytokines is a critical one 
for our understanding of their physiological actions, particularly in relation to the pathophysiology 
of obesity-associated inflammation. What currently is not clear is the relative time course of CNS 
and adipose tissue inflammation in response to obesogenic stimuli such as high-calorie diets: 
does adipose tissue inflammation promote CNS inflammation via the action of adipose-derived 
cytokines in the CNS or does CNS inflammation promote inflammatory changes in WAT? 
Alternatively, do they arise simultaneously in response to common stimuli? Research in rodent 
models indicates that hypothalamic inflammation arises after only 24h of exposure to an 
obesogenic high-fat diet (74, 561), which in the 2012 study of Thaler and colleagues (561) was 
found to be prior to the onset of adipose tissue inflammation. This suggests that hypothalamic 
Page 56 of 119Comprehensive Physiology
  57 
inflammation may be part of a homeostatic response to help restore energy homeostasis via 
modulation of the hypothalamic neuronal circuitry. Indeed, this is supported by data indicating that 
inhibition of NFκB signaling in astrocytes (a type of glial cell) was sufficient to acutely alter the 
feeding response to a high-fat diet (74) suggesting that inflammatory signaling in the brain is 
important for homeostatic regulation in this context. 
Regardless of which arises first, CNS or WAT inflammation, it is highly likely that in obesity the 
presence of inflammation in both these organs perpetuates the inflammatory state in the other by 
promoting dysregulation of normal physiological mechanisms within these tissues. However, 
further work is required to fully clarify the relative contribution of each. In a 2010 review, Banks & 
Erikson summarized a number of potential mechanisms by which a circulating cytokine can 
influence CNS function: 1) vagal or other afferent nerve stimulation; 2) release from immune cell 
transport; 3) stimulation through circumventricular organs; 4) direct passage; and 5) self-
stimulated release from CNS pools (31). Importantly, the CNS itself can act as an endocrine 
organ (28), secreting bio-active substances including centrally-derived TNFα and IL-6 which can 
cross the BBB to enter the blood (101). Furthermore, the BBB itself is also capable of secreting 
neuroimmune-related substances, both constitutively and when induced to do so by CNS or 
peripheral signals (31).  
The BBB is critical for CNS function and protects the brain from acute changes in the periphery 
including infectious agents, toxins and acute nutritional variations (1). Under physiological 
conditions, some peripheral factors cross the BBB (depending on their polarity and size) in a 
regulated manner; however, when BBB integrity is disrupted by damage, inflammation and/or 
oxidative stress (444) this regulation is impacted. Indeed, a positive correlation between 
obesity/diabetes and increased risk of developing dementia, cognitive impairments and/or 
neurodegenerative diseases has been established and adipokine dysregulation may play a key 
role in the development of such disorders (16, 308, 396, 444). 
  
Conclusion 
The discovery of adipokines has fundamentally changed our understanding of endocrinology. 
Through their actions in the CNS, adipokines can influence numerous aspects of physiology as 
diverse as cognition, reproduction and cardiovascular function. In particular, leptin, with its 
widespread receptor distribution in the CNS has a neuromodulatory effect on many key neural 
pathways, including autonomic, mesolimbic dopamine, neuroendocrine, and vagal circuits. A 
challenge in studying CNS targets of adipokines is that much of the work to date has been carried 
out in animals (principally rodents) and its transferability to humans is not easily determined. 
Perhaps by virtue of being the first to be discovered, leptin has been shown to have the most 
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wide-ranging functions of all adipokines. However, as new adipokines are continuously being 
identified, our understanding is constantly developing. Recent work has highlighted that in 
addition to neurons, non-neuronal cells are also important targets for the actions of adipokines 
(23, 272, 310) and this remains an emerging area of study, as indeed is the role of non-neuronal 
cells in the regulation of physiological processes. 
Despite our growing knowledge and appreciation of the importance of adipokines in modulating a 
range of physiological functions, to date, this large body of work has only led to the development 
of one novel Food and Drug Administration (FDA) approved therapeutic application in human 
disease: the use of a leptin analog to treat generalized lipodystrophy (524). Perhaps the Holy 
Grail of pharmacological therapies would be the development of the elusive brain permeable 
leptin-sensitizing agent that could help fight obesity by increasing CNS sensitivity to the patient’s 
high circulating levels of the hormone. Currently, our understanding of how leptin and other 
adipokines enter the CNS to exert their effects is somewhat incomplete. Investigating this further, 
whilst advancing our fundamental knowledge of the actions of adipokines in the CNS, will 
undoubtedly lead to the development of novel therapeutic agents to tackle human disease. 
References 
1. Abbott NJ, Ronnback L, and Hansson E. Astrocyte-endothelial interactions at the 
blood-brain barrier. Nat Rev Neurosci 7: 41-53, 2006. 
2. Adamczak M, Wiȩcek A, Funahashi T, Chudek J, Kokot F, and Matsuzawa Y. 
Decreased plasma adiponectin concentration in patients with essential hypertension*. American 
Journal of Hypertension 16: 72-75, 2003. 
3. Addabbo F, Nacci C, Benedictis LD, Leo V, Tarquinio M, Quon MJ, and Montagnani 
M. Globular adiponectin counteracts VCAM-1-mediated monocyte adhesion via AdipoR1/NF-
κB/COX-2 signaling in human aortic endothelial cells. American Journal of Physiology - 
Endocrinology And Metabolism 301: E1143-E1154, 2011. 
4. Adya R, Tan BK, Chen J, and Randeva HS. Nuclear factor-kappaB induction by visfatin 
in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 
31: 758-760, 2008. 
5. Ahima RS, Bjorbaek C, Osei S, and Flier JS. Regulation of neuronal and glial proteins 
by leptin: implications for brain development. Endocrinology 140: 2755-2762, 1999. 
6. Ahima RS, Dushay J, Flier SN, Prabakaran D, and Flier JS. Leptin accelerates the 
onset of puberty in normal female mice. J Clin Invest 99: 391-395, 1997. 
7. Ahima RS, Prabakaran D, and Flier JS. Postnatal leptin surge and regulation of 
circadian rhythm of leptin by feeding. Implications for energy homeostasis and neuroendocrine 
function. J Clin Invest 101: 1020-1027, 1998. 
8. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, and Flier 
JS. Role of leptin in the neuroendocrine response to fasting. Nature 382: 250-252, 1996. 
Page 58 of 119Comprehensive Physiology
  59 
9. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, 
Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, and Nakao K. Pathophysiological role of leptin 
in obesity-related hypertension. J Clin Invest 105: 1243-1252, 2000. 
10. Akieda-Asai S, Poleni PE, and Date Y. Coinjection of CCK and leptin reduces food 
intake via increased CART/TRH and reduced AMPK phosphorylation in the hypothalamus. Am J 
Physiol Endocrinol Metab 306: E1284-1291, 2014. 
11. Akieda-Asai S, Poleni PE, Hasegawa K, and Date Y. Role of the neural pathway from 
hindbrain to hypothalamus in interaction of GLP1 and leptin in rats. J Endocrinol 220: 109-116, 
2014. 
12. Aksglaede L, Juul A, Olsen LW, and Sorensen TI. Age at puberty and the emerging 
obesity epidemic. PLoS One 4: e8450, 2009. 
13. Alhadeff AL, Hayes MR, and Grill HJ. Leptin receptor signaling in the lateral 
parabrachial nucleus contributes to the control of food intake. Am J Physiol Regul Integr Comp 
Physiol 307: R1338-1344, 2014. 
14. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J-i, Hotta K, 
Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, 
Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, and Matsuzawa Y. Paradoxical 
Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity. Biochemical and Biophysical 
Research Communications 257: 79-83, 1999. 
15. Arnold AC, Shaltout HA, Gallagher PE, and Diz DI. Leptin impairs cardiovagal 
baroreflex function at the level of the solitary tract nucleus. Hypertension 54: 1001-1008, 2009. 
16. Arnoldussen IA, Kiliaan AJ, and Gustafson DR. Obesity and dementia: adipokines 
interact with the brain. Eur Neuropsychopharmacol 24: 1982-1999, 2014. 
17. Arruda AP, Milanski M, Coope A, Torsoni AS, Ropelle E, Carvalho DP, Carvalheira 
JB, and Velloso LA. Low-grade hypothalamic inflammation leads to defective thermogenesis, 
insulin resistance, and impaired insulin secretion. Endocrinology 152: 1314-1326, 2011. 
18. Arruda AP, Milanski M, Romanatto T, Solon C, Coope A, Alberici LC, Festuccia WT, 
Hirabara SM, Ropelle E, Curi R, Carvalheira JB, Vercesi AE, and Velloso LA. Hypothalamic 
actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in 
cachexia. Endocrinology 151: 683-694, 2010. 
19. Asai-Sato M, Okamoto M, Endo M, Yoshida H, Murase M, Ikeda M, Sakakibara H, 
Takahashi T, and Hirahara F. Hypoadiponectinemia in lean lactating women: Prolactin inhibits 
adiponectin secretion from human adipocytes. Endocr J 53: 555-562, 2006. 
20. Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, and Muzzin 
P. Changes in glycemia by leptin administration or high- fat feeding in rodent models of 
obesity/type 2 diabetes suggest a link between resistin expression and control of glucose 
homeostasis. Endocrinology 145: 2206-2213, 2004. 
21. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, and Saruta T. 
Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11: 997-
1001, 2003. 
22. Badoer E, Kosari S, and Stebbing MJ. Resistin, an Adipokine with Non-Generalized 
Actions on Sympathetic Nerve Activity. Front Physiol 6: 321, 2015. 
Page 59 of 119 Comprehensive Physiology
  60 
23. Balland E, Dam J, Langlet F, Caron E, Steculorum S, Messina A, Rasika S, Falluel-
Morel A, Anouar Y, Dehouck B, Trinquet E, Jockers R, Bouret SG, and Prevot V. 
Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. Cell Metab 19: 293-
301, 2014. 
24. Balthasar N, Coppari R, McMinn J, Liu SM, Lee CE, Tang V, Kenny CD, McGovern 
RA, Chua SC, Jr., Elmquist JK, and Lowell BB. Leptin receptor signaling in POMC neurons is 
required for normal body weight homeostasis. Neuron 42: 983-991, 2004. 
25. Bamshad M, Song CK, and Bartness TJ. CNS origins of the sympathetic nervous 
system outflow to brown adipose tissue. Am J Physiol 276: R1569-1578, 1999. 
26. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala 
MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, and Lazar MA. 
Regulation of fasted blood glucose by resistin. Science 303: 1195-1198, 2004. 
27. Banks AS, Davis SM, Bates SH, and Myers MG, Jr. Activation of downstream signals 
by the long form of the leptin receptor. J Biol Chem 275: 14563-14572, 2000. 
28. Banks WA. Brain meets body: the blood-brain barrier as an endocrine interface. 
Endocrinology 153: 4111-4119, 2012. 
29. Banks WA. Enhanced leptin transport across the blood-brain barrier by alpha 1-
adrenergic agents. Brain Res 899: 209-217, 2001. 
30. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, and 
Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53: 1253-
1260, 2004. 
31. Banks WA, and Erickson MA. The blood-brain barrier and immune function and 
dysfunction. Neurobiol Dis 37: 26-32, 2010. 
32. Banks WA, Kastin AJ, Huang W, Jaspan JB, and Maness LM. Leptin enters the brain 
by a saturable system independent of insulin. Peptides 17: 305-311, 1996. 
33. Barash IA, Cheung CC, Weigle DS, Ren H, Kabigting EB, Kuijper JL, Clifton DK, and 
Steiner RA. Leptin is a metabolic signal to the reproductive system. Endocrinology 137: 3144-
3147, 1996. 
34. Barnes MJ, and McDougal DH. Leptin into the rostral ventral lateral medulla (RVLM) 
augments renal sympathetic nerve activity and blood pressure. Front Neurosci 8: 232, 2014. 
35. Barrachina MD, Martinez V, Wang LX, Wei JY, and Tache Y. Synergistic interaction 
between leptin and cholecystokinin to reduce short-term food intake in lean mice. Proceedings of 
the National Academy of Sciences of the United States of America 94: 10455-10460, 1997. 
36. Bartoli F, Crocamo C, Clerici M, and Carrà G. Second-generation antipsychotics and 
adiponectin levels in schizophrenia: A comparative meta-analysis. European 
Neuropsychopharmacology 25: 1767-1774, 2015. 
37. Bates SH, Dundon TA, Seifert M, Carlson M, Maratos-Flier E, and Myers MG, Jr. 
LRb-STAT3 signaling is required for the neuroendocrine regulation of energy expenditure by 
leptin. Diabetes 53: 3067-3073, 2004. 
Page 60 of 119Comprehensive Physiology
  61 
38. Bates SH, Kulkarni RN, Seifert M, and Myers MG, Jr. Roles for leptin receptor/STAT3-
dependent and -independent signals in the regulation of glucose homeostasis. Cell Metab 1: 169-
178, 2005. 
39. Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AWK, Wang Y, Banks AS, 
Lavery HJ, Haq AK, Maratos-Flier E, Neel BG, Schwartz MW, and Myers MG. STAT3 
signalling is required for leptin regulation of energy balance but not reproduction. Nature 421: 
856-859, 2003. 
40. Batt RA. The response of the reproductive system in the female mutant mouse, obese 
(genotype obob) to gonadotrophin-releasing hormones. J Repr Fert 31: 496−497, 1972. 
41. Baumann H, Morella KK, White DW, Dembski M, Bailon PS, Kim H, Lai CF, and 
Tartaglia LA. The full-length leptin receptor has signaling capabilities of interleukin 6-type 
cytokine receptors. Proc Natl Acad Sci U S A 93: 8374-8378, 1996. 
42. Becher B, Spath S, and Goverman J. Cytokine networks in neuroinflammation. Nat Rev 
Immunol 17: 49-59, 2017. 
43. Belgardt BF, and Bruning JC. CNS leptin and insulin action in the control of energy 
homeostasis. Ann N Y Acad Sci 1212: 97-113, 2010. 
44. Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG, and Kahn 
BB. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 12: 917-924, 
2006. 
45. Benoit SC, Air EL, Coolen LM, Strauss R, Jackman A, Clegg DJ, Seeley RJ, and 
Woods SC. The catabolic action of insulin in the brain is mediated by melanocortins. J Neurosci 
22: 9048-9052, 2002. 
46. Benomar Y, Amine H, Crepin D, Al Rifai S, Riffault L, Gertler A, and Taouis M. 
Central Resistin/TLR4 Impairs Adiponectin Signaling, Contributing to Insulin and FGF21 
Resistance. Diabetes 65: 913-926, 2016. 
47. Benomar Y, Gertler A, De Lacy P, Crepin D, Ould Hamouda H, Riffault L, and Taouis 
M. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 
62: 102-114, 2013. 
48. Bereiter DA, and Jeanrenaud B. Altered dendritic orientation of hypothalamic neurons 
from genetically obese (ob/ob) mice. Brain Res 202: 201-206, 1980. 
49. Bereiter DA, and Jeanrenaud B. Altered neuroanatomical organization in the central 
nervous system of the genetically obese (ob/ob) mouse. Brain Res 165: 249-260, 1979. 
50. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, 
and Bluher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in 
humans. Diabetes 54: 2911-2916, 2005. 
51. Bertrand C, Valet P, and Castan-Laurell I. Apelin and energy metabolism. Front Physiol 
6: 115, 2015. 
52. Bingham NC, Anderson KK, Reuter AL, Stallings NR, and Parker KL. Selective loss 
of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a 
metabolic syndrome. Endocrinology 149: 2138-2148, 2008. 
Page 61 of 119 Comprehensive Physiology
  62 
53. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, and Flier JS. Identification of 
SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1: 619-625, 1998. 
54. Bjorbaek C, Elmquist JK, Michl P, Ahima RS, van Bueren A, McCall AL, and Flier 
JS. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 139: 3485-
3491, 1998. 
55. Bjorbaek C, Lavery HJ, Bates SH, Olson RK, Davis SM, Flier JS, and Myers MG, Jr. 
SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem 275: 40649-
40657, 2000. 
56. Bjornholm M, Munzberg H, Leshan RL, Villanueva EC, Bates SH, Louis GW, Jones 
JC, Ishida-Takahashi R, Bjorbaek C, and Myers MG, Jr. Mice lacking inhibitory leptin receptor 
signals are lean with normal endocrine function. J Clin Invest 117: 1354-1360, 2007. 
57. Blevins JE, Schwartz MW, and Baskin DG. Evidence that paraventricular nucleus 
oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size. 
Am J Physiol Regul Integr Comp Physiol 287: R87-96, 2004. 
58. Bokarewa M, Nagaev I, Dahlberg L, Smith U, and Tarkowski A. Resistin, an adipokine 
with potent proinflammatory properties. J Immunol 174: 5789-5795, 2005. 
59. Bonnavion P, Mickelsen LE, Fujita A, de Lecea L, and Jackson AC. Hubs and spokes 
of the lateral hypothalamus: cell types, circuits and behaviour. J Physiol 2016. 
60. Bosier B, Bellocchio L, Metna-Laurent M, Soria-Gomez E, Matias I, Hebert-Chatelain 
E, Cannich A, Maitre M, Leste-Lasserre T, Cardinal P, Mendizabal-Zubiaga J, Canduela MJ, 
Reguero L, Hermans E, Grandes P, Cota D, and Marsicano G. Astroglial CB1 cannabinoid 
receptors regulate leptin signaling in mouse brain astrocytes. Mol Metab 2: 393-404, 2013. 
61. Boston BA, Blaydon KM, Varnerin J, and Cone RD. Independent and additive effects 
of central POMC and leptin pathways on murine obesity. Science 278: 1641-1644, 1997. 
62. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, 
Tack I, Knibiehler B, Carpene C, Audigier Y, Saulnier-Blache JS, and Valet P. Apelin, a newly 
identified adipokine up-regulated by insulin and obesity. Endocrinology 146: 1764-1771, 2005. 
63. Bouchonville M, Armamento-Villareal R, Shah K, Napoli N, Sinacore DR, Qualls C, 
and Villareal DT. Weight loss, exercise or both and cardiometabolic risk factors in obese older 
adults: results of a randomized controlled trial. Int J Obes (Lond) 38: 423-431, 2014. 
64. Bouret SG. Nutritional programming of hypothalamic development: critical periods and 
windows of opportunity. Int J Obes Suppl 2: S19-24, 2012. 
65. Bouret SG, Bates SH, Chen S, Myers MG, Jr., and Simerly RB. Distinct roles for 
specific leptin receptor signals in the development of hypothalamic feeding circuits. J Neurosci 
32: 1244-1252, 2012. 
66. Bouret SG, Draper SJ, and Simerly RB. Trophic action of leptin on hypothalamic 
neurons that regulate feeding. Science 304: 108-110, 2004. 
67. Bouret SG, Gorski JN, Patterson CM, Chen S, Levin BE, and Simerly RB. 
Hypothalamic neural projections are permanently disrupted in diet-induced obese rats. Cell Metab 
7: 179-185, 2008. 
Page 62 of 119Comprehensive Physiology
  63 
68. Bouyer K, and Simerly RB. Neonatal leptin exposure specifies innervation of 
presympathetic hypothalamic neurons and improves the metabolic status of leptin-deficient mice. 
J Neurosci 33: 840-851, 2013. 
69. Bove RM, Brick DJ, Healy BC, Mancuso SM, Gerweck AV, Bredella MA, Sherman 
JC, and Miller KK. Metabolic and endocrine correlates of cognitive function in healthy young 
women. Obesity (Silver Spring) 21: 1343-1349, 2013. 
70. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S, and Kyburz D. Pre-B 
cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with 
proinflammatory and matrix-degrading activities. Arthritis Rheum 56: 2829-2839, 2007. 
71. Broadwell RD, Balin BJ, Salcman M, and Kaplan RS. Brain-blood barrier? Yes and no. 
Proc Natl Acad Sci U S A 80: 7352-7356, 1983. 
72. Brown R, Thompson HJ, Imran SA, Ur E, and Wilkinson M. Traumatic brain injury 
induces adipokine gene expression in rat brain. Neurosci Lett 432: 73-78, 2008. 
73. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, and Richelsen B. 
Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations 
in humans. American Journal of Physiology - Endocrinology And Metabolism 285: E527-E533, 
2003. 
74. Buckman LB, Thompson MM, Lippert RN, Blackwell TS, Yull FE, and Ellacott KL. 
Evidence for a novel functional role of astrocytes in the acute homeostatic response to high-fat 
diet intake in mice. Mol Metab 4: 58-63, 2015. 
75. Buckman LB, Thompson MM, Moreno HN, and Ellacott KL. Regional astrogliosis in 
the mouse hypothalamus in response to obesity. J Comp Neurol 521: 1322-1333, 2013. 
76. Burdyga G, Spiller D, Morris R, Lal S, Thompson DG, Saeed S, Dimaline R, Varro A, 
and Dockray GJ. Expression of the leptin receptor in rat and human nodose ganglion neurones. 
Neuroscience 109: 339-347, 2002. 
77. Burguera B, Couce ME, Curran GL, Jensen MD, Lloyd RV, Cleary MP, and Poduslo 
JF. Obesity is associated with a decreased leptin transport across the blood-brain barrier in rats. 
Diabetes 49: 1219-1223, 2000. 
78. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, and Howard BV. Cross-sectional 
associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 
91: 64-68, 2006. 
79. Buyse M, Ovesjo ML, Goiot H, Guilmeau S, Peranzi G, Moizo L, Walker F, Lewin MJ, 
Meister B, and Bado A. Expression and regulation of leptin receptor proteins in afferent and 
efferent neurons of the vagus nerve. Eur J Neurosci 14: 64-72, 2001. 
80. Cabanelas A, Lisboa PC, Moura EG, and Pazos-Moura CC. Leptin acute modulation of 
the 5'-deiodinase activities in hypothalamus, pituitary and brown adipose tissue of fed rats. Horm 
Metab Res 38: 481-485, 2006. 
81. Calabro P, Samudio I, Willerson JT, and Yeh ET. Resistin promotes smooth muscle 
cell proliferation through activation of extracellular signal-regulated kinase 1/2 and 
phosphatidylinositol 3-kinase pathways. Circulation 110: 3335-3340, 2004. 
Page 63 of 119 Comprehensive Physiology
  64 
82. Caminos JE, Nogueiras R, Gallego R, Bravo S, Tovar S, Garcia-Caballero T, 
Casanueva FF, and Dieguez C. Expression and regulation of adiponectin and receptor in human 
and rat placenta. J Clin Endocrinol Metab 90: 4276-4286, 2005. 
83. Campfield LA, Smith FJ, Guisez Y, Devos R, and Burn P. Recombinant mouse OB 
protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 
269: 546-549, 1995. 
84. Cano G, Passerin AM, Schiltz JC, Card JP, Morrison SF, and Sved AF. Anatomical 
substrates for the central control of sympathetic outflow to interscapular adipose tissue during 
cold exposure. J Comp Neurol 460: 303-326, 2003. 
85. Cano V, Merino B, Ezquerra L, Somoza B, and Ruiz-Gayo M. A cholecystokinin-1 
receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J 
Pharmacol 154: 1009-1015, 2008. 
86. Carlyle M, Jones OB, Kuo JJ, and Hall JE. Chronic cardiovascular and renal actions of 
leptin: role of adrenergic activity. Hypertension 39: 496-501, 2002. 
87. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, 
Lynn RB, Zhang PL, Sinha MK, and Considine RV. Decreased cerebrospinal-fluid/serum leptin 
ratio in obesity: a possible mechanism for leptin resistance. Lancet 348: 159-161, 1996. 
88. Carpene C, Dray C, Attane C, Valet P, Portillo MP, Churruca I, Milagro FI, and 
Castan-Laurell I. Expanding role for the apelin/APJ system in physiopathology. J Physiol 
Biochem 63: 359-373, 2007. 
89. Carpenter LR, Farruggella TJ, Symes A, Karow ML, Yancopoulos GD, and Stahl N. 
Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob 
receptor. Proc Natl Acad Sci U S A 95: 6061-6066, 1998. 
90. Carro E, Pinilla L, Seoane LM, Considine RV, Aguilar E, Casanueva FF, and Dieguez 
C. Influence of endogenous leptin tone on the estrous cycle and luteinizing hormone pulsatility in 
female rats. Neuroendocrinology 66: 375-377, 1997. 
91. Castan-Laurell I, Dray C, Attane C, Duparc T, Knauf C, and Valet P. Apelin, diabetes, 
and obesity. Endocrine 40: 1-9, 2011. 
92. Castan-Laurell I, Vitkova M, Daviaud D, Dray C, Kovacikova M, Kovacova Z, 
Hejnova J, Stich V, and Valet P. Effect of hypocaloric diet-induced weight loss in obese women 
on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 158: 905-
910, 2008. 
93. Casto RM, VanNess JM, and Overton JM. Effects of central leptin administration on 
blood pressure in normotensive rats. Neurosci Lett 246: 29-32, 1998. 
94. Cettour-Rose P, Burger AG, Meier CA, Visser TJ, and Rohner-Jeanrenaud F. Central 
stimulatory effect of leptin on T3 production is mediated by brown adipose tissue type II 
deiodinase. Am J Physiol Endocrinol Metab 283: E980-987, 2002. 
95. Chabry J, Nicolas S, Cazareth J, Murris E, Guyon A, Glaichenhaus N, Heurteaux C, 
and Petit-Paitel A. Enriched environment decreases microglia and brain macrophages 
inflammatory phenotypes through adiponectin-dependent mechanisms: Relevance to depressive-
like behavior. Brain, Behavior, and Immunity 50: 275-287, 2015. 
Page 64 of 119Comprehensive Physiology
  65 
96. Chan KH, Lam KS, Cheng OY, Kwan JS, Ho PW, Cheng KK, Chung SK, Ho JW, Guo 
VY, and Xu A. Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-
beta neurotoxicity. PLoS One 7: e52354, 2012. 
97. Chaves-Almagro C, Castan-Laurell I, Dray C, Knauf C, Valet P, and Masri B. Apelin 
receptors: From signaling to antidiabetic strategy. Eur J Pharmacol 763: 149-159, 2015. 
98. Chehab FF. 20 years of leptin: leptin and reproduction: past milestones, present 
undertakings, and future endeavors. J Endocrinol 223: T37-48, 2014. 
99. Chehab FF, Lim ME, and Lu R. Correction of the sterility defect in homozygous obese 
female mice by treatment with the human recombinant leptin. Nat Genet 12: 318-320, 1996. 
100. Chehab FF, Mounzih K, Lu R, and Lim ME. Early onset of reproductive function in 
normal female mice treated with leptin. Science 275: 88-90, 1997. 
101. Chen G, McCuskey RS, and Reichlin S. Blood interleukin-6 and tumor necrosis factor-
alpha elevation after intracerebroventricular injection of Escherichia coli endotoxin in the rat is 
determined by two opposing factors: peripheral induction by LPS transferred from brain to blood 
and inhibition of peripheral response by a brain-mediated mechanism. Neuroimmunomodulation 
8: 59-69, 2000. 
102. Chen J, Tan B, Karteris E, Zervou S, Digby J, Hillhouse EW, Vatish M, and Randeva 
HS. Secretion of adiponectin by human placenta: differential modulation of adiponectin and its 
receptors by cytokines. Diabetologia 49: 1292-1302, 2006. 
103. Chen L, Tao Y, and Jiang Y. Apelin activates the expression of inflammatory cytokines 
in microglial BV2 cells via PI-3K/Akt and MEK/Erk pathways. Sci China Life Sci 58: 531-540, 
2015. 
104. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, and Lee YJ. Elevated 
plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes 
mellitus. J Clin Endocrinol Metab 91: 295-299, 2006. 
105. Chen WP, Bao JP, Feng J, Hu PF, Shi ZL, and Wu LD. Increased serum 
concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. 
Clin Chem Lab Med 48: 1141-1145, 2010. 
106. Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, McGlade CJ, Kennedy 
BP, and Tremblay ML. Attenuation of leptin action and regulation of obesity by protein tyrosine 
phosphatase 1B. Dev Cell 2: 497-503, 2002. 
107. Cheng XB, Wen JP, Yang J, Yang Y, Ning G, and Li XY. GnRH secretion is inhibited 
by adiponectin through activation of AMP-activated protein kinase and extracellular signal-
regulated kinase. Endocrine 39: 6-12, 2011. 
108. Cheung CC, Clifton DK, and Steiner RA. Proopiomelanocortin neurons are direct 
targets for leptin in the hypothalamus. Endocrinology 138: 4489-4492, 1997. 
109. Cheung CC, Thornton JE, Kuijper JL, Weigle DS, Clifton DK, and Steiner RA. Leptin 
is a metabolic gate for the onset of puberty in the female rat. Endocrinology 138: 855-858, 1997. 
110. Cheunsuang O, and Morris R. Astrocytes in the arcuate nucleus and median eminence 
that take up a fluorescent dye from the circulation express leptin receptors and neuropeptide Y 
Y1 receptors. Glia 52: 228-233, 2005. 
Page 65 of 119 Comprehensive Physiology
  66 
111. Chiappini F, Catalano KJ, Lee J, Peroni OD, Lynch J, Dhaneshwar AS, Wellenstein 
K, Sontheimer A, Neel BG, and Kahn BB. Ventromedial hypothalamus-specific Ptpn1 deletion 
exacerbates diet-induced obesity in female mice. J Clin Invest 124: 3781-3792, 2014. 
112. Chng SC, Ho L, Tian J, and Reversade B. ELABELA: a hormone essential for heart 
development signals via the apelin receptor. Dev Cell 27: 672-680, 2013. 
113. Choe SS, Huh JY, Hwang IJ, Kim JI, and Kim JB. Adipose Tissue Remodeling: Its Role 
in Energy Metabolism and Metabolic Disorders. Front Endocrinol (Lausanne) 7: 30, 2016. 
114. Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, 
Gong H, Arampatzi K, and Mantzoros CS. Leptin is an effective treatment for hypothalamic 
amenorrhea. Proc Natl Acad Sci U S A 108: 6585-6590, 2011. 
115. Chu C, Wang Y, Ren Ky, Yan Dy, Guo Ts, Zheng Wl, Yuan Zy, and Mu Jj. Genetic 
variants in adiponectin and blood pressure responses to dietary sodium or potassium 
interventions: a family-based association study. J Hum Hypertens 30: 563-570, 2016. 
116. Clarke KJ, Whitaker KW, and Reyes TM. Diminished metabolic responses to centrally-
administered apelin-13 in diet-induced obese rats fed a high-fat diet. J Neuroendocrinol 21: 83-
89, 2009. 
117. Clayton PE, Gill MS, Hall CM, Tillmann V, Whatmore AJ, and Price DA. Serum leptin 
through childhood and adolescence. Clin Endocrinol (Oxf) 46: 727-733, 1997. 
118. Cline MA, Nandar W, Prall BC, Bowden CN, and Denbow DM. Central visfatin causes 
orexigenic effects in chicks. Behav Brain Res 186: 293-297, 2008. 
119. Coelho M, Oliveira T, and Fernandes R. Biochemistry of adipose tissue: an endocrine 
organ. Arch Med Sci 9: 191-200, 2013. 
120. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, and 
Friedman JM. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest 108: 
1113-1121, 2001. 
121. Coleman DL. Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 
9: 294-298, 1973. 
122. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity 
syndromes in mice. Diabetologia 14: 141-148, 1978. 
123. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, and Surwit RS. Role of leptin 
in fat regulation. Nature 380: 677, 1996. 
124. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, Patti 
ME, Klein SL, Weinstein RS, and Scherer PE. Sexual Differentiation, Pregnancy, Calorie 
Restriction, and Aging Affect the Adipocyte-Specific Secretory Protein Adiponectin. Diabetes 52: 
268-276, 2003. 
125. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, 
Rajala MW, Parlow AF, Cheeseboro L, Ding Y-Y, Russell RG, Lindemann D, Hartley A, 
Baker GRC, Obici S, Deshaies Y, Ludgate M, Rossetti L, and Scherer PE. A Transgenic 
Mouse with a Deletion in the Collagenous Domain of Adiponectin Displays Elevated Circulating 
Adiponectin and Improved Insulin Sensitivity. Endocrinology 145: 367-383, 2004. 
Page 66 of 119Comprehensive Physiology
  67 
126. Commins SP, Watson PM, Frampton IC, and Gettys TW. Leptin selectively reduces 
white adipose tissue in mice via a UCP1-dependent mechanism in brown adipose tissue. Am J 
Physiol Endocrinol Metab 280: E372-377, 2001. 
127. Connors JM, DeVito WJ, and Hedge GA. Effects of food deprivation on the feedback 
regulation of the hypothalamic-pituitary-thyroid axis of the rat. Endocrinology 117: 900-906, 1985. 
128. Coope A, Milanski M, Araújo EP, Tambascia M, Saad MJA, Geloneze B, and Velloso 
LA. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions of adiponectin in the 
hypothalamus. FEBS Letters 582: 1471-1476, 2008. 
129. Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang V, Liu 
SM, Ludwig T, Chua SC, Jr., Lowell BB, and Elmquist JK. The hypothalamic arcuate nucleus: 
a key site for mediating leptin's effects on glucose homeostasis and locomotor activity. Cell Metab 
1: 63-72, 2005. 
130. Coppola A, Liu ZW, Andrews ZB, Paradis E, Roy MC, Friedman JM, Ricquier D, 
Richard D, Horvath TL, Gao XB, and Diano S. A central thermogenic-like mechanism in feeding 
regulation: an interplay between arcuate nucleus T3 and UCP2. Cell Metab 5: 21-33, 2007. 
131. Correia ML, Morgan DA, Sivitz WI, Mark AL, and Haynes WG. Leptin acts in the 
central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 
37: 936-942, 2001. 
132. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, and Bouloumie 
A. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a 
source of resistin and visfatin. Diabetologia 49: 744-747, 2006. 
133. D'Agostino G, Lyons DJ, Cristiano C, Burke LK, Madara JC, Campbell JN, Garcia 
AP, Land BB, Lowell BB, Dileone RJ, and Heisler LK. Appetite controlled by a cholecystokinin 
nucleus of the solitary tract to hypothalamus neurocircuit. Elife 5: 2016. 
134. da Silva AA, Kuo JJ, and Hall JE. Role of hypothalamic melanocortin 3/4-receptors in 
mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 43: 1312-
1317, 2004. 
135. Dahl TB, Holm S, Aukrust P, and Halvorsen B. Visfatin/NAMPT: a multifaceted 
molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 32: 229-243, 
2012. 
136. Dahl TB, Yndestad A, Skjelland M, Oie E, Dahl A, Michelsen A, Damas JK, Tunheim 
SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Froland SS, Krohg-Sorensen K, 
Russell D, Aukrust P, and Halvorsen B. Increased expression of visfatin in macrophages of 
human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque 
destabilization. Circulation 115: 972-980, 2007. 
137. Dampney RA. Functional organization of central pathways regulating the cardiovascular 
system. Physiol Rev 74: 323-364, 1994. 
138. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, 
Carpene C, Saulnier-Blache JS, Valet P, and Castan-Laurell I. TNFalpha up-regulates apelin 
expression in human and mouse adipose tissue. FASEB J 20: 1528-1530, 2006. 
Page 67 of 119 Comprehensive Physiology
  68 
139. Davis JF, Choi DL, Schurdak JD, Fitzgerald MF, Clegg DJ, Lipton JW, Figlewicz DP, 
and Benoit SC. Leptin Regulates Energy Balance and Motivation Through Action at Distinct 
Neural Circuits. Biological Psychiatry 69: 668-674, 2011. 
140. De Leonibus C, Marcovecchio ML, Chiavaroli V, de Giorgis T, Chiarelli F, and Mohn 
A. Timing of puberty and physical growth in obese children: a longitudinal study in boys and girls. 
Pediatr Obes 9: 292-299, 2014. 
141. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, 
Kordon C, Vaudry H, Moos F, and Llorens-Cortes C. Apelin, a potent diuretic neuropeptide 
counteracting vasopressin actions through inhibition of vasopressin neuron activity and 
vasopressin release. Proc Natl Acad Sci U S A 101: 10464-10469, 2004. 
142. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, and Milgrom E. 
Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor 
GPR54. Proc Natl Acad Sci U S A 100: 10972-10976, 2003. 
143. De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJ, 
and Velloso LA. Consumption of a fat-rich diet activates a proinflammatory response and 
induces insulin resistance in the hypothalamus. Endocrinology 146: 4192-4199, 2005. 
144. DeFazio RA, Elias CF, and Moenter SM. GABAergic transmission to kisspeptin neurons 
is differentially regulated by time of day and estradiol in female mice. J Neurosci 34: 16296-
16308, 2014. 
145. Deng Y, and Scherer PE. Adipokines as novel biomarkers and regulators of the 
metabolic syndrome. Ann N Y Acad Sci 1212: E1-E19, 2010. 
146. Devos R, Richards JG, Campfield LA, Tartaglia LA, Guisez Y, van der Heyden J, 
Travernier J, Plaetinck G, and Burn P. OB protein binds specifically to the choroid plexus of 
mice and rats. Proc Natl Acad Sci U S A 93: 5668-5673, 1996. 
147. Dhar M, Wayman GA, Zhu M, Lambert TJ, Davare MA, and Appleyard SM. Leptin-
induced spine formation requires TrpC channels and the CaM kinase cascade in the 
hippocampus. J Neurosci 34: 10022-10033, 2014. 
148. Dhar M, Zhu M, Impey S, Lambert TJ, Bland T, Karatsoreos IN, Nakazawa T, 
Appleyard SM, and Wayman GA. Leptin induces hippocampal synaptogenesis via CREB-
regulated microRNA-132 suppression of p250GAP. Mol Endocrinol 28: 1073-1087, 2014. 
149. Dhillon H, Zigman JM, Ye C, Lee CE, McGovern RA, Tang V, Kenny CD, 
Christiansen LM, White RD, Edelstein EA, Coppari R, Balthasar N, Cowley MA, Chua S, Jr., 
Elmquist JK, and Lowell BB. Leptin directly activates SF1 neurons in the VMH, and this action 
by leptin is required for normal body-weight homeostasis. Neuron 49: 191-203, 2006. 
150. Dickerson GE, and Gowen JW. Hereditary obesity and efficient food utilization in mice. 
Science 105: 496-498, 1947. 
151. DiLeone RJ, Georgescu D, and Nestler EJ. Lateral hypothalamic neuropeptides in 
reward and drug addiction. Life Sci 73: 759-768, 2003. 
152. do Carmo JM, da Silva AA, Ebaady SE, Sessums PO, Abraham RS, Elmquist JK, 
Lowell BB, and Hall JE. Shp2 signaling in POMC neurons is important for leptin's actions on 
blood pressure, energy balance, and glucose regulation. Am J Physiol Regul Integr Comp Physiol 
307: R1438-1447, 2014. 
Page 68 of 119Comprehensive Physiology
  69 
153. do Carmo JM, da Silva AA, Wang Z, Fang T, Aberdein N, de Lara Rodriguez CE, and 
Hall JE. Obesity-Induced Hypertension: Brain Signaling Pathways. Curr Hypertens Rep 18: 58, 
2016. 
154. Dockray GJ. Gastrointestinal hormones and the dialogue between gut and brain. J 
Physiol 592: 2927-2941, 2014. 
155. Dodd GT, Worth AA, Nunn N, Korpal AK, Bechtold DA, Allison MB, Myers MG, Jr., 
Statnick MA, and Luckman SM. The thermogenic effect of leptin is dependent on a distinct 
population of prolactin-releasing peptide neurons in the dorsomedial hypothalamus. Cell Metab 
20: 639-649, 2014. 
156. Doherty GH, Beccano-Kelly D, Yan SD, Gunn-Moore FJ, and Harvey J. Leptin 
prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta. 
Neurobiol Aging 34: 226-237, 2013. 
157. Donato J, Jr., Cravo RM, Frazao R, Gautron L, Scott MM, Lachey J, Castro IA, 
Margatho LO, Lee S, Lee C, Richardson JA, Friedman J, Chua S, Jr., Coppari R, Zigman 
JM, Elmquist JK, and Elias CF. Leptin's effect on puberty in mice is relayed by the ventral 
premammillary nucleus and does not require signaling in Kiss1 neurons. J Clin Invest 121: 355-
368, 2011. 
158. Drougard A, Duparc T, Brenachot X, Carneiro L, Gouaze A, Fournel A, Geurts L, 
Cadoudal T, Prats AC, Penicaud L, Vieau D, Lesage J, Leloup C, Benani A, Cani PD, Valet 
P, and Knauf C. Hypothalamic apelin/reactive oxygen species signaling controls hepatic glucose 
metabolism in the onset of diabetes. Antioxid Redox Signal 20: 557-573, 2014. 
159. Drougard A, Fournel A, Marlin A, Meunier E, Abot A, Bautzova T, Duparc T, Louche 
K, Batut A, Lucas A, Le-Gonidec S, Lesage J, Fioramonti X, Moro C, Valet P, Cani PD, and 
Knauf C. Central chronic apelin infusion decreases energy expenditure and thermogenesis in 
mice. Sci Rep 6: 31849, 2016. 
160. Duan C, Li M, and Rui L. SH2-B promotes insulin receptor substrate 1 (IRS1)- and 
IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J 
Biol Chem 279: 43684-43691, 2004. 
161. Dukic L, Simundic A-M, Martinic-Popovic I, Kackov S, Diamandis A, Begcevic I, and 
Diamandis EP. The role of human kallikrein 6, clusterin and adiponectin as potential blood 
biomarkers of dementia. Clinical Biochemistry 49: 213-218, 2016. 
162. Dunbar JC, Hu Y, and Lu H. Intracerebroventricular leptin increases lumbar and renal 
sympathetic nerve activity and blood pressure in normal rats. Diabetes 46: 2040-2043, 1997. 
163. Dunbar JC, and Lu H. Leptin-induced increase in sympathetic nervous and 
cardiovascular tone is mediated by proopiomelanocortin (POMC) products. Brain Res Bull 50: 
215-221, 1999. 
164. Dunn SL, Bjornholm M, Bates SH, Chen Z, Seifert M, and Myers MG, Jr. Feedback 
inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of 
cytokine signaling 3. Mol Endocrinol 19: 925-938, 2005. 
165. Durakoglugil M, Irving AJ, and Harvey J. Leptin induces a novel form of NMDA 
receptor-dependent long-term depression. J Neurochem 95: 396-405, 2005. 
Page 69 of 119 Comprehensive Physiology
  70 
166. Dustan HP. Mechanisms of hypertension associated with obesity. Ann Intern Med 98: 
860-864, 1983. 
167. Duvernoy HM, and Risold PY. The circumventricular organs: an atlas of comparative 
anatomy and vascularization. Brain Res Rev 56: 119-147, 2007. 
168. Dyer CJ, Simmons JM, Matteri RL, and Keisler DH. Leptin receptor mRNA is 
expressed in ewe anterior pituitary and adipose tissues and is differentially expressed in 
hypothalamic regions of well-fed and feed-restricted ewes. Domest Anim Endocrinol 14: 119-128, 
1997. 
169. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M, 
Yoshioka T, Hayase M, Matsuoka N, Aizawa-Abe M, Yoshimasa Y, and Nakao K. 
Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin 
receptor, in leptin action. Diabetes 48: 2028-2033, 1999. 
170. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, and Flier JS. Two defects 
contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 105: 
1827-1832, 2000. 
171. El-Mesallamy HO, Kassem DH, El-Demerdash E, and Amin AI. Vaspin and 
visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 
diabetes mellitus. Metabolism 60: 63-70, 2011. 
172. El Messari S, Iturrioz X, Fassot C, De Mota N, Roesch D, and Llorens-Cortes C. 
Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of 
apelin on arterial blood pressure. J Neurochem 90: 1290-1301, 2004. 
173. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, 
Bannon TW, Noda M, Clement K, Vaisse C, and Karsenty G. Leptin regulation of bone 
resorption by the sympathetic nervous system and CART. Nature 434: 514-520, 2005. 
174. Elias CF, Aschkenasi C, Lee C, Kelly J, Ahima RS, Bjorbaek C, Flier JS, Saper CB, 
and Elmquist JK. Leptin differentially regulates NPY and POMC neurons projecting to the lateral 
hypothalamic area. Neuron 23: 775-786, 1999. 
175. Elias CF, Kelly JF, Lee CE, Ahima RS, Drucker DJ, Saper CB, and Elmquist JK. 
Chemical characterization of leptin-activated neurons in the rat brain. J Comp Neurol 423: 261-
281, 2000. 
176. Elias CF, Lee CE, Kelly JF, Ahima RS, Kuhar M, Saper CB, and Elmquist JK. 
Characterization of CART neurons in the rat and human hypothalamus. J Comp Neurol 432: 1-
19, 2001. 
177. Elias CF, Saper CB, Maratos-Flier E, Tritos NA, Lee C, Kelly J, Tatro JB, Hoffman 
GE, Ollmann MM, Barsh GS, Sakurai T, Yanagisawa M, and Elmquist JK. Chemically defined 
projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp 
Neurol 402: 442-459, 1998. 
178. Ellacott KL, Halatchev IG, and Cone RD. Characterization of leptin-responsive neurons 
in the caudal brainstem. Endocrinology 147: 3190-3195, 2006. 
179. Elmquist JK, Ahima RS, MaratosFlier E, Flier JS, and Safer CB. Leptin activates 
neurons in ventrobasal hypothalamus and brainstem. Endocrinology 138: 839-842, 1997. 
Page 70 of 119Comprehensive Physiology
  71 
180. Elmquist JK, Bjorbaek C, Ahima RS, Flier JS, and Saper CB. Distributions of leptin 
receptor mRNA isoforms in the rat brain. J Comp Neurol 395: 535-547, 1998. 
181. Emond M, Ladenheim EE, Schwartz GJ, and Moran TH. Leptin amplifies the feeding 
inhibition and neural activation arising from a gastric nutrient preload. Physiol Behav 72: 123-128, 
2001. 
182. Enriori PJ, Sinnayah P, Simonds SE, Garcia Rudaz C, and Cowley MA. Leptin action 
in the dorsomedial hypothalamus increases sympathetic tone to brown adipose tissue in spite of 
systemic leptin resistance. J Neurosci 31: 12189-12197, 2011. 
183. Erickson JC, Hollopeter G, and Palmiter RD. Attenuation of the obesity syndrome of 
ob/ob mice by the loss of neuropeptide Y. Science 274: 1704-1707, 1996. 
184. Ewart-Toland A, Mounzih K, Qiu J, and Chehab FF. Effect of the genetic background 
on the reproduction of leptin-deficient obese mice. Endocrinology 140: 732-738, 1999. 
185. Faouzi M, Leshan R, Bjornholm M, Hennessey T, Jones J, and Munzberg H. 
Differential accessibility of circulating leptin to individual hypothalamic sites. Endocrinology 148: 
5414-5423, 2007. 
186. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, 
Hughes IA, McCamish MA, and O'Rahilly S. Effects of recombinant leptin therapy in a child 
with congenital leptin deficiency. N Engl J Med 341: 879-884, 1999. 
187. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, and Paschke R. 
Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. 
Biochemical and Biophysical Research Communications 301: 1045-1050, 2003. 
188. Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM, Emerson CH, and 
Lechan RM. alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating 
thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus 
and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. 
J Neurosci 20: 1550-1558, 2000. 
189. Fernandes MF, Matthys D, Hryhorczuk C, Sharma S, Mogra S, Alquier T, and Fulton 
S. Leptin Suppresses the Rewarding Effects of Running via STAT3 Signaling in Dopamine 
Neurons. Cell Metab 22: 741-749, 2015. 
190. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, and Tezapsidis N. 
Obesity-related leptin regulates Alzheimer's Abeta. FASEB J 18: 1870-1878, 2004. 
191. Figlewicz DP, Evans SB, Murphy J, Hoen M, and Baskin DG. Expression of receptors 
for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 
964: 107-115, 2003. 
192. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, and Elisaf MS. Increased 
plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with 
metabolic syndrome. J Endocrinol Invest 30: 323-326, 2007. 
193. Finn PD, Cunningham MJ, Pau KY, Spies HG, Clifton DK, and Steiner RA. The 
stimulatory effect of leptin on the neuroendocrine reproductive axis of the monkey. Endocrinology 
139: 4652-4662, 1998. 
Page 71 of 119 Comprehensive Physiology
  72 
194. Flak JN, Patterson CM, Garfield AS, D'Agostino G, Goforth PB, Sutton AK, Malec 
PA, Wong JM, Germani M, Jones JC, Rajala M, Satin L, Rhodes CJ, Olson DP, Kennedy RT, 
Heisler LK, and Myers MG, Jr. Leptin-inhibited PBN neurons enhance responses to 
hypoglycemia in negative energy balance. Nat Neurosci 17: 1744-1750, 2014. 
195. Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, and Flier JS. Leptin 
levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat 
Med 1: 1311-1314, 1995. 
196. Fresno M, Alvarez R, and Cuesta N. Toll-like receptors, inflammation, metabolism and 
obesity. Arch Physiol Biochem 117: 151-164, 2011. 
197. Frisch RE, Gotz-Welbergen AV, McArthur JW, Albright T, Witschi J, Bullen B, 
Birnholz J, Reed RB, and Hermann H. Delayed menarche and amenorrhea of college athletes 
in relation to age of onset of training. JAMA 246: 1559-1563, 1981. 
198. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, 
and Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein 
increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 
98: 2005-2010, 2001. 
199. Fry M, Hoyda TD, and Ferguson AV. Making sense of it: roles of the sensory 
circumventricular organs in feeding and regulation of energy homeostasis. Exp Biol Med 
(Maywood) 232: 14-26, 2007. 
200. Fry M, Smith PM, Hoyda TD, Duncan M, Ahima RS, Sharkey KA, and Ferguson AV. 
Area Postrema Neurons Are Modulated by the Adipocyte Hormone Adiponectin. The Journal of 
Neuroscience 26: 9695-9702, 2006. 
201. Fryer LGD, Foufelle F, Barnes K, Baldwin SA, Woods A, and Carling D. 
Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose 
transport in skeletal muscle cells. Biochemical Journal 363: 167-174, 2002. 
202. Fuente-Martin E, Garcia-Caceres C, Granado M, de Ceballos ML, Sanchez-Garrido 
MA, Sarman B, Liu ZW, Dietrich MO, Tena-Sempere M, Argente-Arizon P, Diaz F, Argente J, 
Horvath TL, and Chowen JA. Leptin regulates glutamate and glucose transporters in 
hypothalamic astrocytes. J Clin Invest 122: 3900-3913, 2012. 
203. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki 
Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, 
Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa 
Y, and Shimomura I. Retraction. Science 318: 565, 2007. 
204. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki 
Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, 
Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa 
Y, and Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. 
Science 307: 426-430, 2005. 
205. Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, and 
Flier JS. Leptin regulation of the mesoaccumbens dopamine pathway. Neuron 51: 811-822, 
2006. 
206. Fulton S, Woodside B, and Shizgal P. Modulation of brain reward circuitry by leptin. 
Science 287: 125-128, 2000. 
Page 72 of 119Comprehensive Physiology
  73 
207. Garcia-Caceres C, Fuente-Martin E, Burgos-Ramos E, Granado M, Frago LM, 
Barrios V, Horvath T, Argente J, and Chowen JA. Differential acute and chronic effects of 
leptin on hypothalamic astrocyte morphology and synaptic protein levels. Endocrinology 152: 
1809-1818, 2011. 
208. Garcia-Mayor RV, Andrade MA, Rios M, Lage M, Dieguez C, and Casanueva FF. 
Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-
gonadal hormones, and pubertal stage. J Clin Endocrinol Metab 82: 2849-2855, 1997. 
209. Garfield AS, Patterson C, Skora S, Gribble FM, Reimann F, Evans ML, Myers MG, 
Jr., and Heisler LK. Neurochemical characterization of body weight-regulating leptin receptor 
neurons in the nucleus of the solitary tract. Endocrinology 153: 4600-4607, 2012. 
210. Garten A, Petzold S, Korner A, Imai S, and Kiess W. Nampt: linking NAD biology, 
metabolism and cancer. Trends Endocrinol Metab 20: 130-138, 2009. 
211. Genuth SM, Przybylski RJ, and Rosenberg DM. Insulin resistance in genetically obese, 
hyperglycemic mice. Endocrinology 88: 1230-1238, 1971. 
212. Gerges NZ, Aleisa AM, and Alkadhi KA. Impaired long-term potentiation in obese 
zucker rats: possible involvement of presynaptic mechanism. Neuroscience 120: 535-539, 2003. 
213. Ghamari-Langroudi M, Vella KR, Srisai D, Sugrue ML, Hollenberg AN, and Cone RD. 
Regulation of thyrotropin-releasing hormone-expressing neurons in paraventricular nucleus of the 
hypothalamus by signals of adiposity. Mol Endocrinol 24: 2366-2381, 2010. 
214. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, and Skoda RC. Defective 
STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A 93: 6231-6235, 
1996. 
215. Glavas MM, Kirigiti MA, Xiao XQ, Enriori PJ, Fisher SK, Evans AE, Grayson BE, 
Cowley MA, Smith MS, and Grove KL. Early overnutrition results in early-onset arcuate leptin 
resistance and increased sensitivity to high-fat diet. Endocrinology 151: 1598-1610, 2010. 
216. Goforth PB, Leinninger GM, Patterson CM, Satin LS, and Myers MG, Jr. Leptin acts 
via lateral hypothalamic area neurotensin neurons to inhibit orexin neurons by multiple GABA-
independent mechanisms. J Neurosci 34: 11405-11415, 2014. 
217. Golden PL, Maccagnan TJ, and Pardridge WM. Human blood-brain barrier leptin 
receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 99: 14-18, 
1997. 
218. Goldstone AP, Mercer JG, Gunn I, Moar KM, Edwards CM, Rossi M, Howard JK, 
Rasheed S, Turton MD, Small C, Heath MM, O'Shea D, Steere J, Meeran K, Ghatei MA, 
Hoggard N, and Bloom SR. Leptin interacts with glucagon-like peptide-1 neurons to reduce food 
intake and body weight in rodents. FEBS Lett 415: 134-138, 1997. 
219. Gong Y, Ishida-Takahashi R, Villanueva EC, Fingar DC, Munzberg H, and Myers 
MG, Jr. The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via 
alternate mechanisms. J Biol Chem 282: 31019-31027, 2007. 
220. Gorska-Ciebiada M, Saryusz-Wolska M, Borkowska A, Ciebiada M, and Loba J. 
Adiponectin, leptin and IL-1 β in elderly diabetic patients with mild cognitive impairment. Metabolic 
Brain Disease 31: 257-266, 2016. 
Page 73 of 119 Comprehensive Physiology
  74 
221. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, 
Tezapsidis N, and Casadesus G. Leptin reduces pathology and improves memory in a 
transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 19: 1155-1167, 2010. 
222. Greco SJ, Sarkar S, Casadesus G, Zhu X, Smith MA, Ashford JW, Johnston JM, and 
Tezapsidis N. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in 
neuronal cells. Neurosci Lett 455: 191-194, 2009. 
223. Greco SJ, Sarkar S, Johnston JM, and Tezapsidis N. Leptin regulates tau 
phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun 
380: 98-104, 2009. 
224. Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Casadesus G, Ashford JW, Smith 
MA, and Tezapsidis N. Leptin reduces Alzheimer's disease-related tau phosphorylation in 
neuronal cells. Biochem Biophys Res Commun 376: 536-541, 2008. 
225. Grill HJ, Schwartz MW, Kaplan JM, Foxhall JS, Breininger J, and Baskin DG. 
Evidence that the caudal brainstem is a target for the inhibitory effect of leptin on food intake. 
Endocrinology 143: 239-246, 2002. 
226. Guan XM, Hess JF, Yu H, Hey PJ, and van der Ploeg LH. Differential expression of 
mRNA for leptin receptor isoforms in the rat brain. Mol Cell Endocrinol 133: 1-7, 1997. 
227. Guan XM, Yu H, Trumbauer M, Frazier E, Van der Ploeg LH, and Chen H. Induction of 
neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. 
Neuroreport 9: 3415-3419, 1998. 
228. Guillemot-Legris O, and Muccioli GG. Obesity-Induced Neuroinflammation: Beyond the 
Hypothalamus. Trends Neurosci 2017. 
229. Guillod-Maximin E, Roy AF, Vacher CM, Aubourg A, Bailleux V, Lorsignol A, 
Pénicaud L, Parquet M, and Taouis M. Adiponectin receptors are expressed in hypothalamus 
and colocalized with proopiomelanocortin and neuropeptide Y in rodent arcuate neurons. Journal 
of Endocrinology 200: 93-105, 2009. 
230. Gustafson B, Jack MM, Cushman SW, and Smith U. Adiponectin gene activation by 
thiazolidinediones requires PPARγ2, but not C/EBPα—evidence for differential regulation of the 
aP2 and adiponectin genes. Biochemical and Biophysical Research Communications 308: 933-
939, 2003. 
231. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, Kitada C, 
Nishizawa N, Murosaki S, Kurokawa T, Onda H, Tatemoto K, and Fujino M. Apelin, the 
natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim 
Biophys Acta 1452: 25-35, 1999. 
232. Hagan MM, Rushing PA, Pritchard LM, Schwartz MW, Strack AM, Van Der Ploeg LH, 
Woods SC, and Seeley RJ. Long-term orexigenic effects of AgRP-(83---132) involve 
mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 
279: R47-52, 2000. 
233. Hahn TM, Breininger JF, Baskin DG, and Schwartz MW. Coexpression of Agrp and 
NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1: 271-272, 1998. 
234. Hakansson ML, and Meister B. Transcription factor STAT3 in leptin target neurons of 
the rat hypothalamus. Neuroendocrinology 68: 420-427, 1998. 
Page 74 of 119Comprehensive Physiology
  75 
235. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, 
Burley SK, and Friedman JM. Weight-reducing effects of the plasma protein encoded by the 
obese gene. Science 269: 543-546, 1995. 
236. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 43: 
1402-1417, 1993. 
237. Hall JE, do Carmo JM, da Silva AA, Wang Z, and Hall ME. Obesity-induced 
hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 116: 991-1006, 2015. 
238. Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, Hamza S, 
Speed J, and Hall ME. Hypertension: physiology and pathophysiology. Compr Physiol 2: 2393-
2442, 2012. 
239. Hallschmid M, Randeva H, Tan BK, Kern W, and Lehnert H. Relationship between 
cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans. Diabetes 58: 637-640, 
2009. 
240. Hamilton BS, Paglia D, Kwan AY, and Deitel M. Increased obese mRNA expression in 
omental fat cells from massively obese humans. Nat Med 1: 953-956, 1995. 
241. Han Q, Shu Z, Liang X, Mi R, Yang L, and Li P. Relationship between adiponectin 
receptor 1 gene polymorphisms and ischemic stroke. International Journal of Clinical and 
Experimental Medicine 8: 16719-16723, 2015. 
242. Han RW, Xu HJ, Zhang RS, and Wang R. The role of apelin-13 in novel object 
recognition memory. Peptides 62: 155-158, 2014. 
243. Haque MS, Minokoshi Y, Hamai M, Iwai M, Horiuchi M, and Shimazu T. Role of the 
sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after 
intrahypothalamic injection of leptin in rats. Diabetes 48: 1706-1712, 1999. 
244. Hardie DG, Scott JW, Pan DA, and Hudson ER. Management of cellular energy by the 
AMP-activated protein kinase system. FEBS Lett 546: 113-120, 2003. 
245. Harlan SM, Morgan DA, Dellsperger DJ, Myers MG, Jr., Mark AL, and Rahmouni K. 
Cardiovascular and sympathetic effects of disrupting tyrosine 985 of the leptin receptor. 
Hypertension 57: 627-632, 2011. 
246. Harris GC, Wimmer M, and Aston-Jones G. A role for lateral hypothalamic orexin 
neurons in reward seeking. Nature 437: 556-559, 2005. 
247. Harris M, Aschkenasi C, Elias CF, Chandrankunnel A, Nillni EA, Bjoorbaek C, 
Elmquist JK, Flier JS, and Hollenberg AN. Transcriptional regulation of the thyrotropin-
releasing hormone gene by leptin and melanocortin signaling. J Clin Invest 107: 111-120, 2001. 
248. Hawke Z, Ivanov TR, Bechtold DA, Dhillon H, Lowell BB, and Luckman SM. PACAP 
neurons in the hypothalamic ventromedial nucleus are targets of central leptin signaling. J 
Neurosci 29: 14828-14835, 2009. 
249. Hayes MR, Skibicka KP, Bence KK, and Grill HJ. Dorsal hindbrain 5'-adenosine 
monophosphate-activated protein kinase as an intracellular mediator of energy balance. 
Endocrinology 150: 2175-2182, 2009. 
Page 75 of 119 Comprehensive Physiology
  76 
250. Hayes MR, Skibicka KP, Leichner TM, Guarnieri DJ, DiLeone RJ, Bence KK, and 
Grill HJ. Endogenous leptin signaling in the caudal nucleus tractus solitarius and area postrema 
is required for energy balance regulation. Cell Metab 11: 77-83, 2010. 
251. Haynes WG, Morgan DA, Walsh SA, Mark AL, and Sivitz WI. Receptor-mediated 
regional sympathetic nerve activation by leptin. J Clin Invest 100: 270-278, 1997. 
252. Hebebrand J, Blum WF, Barth N, Coners H, Englaro P, Juul A, Ziegler A, Warnke A, 
Rascher W, and Remschmidt H. Leptin levels in patients with anorexia nervosa are reduced in 
the acute stage and elevated upon short-term weight restoration. Mol Psychiatry 2: 330-334, 
1997. 
253. Heinonen MV, Purhonen AK, Miettinen P, Paakkonen M, Pirinen E, Alhava E, 
Akerman K, and Herzig KH. Apelin, orexin-A and leptin plasma levels in morbid obesity and 
effect of gastric banding. Regul Pept 130: 7-13, 2005. 
254. Hetherington A, and Ranson S. Hypothalamic lesions and adiposity in the rat. The 
Anatomical Record 78: 149-172, 1940. 
255. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, and 
Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favors the 
messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology 148: 2690-
2697, 2007. 
256. Hill JW, Elias CF, Fukuda M, Williams KW, Berglund ED, Holland WL, Cho YR, 
Chuang JC, Xu Y, Choi M, Lauzon D, Lee CE, Coppari R, Richardson JA, Zigman JM, Chua 
S, Scherer PE, Lowell BB, Bruning JC, and Elmquist JK. Direct insulin and leptin action on 
pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab 
11: 286-297, 2010. 
257. Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, 
Lowell BB, and Elmquist JK. Acute effects of leptin require PI3K signaling in hypothalamic 
proopiomelanocortin neurons in mice. J Clin Invest 118: 1796-1805, 2008. 
258. Hilzendeger AM, Morais RL, Todiras M, Plehm R, da Costa Goncalves A, Qadri F, 
Araujo RC, Gross V, Nakaie CR, Casarini DE, Carmona AK, Bader M, and Pesquero JB. 
Leptin regulates ACE activity in mice. J Mol Med (Berl) 88: 899-907, 2010. 
259. Hilzendeger AM, Morgan DA, Brooks L, Dellsperger D, Liu X, Grobe JL, Rahmouni 
K, Sigmund CD, and Mark AL. A brain leptin-renin angiotensin system interaction in the 
regulation of sympathetic nerve activity. Am J Physiol Heart Circ Physiol 303: H197-206, 2012. 
260. Himms-Hagen J. Defective brown adipose tissue thermogenesis in obese mice. Int J 
Obes 9 Suppl 2: 17-24, 1985. 
261. Hisadome K, Reimann F, Gribble FM, and Trapp S. Leptin directly depolarizes 
preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like 
Peptide 1 neurons. Diabetes 59: 1890-1898, 2010. 
262. Hoggard N, Hunter L, Lea RG, Trayhurn P, and Mercer JG. Ontogeny of the 
expression of leptin and its receptor in the murine fetus and placenta. Br J Nutr 83: 317-326, 
2000. 
Page 76 of 119Comprehensive Physiology
  77 
263. Holden KF, Lindquist K, Tylavsky FA, Rosano C, Harris TB, and Yaffe K. Serum 
leptin level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging 30: 
1483-1489, 2009. 
264. Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon JJ, 
Marinelli M, and DiLeone RJ. Leptin receptor signaling in midbrain dopamine neurons regulates 
feeding. Neuron 51: 801-810, 2006. 
265. Horvath TL, Sarman B, Garcia-Caceres C, Enriori PJ, Sotonyi P, Shanabrough M, 
Borok E, Argente J, Chowen JA, Perez-Tilve D, Pfluger PT, Bronneke HS, Levin BE, Diano 
S, Cowley MA, and Tschop MH. Synaptic input organization of the melanocortin system predicts 
diet-induced hypothalamic reactive gliosis and obesity. Proc Natl Acad Sci U S A 107: 14875-
14880, 2010. 
266. Hosoi T, Kawagishi T, Okuma Y, Tanaka J, and Nomura Y. Brainstem is a direct target 
for leptin's action in the central nervous system. Endocrinology 143: 3498-3205, 2002. 
267. Hotamisligil GS. Inflammation and metabolic disorders. Nature 444: 860-867, 2006. 
268. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, 
Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, 
Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, and Matsuzawa Y. Plasma 
Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. 
Arteriosclerosis, Thrombosis, and Vascular Biology 20: 1595-1599, 2000. 
269. Hou N, Liu Y, Han F, Wang D, Hou X, Hou S, and Sun X. Irisin improves perivascular 
adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-
induced obese mice. J Mol Cell Cardiol 99: 188-196, 2016. 
270. Hoyda TD, Smith PM, and Ferguson AV. Adiponectin acts in the nucleus of the solitary 
tract to decrease blood pressure by modulating the excitability of neuropeptide Y neurons. Brain 
Research 1256: 76-84, 2009. 
271. Hsuchou H, He Y, Kastin AJ, Tu H, Markadakis EN, Rogers RC, Fossier PB, and Pan 
W. Obesity induces functional astrocytic leptin receptors in hypothalamus. Brain 132: 889-902, 
2009. 
272. Hsuchou H, Pan W, Barnes MJ, and Kastin AJ. Leptin receptor mRNA in rat brain 
astrocytes. Peptides 30: 2275-2280, 2009. 
273. Hu E, Liang P, and Spiegelman BM. AdipoQ Is a Novel Adipose-specific Gene 
Dysregulated in Obesity. Journal of Biological Chemistry 271: 10697-10703, 1996. 
274. Hu YF, Chen YJ, Lin YJ, and Chen SA. Inflammation and the pathogenesis of atrial 
fibrillation. Nat Rev Cardiol 12: 230-243, 2015. 
275. Hubschle T, Thom E, Watson A, Roth J, Klaus S, and Meyerhof W. Leptin-induced 
nuclear translocation of STAT3 immunoreactivity in hypothalamic nuclei involved in body weight 
regulation. J Neurosci 21: 2413-2424, 2001. 
276. Hug C, and Lodish HF. Medicine. Visfatin: a new adipokine. Science 307: 366-367, 
2005. 
Page 77 of 119 Comprehensive Physiology
  78 
277. Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, Feng T, Zhong C, Wang Y, Lam Karen SL, 
and Xu A. Adiponectin Enhances Cold-Induced Browning of Subcutaneous Adipose Tissue via 
Promoting M2 Macrophage Proliferation. Cell Metabolism 22: 279-290, 2015. 
278. Hulsey MG, and Martin RJ. An anorectic agent from adipose tissue of overfed rats: 
effects on feeding behavior. Physiol Behav 52: 1141-1149, 1992. 
279. Hummel KP. Transplantation of ovaries of the obese mouse. Anat Rec 569, 1957. 
280. Hung Y-J, Hsieh C-H, Chen Y-J, Pei D, Kuo S-W, Shen D-C, Sheu WH-H, and Chen 
Y-C. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different 
subtypes of depressive disorder. Clinical Endocrinology 67: 784-789, 2007. 
281. Huo L, Gamber KM, Grill HJ, and Bjorbaek C. Divergent leptin signaling in proglucagon 
neurons of the nucleus of the solitary tract in mice and rats. Endocrinology 149: 492-497, 2008. 
282. Huo L, Grill HJ, and Bjorbaek C. Divergent regulation of proopiomelanocortin neurons 
by leptin in the nucleus of the solitary tract and in the arcuate hypothalamic nucleus. Diabetes 55: 
567-573, 2006. 
283. Huo L, Munzberg H, Nillni EA, and Bjorbaek C. Role of signal transducer and activator 
of transcription 3 in regulation of hypothalamic trh gene expression by leptin. Endocrinology 145: 
2516-2523, 2004. 
284. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, 
Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, and Lee F. 
Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141, 
1997. 
285. Ingalls AM, Dickie MM, and Snell GD. Obese, a new mutation in the house mouse. J 
Hered 41: 317-318, 1950. 
286. Ingelsson E, Larson MG, Fox CS, Yin X, Wang TJ, Lipinska I, Pou KM, Hoffmann U, 
Benjamin EJ, Keaney JF, Jr., and Vasan RS. Clinical correlates of circulating visfatin levels in a 
community-based sample. Diabetes Care 30: 1278-1280, 2007. 
287. Irving AJ, and Harvey J. Leptin regulation of hippocampal synaptic function in health 
and disease. Philos Trans R Soc Lond B Biol Sci 369: 20130155, 2014. 
288. Israel DD, Sheffer-Babila S, de Luca C, Jo YH, Liu SM, Xia Q, Spergel DJ, Dun SL, 
Dun NJ, and Chua SC, Jr. Effects of leptin and melanocortin signaling interactions on pubertal 
development and reproduction. Endocrinology 153: 2408-2419, 2012. 
289. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone 
M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, and 
Ogihara T. Hypoadiponectinemia Is an Independent Risk Factor for Hypertension. Hypertension 
43: 1318-1323, 2004. 
290. Jacob RJ, Dziura J, Medwick MB, Leone P, Caprio S, During M, Shulman GI, and 
Sherwin RS. The effect of leptin is enhanced by microinjection into the ventromedial 
hypothalamus. Diabetes 46: 150-152, 1997. 
291. Janke J, Engeli S, Gorzelniak K, Luft FC, and Sharma AM. Resistin gene expression 
in human adipocytes is not related to insulin resistance. Obes Res 10: 1-5, 2002. 
Page 78 of 119Comprehensive Physiology
  79 
292. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, Sharma S, Neilson 
I, Webb DJ, Megson IL, Flapan AD, and Newby DE. Vascular effects of apelin in vivo in man. J 
Am Coll Cardiol 52: 908-913, 2008. 
293. Jayaram B, Pan W, Wang Y, Hsuchou H, Mace A, Cornelissen-Guillaume GG, 
Mishra PK, Koza RA, and Kastin AJ. Astrocytic leptin-receptor knockout mice show partial 
rescue of leptin resistance in diet-induced obesity. J Appl Physiol (1985) 114: 734-741, 2013. 
294. Jeon BT, Shin HJ, Kim JB, Kim YK, Lee DH, Kim KH, Kim HJ, Kang SS, Cho GJ, 
Choi WS, and Roh GS. Adiponectin protects hippocampal neurons against kainic acid-induced 
excitotoxicity. Brain Research Reviews 61: 81-88, 2009. 
295. Jonasson JM, Brismar K, Sparen P, Lambe M, Nyren O, Ostenson CG, and Ye W. 
Fertility in women with type 1 diabetes: a population-based cohort study in Sweden. Diabetes 
Care 30: 2271-2276, 2007. 
296. Kai K, Hashimoto M, Amano K, Tanaka H, Fukuhara R, and Ikeda M. Relationship 
between eating disturbance and dementia severity in patients with Alzheimer's disease. PLoS 
One 10: e0133666, 2015. 
297. Kajimura D, Lee Ha W, Riley Kyle J, Arteaga-Solis E, Ferron M, Zhou B, Clarke 
Christopher J, Hannun Yusuf A, DePinho Ronald A, Guo XE, Mann JJ, and Karsenty G. 
Adiponectin Regulates Bone Mass via Opposite Central and Peripheral Mechanisms through 
FoxO1. Cell Metabolism 17: 901-915, 2013. 
298. Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, and 
Baba A. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res 
Commun 325: 395-400, 2004. 
299. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, and Granger JP. Renal denervation 
attenuates the sodium retention and hypertension associated with obesity. Hypertension 25: 893-
897, 1995. 
300. Kastin AJ, and Akerstrom V. Fasting, but not adrenalectomy, reduces transport of leptin 
into the brain. Peptides 21: 679-682, 2000. 
301. Kastin AJ, and Akerstrom V. Glucose and insulin increase the transport of leptin 
through the blood-brain barrier in normal mice but not in streptozotocin-diabetic mice. 
Neuroendocrinology 73: 237-242, 2001. 
302. Kastin AJ, Akerstrom V, and Maness LM. Chronic loss of ovarian function decreases 
transport of leptin into mouse brain. Neurosci Lett 310: 69-71, 2001. 
303. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, 
Kitada C, Onda H, Nishimura O, and Fujino M. Molecular properties of apelin: tissue 
distribution and receptor binding. Biochim Biophys Acta 1538: 162-171, 2001. 
304. Kazumi T, Kawaguchi A, Sakai K, Hirano T, and Yoshino G. Young Men With High-
Normal Blood Pressure Have Lower Serum Adiponectin, Smaller LDL Size, and Higher Elevated 
Heart Rate Than Those With Optimal Blood Pressure. Diabetes Care 25: 971-976, 2002. 
305. Kelley AE, Baldo BA, and Pratt WE. A proposed hypothalamic-thalamic-striatal axis for 
the integration of energy balance, arousal, and food reward. J Comp Neurol 493: 72-85, 2005. 
Page 79 of 119 Comprehensive Physiology
  80 
306. Khemka VK, Bagchi D, Bandyopadhyay K, Bir A, Chattopadhyay M, Biswas A, Basu 
D, and Chakrabarti S. Altered serum levels of adipokines and insulin in probable Alzheimer's 
disease. J Alzheimers Dis 41: 525-533, 2014. 
307. Kievit P, Howard JK, Badman MK, Balthasar N, Coppari R, Mori H, Lee CE, Elmquist 
JK, Yoshimura A, and Flier JS. Enhanced leptin sensitivity and improved glucose homeostasis 
in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab 4: 123-
132, 2006. 
308. Kiliaan AJ, Arnoldussen IA, and Gustafson DR. Adipokines: a link between obesity 
and dementia? Lancet Neurol 13: 913-923, 2014. 
309. Kim DS, Kang S, Moon NR, and Park S. Central visfatin potentiates glucose-stimulated 
insulin secretion and beta-cell mass without increasing serum visfatin levels in diabetic rats. 
Cytokine 65: 159-166, 2014. 
310. Kim JG, Suyama S, Koch M, Jin S, Argente-Arizon P, Argente J, Liu ZW, Zimmer 
MR, Jeong JK, Szigeti-Buck K, Gao Y, Garcia-Caceres C, Yi CX, Salmaso N, Vaccarino FM, 
Chowen J, Diano S, Dietrich MO, Tschop MH, and Horvath TL. Leptin signaling in astrocytes 
regulates hypothalamic neuronal circuits and feeding. Nat Neurosci 17: 908-910, 2014. 
311. Kim MS, Small CJ, Stanley SA, Morgan DG, Seal LJ, Kong WM, Edwards CM, 
Abusnana S, Sunter D, Ghatei MA, and Bloom SR. The central melanocortin system affects 
the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin. J Clin Invest 105: 
1005-1011, 2000. 
312. Kishida K, Nagaretani H, Kondo H, Kobayashi H, Tanaka S, Maeda N, Nagasawa A, 
Hibuse T, Ohashi K, Kumada M, Nishizawa H, Okamoto Y, Ouchi N, Maeda K, Kihara S, 
Funahashi T, and Matsuzawa Y. Disturbed secretion of mutant adiponectin associated with the 
metabolic syndrome. Biochemical and Biophysical Research Communications 306: 286-292, 
2003. 
313. Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V, Leibel RL, 
and Rosenbaum M. Leptin reverses declines in satiation in weight-reduced obese humans. Am J 
Clin Nutr 95: 309-317, 2012. 
314. Kitagawa K, Miwa K, Okazaki S, Sakaguchi M, and Mochizuki H. Serum high-
molecular-weight adiponectin level and incident dementia in patients with vascular risk factors. 
European Journal of Neurology 23: 641-647, 2016. 
315. Kitani T, Okuno S, and Fujisawa H. Growth phase-dependent changes in the 
subcellular localization of pre-B-cell colony-enhancing factor. FEBS Lett 544: 74-78, 2003. 
316. Klein I, Sanchez-Alavez M, Tabarean I, Schaefer J, Holmberg KH, Klaus J, Xia F, 
Marcondes MCG, Dubins JS, Morrison B, Zhukov V, Sanchez-Gonzalez A, Mitsukawa K, 
Hadcock JR, Bartfai T, and Conti B. AdipoR1 and 2 are expressed on warm sensitive neurons 
of the hypothalamic preoptic area and contribute to central hyperthermic effects of adiponectin. 
Brain Research 1423: 1-9, 2011. 
317. Kleinridders A, Schenten D, Konner AC, Belgardt BF, Mauer J, Okamura T, 
Wunderlich FT, Medzhitov R, and Bruning JC. MyD88 signaling in the CNS is required for 
development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab 10: 249-
259, 2009. 
Page 80 of 119Comprehensive Physiology
  81 
318. Klemettilä J-P, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, and 
Leinonen E. Cytokine and adipokine alterations in patients with schizophrenia treated with 
clozapine. Psychiatry Research 218: 277-283, 2014. 
319. Klemettilä JP, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, 
Mononen N, Lehtimäki T, and Leinonen E. Association study of the HTR2C, leptin and 
adiponectin genes and serum marker analyses in clozapine treated long-term patients with 
schizophrenia. European Psychiatry 30: 296-302, 2015. 
320. Klenke U, Taylor-Burds C, and Wray S. Metabolic Influences on Reproduction: 
Adiponectin Attenuates GnRH Neuronal Activity in Female Mice. Endocrinology 155: 1851-1863, 
2014. 
321. Kobayashi RM, Brown M, and Vale W. Regional distribution of neurotensin and 
somatostatin in rat brain. Brain Res 126: 584-588, 1977. 
322. Kohsaka A, Watanobe H, Kakizaki Y, Habu S, and Suda T. A significant role of leptin 
in the generation of steroid-induced luteinizing hormone and prolactin surges in female rats. 
Biochem Biophys Res Commun 254: 578-581, 1999. 
323. Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, 
Wyatt SK, Gandham VD, Carano RAD, Dunshee DR, Wu A-L, Haley B, Anderson K, 
Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, 
Stevens D, Rajan S, Bainbridge TW, Vernes J-M, Meng YG, Ziai J, Soriano RH, Brauer MJ, 
Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, 
McGuinness OP, Peterson AS, and Sonoda J. Sustained Brown Fat Stimulation and Insulin 
Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 
1/βKlotho Complex. EBioMedicine 2: 730-743, 2015. 
324. Kopp W, Blum WF, von Prittwitz S, Ziegler A, Lubbert H, Emons G, Herzog W, 
Herpertz S, Deter HC, Remschmidt H, and Hebebrand J. Low leptin levels predict amenorrhea 
in underweight and eating disordered females. Mol Psychiatry 2: 335-340, 1997. 
325. Kos K, Harte AL, da Silva NF, Tonchev A, Chaldakov G, James S, Snead DR, 
Hoggart B, O'Hare JP, McTernan PG, and Kumar S. Adiponectin and resistin in human 
cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin 
Endocrinol Metab 92: 1129-1136, 2007. 
326. Kosari S, Camera DM, Hawley JA, Stebbing M, and Badoer E. ERK1/2 in the brain 
mediates the effects of central resistin on reducing thermogenesis in brown adipose tissue. Int J 
Physiol Pathophysiol Pharmacol 5: 184-189, 2013. 
327. Kosari S, Rathner JA, and Badoer E. Central resistin enhances renal sympathetic 
nerve activity via phosphatidylinositol 3-kinase but reduces the activity to brown adipose tissue 
via extracellular signal-regulated kinase 1/2. J Neuroendocrinol 24: 1432-1439, 2012. 
328. Kosari S, Rathner JA, Chen F, Kosari S, and Badoer E. Centrally administered resistin 
enhances sympathetic nerve activity to the hindlimb but attenuates the activity to brown adipose 
tissue. Endocrinology 152: 2626-2633, 2011. 
329. Kotidis EV, Koliakos GG, Baltzopoulos VG, Ioannidis KN, Yovos JG, and 
Papavramidis ST. Serum ghrelin, leptin and adiponectin levels before and after weight loss: 
comparison of three methods of treatment--a prospective study. Obes Surg 16: 1425-1432, 2006. 
Page 81 of 119 Comprehensive Physiology
  82 
330. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, 
Jensen PB, Madsen OD, Vrang N, Larsen PJ, and Hastrup S. Hypothalamic CART is a new 
anorectic peptide regulated by leptin. Nature 393: 72-76, 1998. 
331. Kubota N, Terauchi Y, Kubota T, Kumagai H, Itoh S, Satoh H, Yano W, Ogata H, 
Tokuyama K, Takamoto I, Mineyama T, Ishikawa M, Moroi M, Sugi K, Yamauchi T, Ueki K, 
Tobe K, Noda T, Nagai R, and Kadowaki T. Pioglitazone Ameliorates Insulin Resistance and 
Diabetes by Both Adiponectin-dependent and -independent Pathways. Journal of Biological 
Chemistry 281: 8748-8755, 2006. 
332. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita 
T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, and Noda T. 
Disruption of Adiponectin Causes Insulin Resistance and Neointimal Formation. Journal of 
Biological Chemistry 277: 25863-25866, 2002. 
333. Kubota N, Yano W, Kubota T, Ueki K, Yamauchi T, Terauchi Y, Ezaki O, Tobe K, 
Minokoshi Y, and Kadowaki T. Adiponectin stimulates AMP-activated protein kinase in the 
hypothalamus and increases food intake. Diabetes 56: A7-A7, 2007. 
334. Kusminski CM, McTernan PG, Schraw T, Kos K, O’Hare JP, Ahima R, Kumar S, and 
Scherer PE. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution 
from serum. Diabetologia 50: 634-642, 2007. 
335. Labad J, Price JF, Strachan MW, Deary IJ, Seckl JR, Sattar N, and Reynolds RM. 
Serum leptin and cognitive function in people with type 2 diabetes. Neurobiol Aging 33: 2938-
2941 e2932, 2012. 
336. Ladyman SR, and Grattan DR. Suppression of leptin receptor messenger ribonucleic 
acid and leptin responsiveness in the ventromedial nucleus of the hypothalamus during 
pregnancy in the rat. Endocrinology 146: 3868-3874, 2005. 
337. Lappas M, Permezel M, and Rice GE. Leptin and adiponectin stimulate the release of 
proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue 
via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly 
regulated kinase 1/2. Endocrinology 146: 3334-3342, 2005. 
338. Laque A, Yu S, Qualls-Creekmore E, Gettys S, Schwartzenburg C, Bui K, Rhodes C, 
Berthoud HR, Morrison CD, Richards BK, and Munzberg H. Leptin modulates nutrient reward 
via inhibitory galanin action on orexin neurons. Mol Metab 4: 706-717, 2015. 
339. Laque A, Zhang Y, Gettys S, Nguyen TA, Bui K, Morrison CD, and Munzberg H. 
Leptin receptor neurons in the mouse hypothalamus are colocalized with the neuropeptide 
galanin and mediate anorexigenic leptin action. Am J Physiol Endocrinol Metab 304: E999-1011, 
2013. 
340. Larsen PJ, Tang-Christensen M, Holst JJ, and Orskov C. Distribution of glucagon-like 
peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. 
Neuroscience 77: 257-270, 1997. 
341. Laughlin GA, and Yen SS. Hypoleptinemia in women athletes: absence of a diurnal 
rhythm with amenorrhea. J Clin Endocrinol Metab 82: 318-321, 1997. 
342. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George 
SR, and O'Dowd BF. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 
74: 34-41, 2000. 
Page 82 of 119Comprehensive Physiology
  83 
343. Lee DK, Jeong JH, Oh S, and Jo YH. Apelin-13 enhances arcuate POMC neuron 
activity via inhibiting M-current. PLoS One 10: e0119457, 2015. 
344. Lee EB, Warmann G, Dhir R, and Ahima RS. Metabolic dysfunction associated with 
adiponectin deficiency enhances kainic acid-induced seizure severity. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 31: 14361-14366, 2011. 
345. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, and Friedman 
JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635, 1996. 
346. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, and 
Mantzoros CS. Circulating resistin levels are not associated with obesity or insulin resistance in 
humans and are not regulated by fasting or leptin administration: cross-sectional and 
interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 
88: 4848-4856, 2003. 
347. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, 
McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, and Karsenty G. 
Endocrine Regulation of Energy Metabolism by the Skeleton. Cell 130: 456-469, 2007. 
348. Lee SJ, Verma S, Simonds SE, Kirigiti MA, Kievit P, Lindsley SR, Loche A, Smith 
MS, Cowley MA, and Grove KL. Leptin stimulates neuropeptide Y and cocaine amphetamine-
regulated transcript coexpressing neuronal activity in the dorsomedial hypothalamus in diet-
induced obese mice. J Neurosci 33: 15306-15317, 2013. 
349. Legradi G, Emerson CH, Ahima RS, Flier JS, and Lechan RM. Leptin prevents fasting-
induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons 
of the hypothalamic paraventricular nucleus. Endocrinology 138: 2569-2576, 1997. 
350. Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi 
K, Ruotsalainen H, Herzig KH, Viinamäki H, and Hintikka J. Serum adiponectin and resistin 
levels in major depressive disorder. Acta Psychiatrica Scandinavica 121: 209-215, 2010. 
351. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, and Palumbo 
PJ. Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study. 
American Journal of Epidemiology 145: 301-308, 1997. 
352. Leinninger GM, Jo YH, Leshan RL, Louis GW, Yang H, Barrera JG, Wilson H, 
Opland DM, Faouzi MA, Gong Y, Jones JC, Rhodes CJ, Chua S, Jr., Diano S, Horvath TL, 
Seeley RJ, Becker JB, Munzberg H, and Myers MG, Jr. Leptin acts via leptin receptor-
expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and 
suppress feeding. Cell Metab 10: 89-98, 2009. 
353. Leinninger GM, Opland DM, Jo YH, Faouzi M, Christensen L, Cappellucci LA, 
Rhodes CJ, Gnegy ME, Becker JB, Pothos EN, Seasholtz AF, Thompson RC, and Myers 
MG, Jr. Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system 
and energy balance. Cell Metab 14: 313-323, 2011. 
354. Leo R, Di Lorenzo G, Tesauro M, Cola C, Fortuna E, Zanasi M, Troisi A, Siracusano 
A, Lauro R, and Romeo F. Decreased plasma adiponectin concentration in major depression. 
Neuroscience Letters 407: 211-213, 2006. 
355. Leshan RL, Louis GW, Jo YH, Rhodes CJ, Munzberg H, and Myers MG, Jr. Direct 
innervation of GnRH neurons by metabolic- and sexual odorant-sensing leptin receptor neurons 
in the hypothalamic ventral premammillary nucleus. J Neurosci 29: 3138-3147, 2009. 
Page 83 of 119 Comprehensive Physiology
  84 
356. Li B, Shi Z, Cassaglia PA, and Brooks VL. Leptin acts in the forebrain to differentially 
influence baroreflex control of lumbar, renal, and splanchnic sympathetic nerve activity and heart 
rate. Hypertension 61: 812-819, 2013. 
357. Li C, and Friedman JM. Leptin receptor activation of SH2 domain containing protein 
tyrosine phosphatase 2 modulates Ob receptor signal transduction. Proc Natl Acad Sci U S A 96: 
9677-9682, 1999. 
358. Li E, Deng H, Wang B, Fu W, You Y, and Tian S. Apelin-13 exerts antidepressant-like 
and recognition memory improving activities in stressed rats. Eur Neuropsychopharmacol 26: 
420-430, 2016. 
359. Li J, Wei D, McCrory MA, Szalai AJ, Yang G, Li L, Li F, and Zhao AZ. Human C-
reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in 
the CNS. Biochem J 473: 1215-1224, 2016. 
360. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, and Li K. Changes and relations of 
circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 
diabetic subjects. Exp Clin Endocrinol Diabetes 114: 544-548, 2006. 
361. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, and Hori T. Impairment of long-term 
potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience 113: 607-615, 
2002. 
362. Lindqvist A, Mohapel P, Bouter B, Frielingsdorf H, Pizzo D, Brundin P, and 
Erlanson-Albertsson C. High-fat diet impairs hippocampal neurogenesis in male rats. European 
Journal of Neurology 13: 1385-1388, 2006. 
363. Liu X, Ji Y, Chen J, Li S, and Luo F. Circulating visfatin in chronic obstructive 
pulmonary disease. Nutrition 25: 373-378, 2009. 
364. Lombardo F, Salzano G, Crisafulli G, Valenzise M, Zirilli G, Manzo V, Aversa T, and 
De Luca F. Menarcheal timing in intensively treated girls with type 1 diabetes mellitus. Nutr 
Metab Cardiovasc Dis 19: 35-38, 2009. 
365. London ED, Berman SM, Chakrapani S, Delibasi T, Monterosso J, Erol HK, Paz-
Filho G, Wong ML, and Licinio J. Short-term plasticity of gray matter associated with leptin 
deficiency and replacement. J Clin Endocrinol Metab 96: E1212-1220, 2011. 
366. Lonnqvist F, Arner P, Nordfors L, and Schalling M. Overexpression of the obese (ob) 
gene in adipose tissue of human obese subjects. Nat Med 1: 950-953, 1995. 
367. Lopez-Gallardo M, Anton-Fernandez A, Llorente R, Mela V, Llorente-Berzal A, Prada 
C, and Viveros MP. Neonatal Treatment with a Pegylated Leptin Antagonist Induces Sexually 
Dimorphic Effects on Neurones and Glial Cells, and on Markers of Synaptic Plasticity in the 
Developing Rat Hippocampal Formation. J Neuroendocrinol 27: 658-669, 2015. 
368. Louis GW, Leinninger GM, Rhodes CJ, and Myers MG, Jr. Direct innervation and 
modulation of orexin neurons by lateral hypothalamic LepRb neurons. J Neurosci 30: 11278-
11287, 2010. 
369. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik 
RP, Wilkison WO, and Cone RD. Agouti protein is an antagonist of the melanocyte-stimulating-
hormone       receptor. Nature 371: 799-802, 1994. 
Page 84 of 119Comprehensive Physiology
  85 
370. Lu M, Tang Q, Olefsky JM, Mellon PL, and Webster NJG. Adiponectin Activates 
Adenosine Monophosphate-Activated Protein Kinase and Decreases Luteinizing Hormone 
Secretion in LβT2 Gonadotropes. Molecular Endocrinology 22: 760-771, 2008. 
371. Luchsinger JA, Tang M-X, Stern Y, Shea S, and Mayeux R. Diabetes Mellitus and Risk 
of Alzheimer's Disease and Dementia with Stroke in a Multiethnic Cohort. American Journal of 
Epidemiology 154: 635-641, 2001. 
372. Luo X, McGregor G, Irving AJ, and Harvey J. Leptin Induces a Novel Form of NMDA 
Receptor-Dependent LTP at Hippocampal Temporoammonic-CA1 Synapses(1,2,3). eNeuro 2: 
2015. 
373. Maciel MN, Zieba DA, Amstalden M, Keisler DH, Neves JP, and Williams GL. Leptin 
prevents fasting-mediated reductions in pulsatile secretion of luteinizing hormone and enhances 
its gonadotropin-releasing hormone-mediated release in heifers. Biol Reprod 70: 229-235, 2004. 
374. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, 
Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, 
Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, and Matsuzawa Y. Diet-induced 
insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-737, 2002. 
375. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani 
H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and 
Matsuzawa Y. PPARγ Ligands Increase Expression and Plasma Concentrations of Adiponectin, 
an Adipose-Derived Protein. Diabetes 50: 2094-2099, 2001. 
376. Maffei M, Fei H, Lee GH, Dani C, Leroy P, Zhang Y, Proenca R, Negrel R, Ailhaud G, 
and Friedman JM. Increased expression in adipocytes of ob RNA in mice with lesions of the 
hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A 92: 6957-6960, 1995. 
377. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone 
R, Ranganathan S, and et al. Leptin levels in human and rodent: measurement of plasma leptin 
and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161, 1995. 
378. Majdic G, Young M, Gomez-Sanchez E, Anderson P, Szczepaniak LS, Dobbins RL, 
McGarry JD, and Parker KL. Knockout mice lacking steroidogenic factor 1 are a novel genetic 
model of hypothalamic obesity. Endocrinology 143: 607-614, 2002. 
379. Mannucci E, Ognibene A, Cremasco F, Dicembrini I, Bardini G, Brogi M, Terreni A, 
Caldini A, Messeri G, and Rotella CM. Plasma adiponectin and hyperglycaemia in diabetic 
patients. Clin Chem Lab Med 41: 1131-1135, 2003. 
380. Mantzoros CS, Flier JS, and Rogol AD. A longitudinal assessment of hormonal and 
physical alterations during normal puberty in boys. V. Rising leptin levels may signal the onset of 
puberty. J Clin Endocrinol Metab 82: 1066-1070, 1997. 
381. Mark AL, Agassandian K, Morgan DA, Liu X, Cassell MD, and Rahmouni K. Leptin 
signaling in the nucleus tractus solitarii increases sympathetic nerve activity to the kidney. 
Hypertension 53: 375-380, 2009. 
382. Mark AL, Shaffer RA, Correia ML, Morgan DA, Sigmund CD, and Haynes WG. 
Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow 
obese mice. J Hypertens 17: 1949-1953, 1999. 
Page 85 of 119 Comprehensive Physiology
  86 
383. Marsh AJ, Fontes MA, Killinger S, Pawlak DB, Polson JW, and Dampney RA. 
Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and 
dorsomedial hypothalamus. Hypertension 42: 488-493, 2003. 
384. Martin C, Navarro VM, Simavli S, Vong L, Carroll RS, Lowell BB, and Kaiser UB. 
Leptin-responsive GABAergic neurons regulate fertility through pathways that result in reduced 
kisspeptinergic tone. J Neurosci 34: 6047-6056, 2014. 
385. Martinez de Morentin PB, Urisarri A, Couce ML, and Lopez M. Molecular mechanisms 
of appetite and obesity: a role for brain AMPK. Clin Sci (Lond) 130: 1697-1709, 2016. 
386. Masri B, Morin N, Pedebernade L, Knibiehler B, and Audigier Y. The apelin receptor 
is coupled to Gi1 or Gi2 protein and is differentially desensitized by apelin fragments. J Biol Chem 
281: 18317-18326, 2006. 
387. Matheny M, Shapiro A, Tumer N, and Scarpace PJ. Region-specific diet-induced and 
leptin-induced cellular leptin resistance includes the ventral tegmental area in rats. 
Neuropharmacology 60: 480-487, 2011. 
388. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab 17: 851-859, 
2013. 
389. Matochik JA, London ED, Yildiz BO, Ozata M, Caglayan S, DePaoli AM, Wong ML, 
and Licinio J. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. 
J Clin Endocrinol Metab 90: 2851-2854, 2005. 
390. Matson CA, Reid DF, Cannon TA, and Ritter RC. Cholecystokinin and leptin act 
synergistically to reduce body weight. Am J Physiol Regul Integr Comp Physiol 278: R882-890, 
2000. 
391. Matsui H, Tsutsumi A, Sugihara M, Suzuki T, Iwanami K, Kohno M, Goto D, 
Matsumoto I, Ito S, and Sumida T. Visfatin (pre-B cell colony-enhancing factor) gene expression 
in patients with rheumatoid arthritis. Ann Rheum Dis 67: 571-572, 2008. 
392. Matsumoto M, Hidaka K, Akiho H, Tada S, Okada M, and Yamaguchi T. Low 
stringency hybridization study of the dopamine D4 receptor revealed D4-like mRNA distribution of 
the orphan seven-transmembrane receptor, APJ, in human brain. Neurosci Lett 219: 119-122, 
1996. 
393. McMinn JE, Sindelar DK, Havel PJ, and Schwartz MW. Leptin deficiency induced by 
fasting impairs the satiety response to cholecystokinin. Endocrinology 141: 4442-4448, 2000. 
394. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie 
KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, and Darker JG. Pharmacological 
and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. 
J Neurochem 84: 1162-1172, 2003. 
395. Mela V, Diaz F, Gertler A, Solomon G, Argente J, Viveros MP, and Chowen JA. 
Neonatal treatment with a pegylated leptin antagonist has a sexually dimorphic effect on 
hypothalamic trophic factors and neuropeptide levels. J Neuroendocrinol 24: 756-765, 2012. 
396. Mellendijk L, Wiesmann M, and Kiliaan AJ. Impact of Nutrition on Cerebral Circulation 
and Cognition in the Metabolic Syndrome. Nutrients 7: 9416-9439, 2015. 
Page 86 of 119Comprehensive Physiology
  87 
397. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Morgan PJ, and 
Trayhurn P. Coexpression of leptin receptor and preproneuropeptide Y mRNA in arcuate nucleus 
of mouse hypothalamus. J Neuroendocrinol 8: 733-735, 1996. 
398. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, and Trayhurn P. 
Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse 
hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 387: 113-116, 1996. 
399. Mercer JG, Moar KM, Findlay PA, Hoggard N, and Adam CL. Association of leptin 
receptor (OB-Rb), NPY and GLP-1 gene expression in the ovine and murine brainstem. Regul 
Pept 75-76: 271-278, 1998. 
400. Mercer JG, Moar KM, and Hoggard N. Localization of leptin receptor (Ob-R) messenger 
ribonucleic acid in the rodent hindbrain. Endocrinology 139: 29-34, 1998. 
401. Merino B, Cano V, Guzman R, Somoza B, and Ruiz-Gayo M. Leptin-mediated 
hypothalamic pathway of cholecystokinin (CCK-8) to regulate body weight in free-feeding rats. 
Endocrinology 149: 1994-2000, 2008. 
402. Milanski M, Arruda AP, Coope A, Ignacio-Souza LM, Nunez CE, Roman EA, 
Romanatto T, Pascoal LB, Caricilli AM, Torsoni MA, Prada PO, Saad MJ, and Velloso LA. 
Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. 
Diabetes 61: 1455-1462, 2012. 
403. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferre 
P, Birnbaum MJ, Stuck BJ, and Kahn BB. AMP-kinase regulates food intake by responding to 
hormonal and nutrient signals in the hypothalamus. Nature 428: 569-574, 2004. 
404. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, 
Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, and 
O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. 
Nature 387: 903-908, 1997. 
405. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien 
KR, Yasukawa H, and Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity and 
confers resistance to diet-induced obesity. Nat Med 10: 739-743, 2004. 
406. Mortel KF, Wood S, Pavol MA, Meyer JS, and Rexer JL. Analysis of Familial and 
Individual Risk Factors Among Patients with Ischemic Vascular Dementia and Alzheimer's 
Disease. Angiology 44: 599-605, 1993. 
407. Morton GJ, Blevins JE, Kim F, Matsen M, and Figlewicz DP. The action of leptin in the 
ventral tegmental area to decrease food intake is dependent on Jak-2 signaling. Am J Physiol 
Endocrinol Metab 297: E202-210, 2009. 
408. Morton GJ, Blevins JE, Williams DL, Niswender KD, Gelling RW, Rhodes CJ, 
Baskin DG, and Schwartz MW. Leptin action in the forebrain regulates the hindbrain response 
to satiety signals. J Clin Invest 115: 703-710, 2005. 
409. Morton GJ, Niswender KD, Rhodes CJ, Myers MG, Jr., Blevins JE, Baskin DG, and 
Schwartz MW. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity 
phenotype of Koletsky (fa(k)/fa(k)) rats. Endocrinology 144: 2016-2024, 2003. 
410. Morton GJ, and Schwartz MW. Leptin and the central nervous system control of glucose 
metabolism. Physiol Rev 91: 389-411, 2011. 
Page 87 of 119 Comprehensive Physiology
  88 
411. Moult PR, Milojkovic B, and Harvey J. Leptin reverses long-term potentiation at 
hippocampal CA1 synapses. J Neurochem 108: 685-696, 2009. 
412. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, and Cone RD. Localization of the 
melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. 
Mol Endocrinol 8: 1298-1308, 1994. 
413. Munzberg H, Flier JS, and Bjorbaek C. Region-specific leptin resistance within the 
hypothalamus of diet-induced obese mice. Endocrinology 145: 4880-4889, 2004. 
414. Muse ED, Lam TK, Scherer PE, and Rossetti L. Hypothalamic resistin induces hepatic 
insulin resistance. J Clin Invest 117: 1670-1678, 2007. 
415. Mutze J, Roth J, Gerstberger R, and Hubschle T. Nuclear translocation of the 
transcription factor STAT5 in the rat brain after systemic leptin administration. Neurosci Lett 417: 
286-291, 2007. 
416. Myers MG, Jr., Leibel RL, Seeley RJ, and Schwartz MW. Obesity and leptin resistance: 
distinguishing cause from effect. Trends Endocrinol Metab 21: 643-651, 2010. 
417. Myers MG, Jr., Munzberg H, Leinninger GM, and Leshan RL. The geometry of leptin 
action in the brain: more complicated than a simple ARC. Cell Metab 9: 117-123, 2009. 
418. Nagatani S, Guthikonda P, Thompson RC, Tsukamura H, Maeda KI, and Foster DL. 
Evidence for GnRH regulation by leptin: leptin administration prevents reduced pulsatile LH 
secretion during fasting. Neuroendocrinology 67: 370-376, 1998. 
419. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, and Tomita M. Isolation and 
characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J 
Biochem 120: 803-812, 1996. 
420. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, 
Chen AS, Ruderman NB, Chen H, Rossetti L, and Scherer PE. Mice Lacking Adiponectin 
Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome 
Proliferator-activated Receptor γ Agonists. Journal of Biological Chemistry 281: 2654-2660, 2006. 
421. Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjorbak C, and Flier JS. Leptin regulates 
prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol 
Chem 275: 36124-36133, 2000. 
422. Nishimura M, Izumiya Y, Higuchi A, Shibata R, Qiu J, Kudo C, Shin HK, Moskowitz 
MA, and Ouchi N. Adiponectin Prevents Cerebral Ischemic Injury Through Endothelial Nitric 
Oxide Synthase–Dependent Mechanisms. Circulation 117: 216-223, 2008. 
423. Niswender KD, Morton GJ, Stearns WH, Rhodes CJ, Myers MG, Jr., and Schwartz 
MW. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 413: 794-795, 2001. 
424. Nohira T, Nagao K, Kameyama K, Nakai H, Fukumine N, Okabe K, Kitano S, and 
Hisatomi H. Identification of an alternative splicing transcript for the resistin gene and distribution 
of its mRNA in human tissue. Eur J Endocrinol 151: 151-154, 2004. 
425. Nonaka N, Hileman SM, Shioda S, Vo TQ, and Banks WA. Effects of 
lipopolysaccharide on leptin transport across the blood-brain barrier. Brain Res 1016: 58-65, 
2004. 
Page 88 of 119Comprehensive Physiology
  89 
426. Norsted E, Gomuc B, and Meister B. Protein components of the blood-brain barrier 
(BBB) in the mediobasal hypothalamus. J Chem Neuroanat 36: 107-121, 2008. 
427. O'Carroll AM, Lolait SJ, Harris LE, and Pope GR. The apelin receptor APJ: journey 
from an orphan to a multifaceted regulator of homeostasis. J Endocrinol 219: R13-35, 2013. 
428. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, 
George SR, and Nguyen T. A human gene that shows identity with the gene encoding the 
angiotensin receptor is located on chromosome 11. Gene 136: 355-360, 1993. 
429. O'Malley D, MacDonald N, Mizielinska S, Connolly CN, Irving AJ, and Harvey J. 
Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol Cell Neurosci 
35: 559-572, 2007. 
430. O'Shea M, Hansen MJ, Tatemoto K, and Morris MJ. Inhibitory effect of apelin-12 on 
nocturnal food intake in the rat. Nutr Neurosci 6: 163-167, 2003. 
431. Oania R, and McEvoy LK. Plasma leptin levels are not predictive of dementia in patients 
with mild cognitive impairment. Age Ageing 44: 53-58, 2015. 
432. Ohtake M, Bray GA, and Azukizawa M. Studies on hypothermia and thyroid function in 
the obese (ob/ob) mouse. Am J Physiol 233: R110-115, 1977. 
433. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, and Barsh GS. 
Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. 
Science 278: 135-138, 1997. 
434. Oomura Y, Hori N, Shiraishi T, Fukunaga K, Takeda H, Tsuji M, Matsumiya T, 
Ishibashi M, Aou S, Li XL, Kohno D, Uramura K, Sougawa H, Yada T, Wayner MJ, and 
Sasaki K. Leptin facilitates learning and memory performance and enhances hippocampal CA1 
long-term potentiation and CaMK II phosphorylation in rats. Peptides 27: 2738-2749, 2006. 
435. Opland DM, Leinninger GM, and Myers MG, Jr. Modulation of the mesolimbic 
dopamine system by leptin. Brain Res 1350: 65-70, 2010. 
436. Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ, and Gualillo O. 
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in 
patients with rheumatoid arthritis. Ann Rheum Dis 65: 1198-1201, 2006. 
437. Ouchi N, Parker JL, Lugus JJ, and Walsh K. Adipokines in inflammation and metabolic 
disease. Nat Rev Immunol 11: 85-97, 2011. 
438. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG, Jr., and Ozcan U. 
Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 
9: 35-51, 2009. 
439. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, 
Federspil G, and Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in 
obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91: 3165-3170, 
2006. 
440. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee 
M, and Scherer PE. Structure-function studies of the adipocyte-secreted hormone 
Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278: 9073-
9085, 2003. 
Page 89 of 119 Comprehensive Physiology
  90 
441. Pan W, Barron M, Hsuchou H, Tu H, and Kastin AJ. Increased leptin permeation 
across the blood-brain barrier after chronic alcohol ingestion. Neuropsychopharmacology 33: 
859-866, 2008. 
442. Pan W, Hsuchou H, He Y, Sakharkar A, Cain C, Yu C, and Kastin AJ. Astrocyte leptin 
receptor (ObR) and leptin transport in adult-onset obese mice. Endocrinology 149: 2798-2806, 
2008. 
443. Panzhinskiy E, Ren J, and Nair S. Protein tyrosine phosphatase 1B and insulin 
resistance: role of endoplasmic reticulum stress/reactive oxygen species/nuclear factor kappa B 
axis. PLoS One 8: e77228, 2013. 
444. Parimisetty A, Dorsemans AC, Awada R, Ravanan P, Diotel N, and Lefebvre 
d'Hellencourt C. Secret talk between adipose tissue and central nervous system via secreted 
factors-an emerging frontier in the neurodegenerative research. J Neuroinflammation 13: 67, 
2016. 
445. Park HK, Qatanani M, Briggs ER, Ahima RS, and Lazar MA. Inflammatory induction of 
human resistin causes insulin resistance in endotoxemic mice. Diabetes 60: 775-783, 2011. 
446. Park HR, Park M, Choi J, Park K-Y, Chung HY, and Lee J. A high-fat diet impairs 
neurogenesis: Involvement of lipid peroxidation and brain-derived neurotrophic factor. 
Neuroscience Letters 482: 235-239, 2010. 
447. Park S, Hong SM, Sung SR, and Jung HK. Long-term effects of central leptin and 
resistin on body weight, insulin resistance, and beta-cell function and mass by the modulation of 
hypothalamic leptin and insulin signaling. Endocrinology 149: 445-454, 2008. 
448. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee 
CH, and Smith SA. Resistin is expressed in human macrophages and directly regulated by 
PPAR gamma activators. Biochem Biophys Res Commun 300: 472-476, 2003. 
449. Patterson CM, Leshan RL, Jones JC, and Myers MG, Jr. Molecular mapping of mouse 
brain regions innervated by leptin receptor-expressing cells. Brain Res 1378: 18-28, 2011. 
450. Patterson CM, Villanueva EC, Greenwald-Yarnell M, Rajala M, Gonzalez IE, Saini N, 
Jones J, and Myers MG, Jr. Leptin action via LepR-b Tyr1077 contributes to the control of 
energy balance and female reproduction. Mol Metab 1: 61-69, 2012. 
451. Pauli A, Norris ML, Valen E, Chew GL, Gagnon JA, Zimmerman S, Mitchell A, Ma J, 
Dubrulle J, Reyon D, Tsai SQ, Joung JK, Saghatelian A, and Schier AF. Toddler: an 
embryonic signal that promotes cell movement via Apelin receptors. Science 343: 1248636, 
2014. 
452. Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, and Collins 
F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269: 540-
543, 1995. 
453. Perello M, Cakir I, Cyr NE, Romero A, Stuart RC, Chiappini F, Hollenberg AN, and 
Nillni EA. Maintenance of the thyroid axis during diet-induced obesity in rodents is controlled at 
the central level. Am J Physiol Endocrinol Metab 299: E976-989, 2010. 
454. Perez-Gonzalez R, Alvira-Botero MX, Robayo O, Antequera D, Garzon M, Martin-
Moreno AM, Brera B, de Ceballos ML, and Carro E. Leptin gene therapy attenuates neuronal 
Page 90 of 119Comprehensive Physiology
  91 
damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. Gene Ther 21: 
298-308, 2014. 
455. Pinteaux E, Inoue W, Schmidt L, Molina-Holgado F, Rothwell NJ, and Luheshi GN. 
Leptin induces interleukin-1beta release from rat microglial cells through a caspase 1 
independent mechanism. J Neurochem 102: 826-833, 2007. 
456. Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK, and Bruce-
Keller AJ. Cognitive impairment following high fat diet consumption is associated with brain 
inflammation. J Neuroimmunol 219: 25-32, 2010. 
457. Pitkin SL, Maguire JJ, Bonner TI, and Davenport AP. International Union of Basic and 
Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and 
function. Pharmacol Rev 62: 331-342, 2010. 
458. Pitkin SL, Maguire JJ, Kuc RE, and Davenport AP. Modulation of the apelin/APJ 
system in heart failure and atherosclerosis in man. Br J Pharmacol 160: 1785-1795, 2010. 
459. Plum L, Ma X, Hampel B, Balthasar N, Coppari R, Munzberg H, Shanabrough M, 
Burdakov D, Rother E, Janoschek R, Alber J, Belgardt BF, Koch L, Seibler J, Schwenk F, 
Fekete C, Suzuki A, Mak TW, Krone W, Horvath TL, Ashcroft FM, and Bruning JC. Enhanced 
PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive 
obesity. J Clin Invest 116: 1886-1901, 2006. 
460. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, and Eckel RH. Obesity 
and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of 
the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the 
Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113: 
898-918, 2006. 
461. Pope GR, Roberts EM, Lolait SJ, and O'Carroll AM. Central and peripheral apelin 
receptor distribution in the mouse: species differences with rat. Peptides 33: 139-148, 2012. 
462. Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, and Varakis JN. 
Expression of Adiponectin and Adiponectin Receptors in Human Pituitary Gland and Brain. 
Neuroendocrinology 89: 38-47, 2009. 
463. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, and Ahima RS. Loss of 
resistin improves glucose homeostasis in leptin deficiency. Diabetes 55: 3083-3090, 2006. 
464. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, and 
Ahima RS. Adiponectin acts in the brain to decrease body weight. Nat Med 10: 524-529, 2004. 
465. Qiao L, Yoo Hs, Bosco C, Lee B, Feng G-S, Schaack J, Chi N-W, and Shao J. 
Adiponectin reduces thermogenesis by inhibiting brown adipose tissue activation in mice. 
Diabetologia 57: 1027-1036, 2014. 
466. Quaresma PGF, Reencober N, Zanotto TM, Santos AC, Weissmann L, de Matos 
AHB, Lopes-Cendes I, Folli F, Saad MJA, and Prada PO. Pioglitazone treatment increases 
food intake and decreases energy expenditure partially via hypothalamic 
adiponectin/adipoR1/AMPK pathway. Int J Obes 40: 138-146, 2016. 
467. Quennell JH, Mulligan AC, Tups A, Liu X, Phipps SJ, Kemp CJ, Herbison AE, 
Grattan DR, and Anderson GM. Leptin indirectly regulates gonadotropin-releasing hormone 
neuronal function. Endocrinology 150: 2805-2812, 2009. 
Page 91 of 119 Comprehensive Physiology
  92 
468. Rahmouni K, Haynes WG, Morgan DA, and Mark AL. Intracellular mechanisms 
involved in leptin regulation of sympathetic outflow. Hypertension 41: 763-767, 2003. 
469. Rahmouni K, and Morgan DA. Hypothalamic arcuate nucleus mediates the sympathetic 
and arterial pressure responses to leptin. Hypertension 49: 647-652, 2007. 
470. Rahmouni K, Morgan DA, Morgan GM, Mark AL, and Haynes WG. Role of selective 
leptin resistance in diet-induced obesity hypertension. Diabetes 54: 2012-2018, 2005. 
471. Rahmouni K, Sigmund CD, Haynes WG, and Mark AL. Hypothalamic ERK mediates 
the anorectic and thermogenic sympathetic effects of leptin. Diabetes 58: 536-542, 2009. 
472. Rajala MW, Obici S, Scherer PE, and Rossetti L. Adipose-derived resistin and gut-
derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin 
Invest 111: 225-230, 2003. 
473. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, 
Gingerich RL, Scherer PE, and Ahima RS. Regulation of resistin expression and circulating 
levels in obesity, diabetes, and fasting. Diabetes 53: 1671-1679, 2004. 
474. Randeva HS, Vatish M, Tan BK, Qureshi Z, Boovalingam P, Lewandowski KC, and 
O’Hare P. Raised plasma adiponectin levels in type 1 diabetic pregnancies. Clinical 
Endocrinology 65: 17-21, 2006. 
475. Ravussin Y, Gutman R, Diano S, Shanabrough M, Borok E, Sarman B, Lehmann A, 
LeDuc CA, Rosenbaum M, Horvath TL, and Leibel RL. Effects of chronic weight perturbation 
on energy homeostasis and brain structure in mice. Am J Physiol Regul Integr Comp Physiol 300: 
R1352-1362, 2011. 
476. Ravussin Y, LeDuc CA, Watanabe K, Mueller BR, Skowronski A, Rosenbaum M, 
and Leibel RL. Effects of chronic leptin infusion on subsequent body weight and composition in 
mice: Can body weight set point be reset? Mol Metab 3: 432-440, 2014. 
477. Reaux-Le Goazigo A, Bodineau L, De Mota N, Jeandel L, Chartrel N, Knauf C, Raad 
C, Valet P, and Llorens-Cortes C. Apelin and the proopiomelanocortin system: a new regulatory 
pathway of hypothalamic alpha-MSH release. Am J Physiol Endocrinol Metab 301: E955-966, 
2011. 
478. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, Corvol P, 
Palkovits M, and Llorens-Cortes C. Physiological role of a novel neuropeptide, apelin, and its 
receptor in the rat brain. J Neurochem 77: 1085-1096, 2001. 
479. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, and Rader DJ. Resistin is an 
inflammatory marker of atherosclerosis in humans. Circulation 111: 932-939, 2005. 
480. Ren D, Li M, Duan C, and Rui L. Identification of SH2-B as a key regulator of leptin 
sensitivity, energy balance, and body weight in mice. Cell Metab 2: 95-104, 2005. 
481. Retnakaran R, Hanley AJG, Raif N, Connelly PW, Sermer M, and Zinman B. Reduced 
Adiponectin Concentration in Women With Gestational Diabetes. A potential factor in progression 
to type 2 diabetes 27: 799-800, 2004. 
482. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, 
Wolberger C, Townsend RR, Milbrandt J, Kiess W, and Imai S. Nampt/PBEF/Visfatin 
Page 92 of 119Comprehensive Physiology
  93 
regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 
363-375, 2007. 
483. Rezai-Zadeh K, Yu S, Jiang Y, Laque A, Schwartzenburg C, Morrison CD, Derbenev 
AV, Zsombok A, and Munzberg H. Leptin receptor neurons in the dorsomedial hypothalamus 
are key regulators of energy expenditure and body weight, but not food intake. Mol Metab 3: 681-
693, 2014. 
484. Robbins LS, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, 
Mountjoy KG, and Cone RD. Pigmentation phenotypes of variant extension locus alleles result 
from point mutations that alter MSH receptor function. Cell 72: 827-834, 1993. 
485. Roberts EM, Newson MJ, Pope GR, Landgraf R, Lolait SJ, and O'Carroll AM. 
Abnormal fluid homeostasis in apelin receptor knockout mice. J Endocrinol 202: 453-462, 2009. 
486. Rocchini AP, Moorehead CP, DeRemer S, and Bondie D. Pathogenesis of weight-
related changes in blood pressure in dogs. Hypertension 13: 922-928, 1989. 
487. Rodriguez-Pacheco F, Vazquez-Martinez R, Martinez-Fuentes AJ, Pulido MR, 
Gahete MD, Vaudry H, Gracia-Navarro F, Dieguez C, Castano JP, and Malagon MM. Resistin 
regulates pituitary somatotrope cell function through the activation of multiple signaling pathways. 
Endocrinology 150: 4643-4652, 2009. 
488. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, and Andris F. Pre-B-cell 
colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a 
nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J 
Immunol 32: 3225-3234, 2002. 
489. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, 
Gallagher D, Mayer L, Murphy E, and Leibel RL. Low-dose leptin reverses skeletal muscle, 
autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 115: 
3579-3586, 2005. 
490. Rosenbaum M, Murphy EM, Heymsfield SB, Matthews DE, and Leibel RL. Low dose 
leptin administration reverses effects of sustained weight-reduction on energy expenditure and 
circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 87: 2391-2394, 2002. 
491. Rottkamp DM, Rudenko IA, Maier MT, Roshanbin S, Yulyaningsih E, Perez L, 
Valdearcos M, Chua S, Koliwad SK, and Xu AW. Leptin potentiates astrogenesis in the 
developing hypothalamus. Mol Metab 4: 881-889, 2015. 
492. Routh VH, Hao L, Santiago AM, Sheng Z, and Zhou C. Hypothalamic glucose sensing: 
making ends meet. Front Syst Neurosci 8: 236, 2014. 
493. Runner MN. Inherited hypofunction of the female pituitary in the sterile-obese syndrome 
in the mouse. Rec Genet Soc Am 23: 63-64, 1954. 
494. Runner MN, and Gates A. Sterile obese mothers. J Hered 45: 51-55, 1954. 
495. Runner MN, and Roscoe B. Inherited hypofunction of the female pituitary in the sterile-
obese syndrome in the mouse. Genetics 39: 990-991, 1954. 
496. Saha AK, Avilucea PR, Ye JM, Assifi MM, Kraegen EW, and Ruderman NB. 
Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in 
vivo. Biochem Biophys Res Commun 314: 580-585, 2004. 
Page 93 of 119 Comprehensive Physiology
  94 
497. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, 
Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, 
Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, and Yanagisawa 
M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled 
receptors that regulate feeding behavior. Cell 92: 573-585, 1998. 
498. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, and Auwerx J. 
Transient increase in obese gene expression after food intake or insulin administration. Nature 
377: 527-529, 1995. 
499. Samal B, Sun Y, Stearns G, Xie C, Suggs S, and McNiece I. Cloning and 
characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol 
Cell Biol 14: 1431-1437, 1994. 
500. Saper CB, and Loewy AD. Efferent connections of the parabrachial nucleus in the rat. 
Brain Res 197: 291-317, 1980. 
501. Satoh N, Ogawa Y, Katsuura G, Hayase M, Tsuji T, Imagawa K, Yoshimasa Y, Nishi 
S, Hosoda K, and Nakao K. The arcuate nucleus as a primary site of satiety effect of leptin in 
rats. Neurosci Lett 224: 149-152, 1997. 
502. Satoh N, Ogawa Y, Katsuura G, Numata Y, Tsuji T, Hayase M, Ebihara K, Masuzaki 
H, Hosoda K, Yoshimasa Y, and Nakao K. Sympathetic activation of leptin via the ventromedial 
hypothalamus: leptin-induced increase in catecholamine secretion. Diabetes 48: 1787-1793, 
1999. 
503. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, and 
O'Rahilly S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-
activated receptor-gamma action in humans. Diabetes 50: 2199-2202, 2001. 
504. Scarpace PJ, and Matheny M. Leptin induction of UCP1 gene expression is dependent 
on sympathetic innervation. Am J Physiol 275: E259-264, 1998. 
505. Schwartz GJ, and Moran TH. Leptin and neuropeptide y have opposing modulatory 
effects on nucleus of the solitary tract neurophysiological responses to gastric loads: implications 
for the control of food intake. Endocrinology 143: 3779-3784, 2002. 
506. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G, Prunkard 
DE, Porte D, Jr., Woods SC, Seeley RJ, and Weigle DS. Specificity of leptin action on elevated 
blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 
45: 531-535, 1996. 
507. Schwartz MW, Seeley RJ, Campfield LA, Burn P, and Baskin DG. Identification of 
targets of leptin action in rat hypothalamus. J Clin Invest 98: 1101-1106, 1996. 
508. Scott MM, Lachey JL, Sternson SM, Lee CE, Elias CF, Friedman JM, and Elmquist 
JK. Leptin targets in the mouse brain. J Comp Neurol 514: 518-532, 2009. 
509. Scott MM, Williams KW, Rossi J, Lee CE, and Elmquist JK. Leptin receptor 
expression in hindbrain Glp-1 neurons regulates food intake and energy balance in mice. J Clin 
Invest 121: 2413-2421, 2011. 
510. Seeley RJ, Yagaloff KA, Fisher SL, Burn P, Thiele TE, van Dijk G, Baskin DG, and 
Schwartz MW. Melanocortin receptors in leptin effects. Nature 390: 349, 1997. 
Page 94 of 119Comprehensive Physiology
  95 
511. Selthofer-Relatic K, Bosnjak I, and Kibel A. Obesity Related Coronary Microvascular 
Dysfunction: From Basic to Clinical Practice. Cardiol Res Pract 2016: 8173816, 2016. 
512. Semaan SJ, Tolson KP, and Kauffman AS. The development of kisspeptin circuits in 
the Mammalian brain. Adv Exp Med Biol 784: 221-252, 2013. 
513. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS, Jr., Shagoury 
JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, 
Slaugenhaupt SA, Gusella JF, O'Rahilly S, Carlton MB, Crowley WF, Jr., Aparicio SA, and 
Colledge WH. The GPR54 gene as a regulator of puberty. N Engl J Med 349: 1614-1627, 2003. 
514. Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, and Kim MO. Novel 
osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer/'s disease 
neuropathological deficits. Mol Psychiatry 2016. 
515. Shanley LJ, Irving AJ, and Harvey J. Leptin enhances NMDA receptor function and 
modulates hippocampal synaptic plasticity. J Neurosci 21: RC186, 2001. 
516. Sharma AN, Elased KM, Garrett TL, and Lucot JB. Neurobehavioral deficits in db/db 
diabetic mice. Physiol Behav 101: 381-388, 2010. 
517. Shek EW, Brands MW, and Hall JE. Chronic leptin infusion increases arterial pressure. 
Hypertension 31: 409-414, 1998. 
518. Shimada M, Tritos NA, Lowell BB, Flier JS, and Maratos-Flier E. Mice lacking 
melanin-concentrating hormone are hypophagic and lean. Nature 396: 670-674, 1998. 
519. Shuldiner AR, Yang R, and Gong DW. Resistin, obesity and insulin resistance--the 
emerging role of the adipocyte as an endocrine organ. N Engl J Med 345: 1345-1346, 2001. 
520. Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, and Stark KL. Hypothalamic 
expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant 
mice. Genes Dev 11: 593-602, 1997. 
521. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, and Ehtesham NZ. 
Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages 
by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 334: 1092-1101, 2005. 
522. Simonds SE, Pryor JT, Ravussin E, Greenway FL, Dileone R, Allen AM, Bassi J, 
Elmquist JK, Keogh JM, Henning E, Myers MG, Jr., Licinio J, Brown RD, Enriori PJ, 
O'Rahilly S, Sternson SM, Grove KL, Spanswick DC, Farooqi IS, and Cowley MA. Leptin 
mediates the increase in blood pressure associated with obesity. Cell 159: 1404-1416, 2014. 
523. Singhal NS, Lazar MA, and Ahima RS. Central resistin induces hepatic insulin 
resistance via neuropeptide Y. J Neurosci 27: 12924-12932, 2007. 
524. Sinha G. Leptin therapy gains FDA approval. Nat Biotechnol 32: 300-302, 2014. 
525. Skofitsch G, and Jacobowitz DM. Immunohistochemical mapping of galanin-like 
neurons in the rat central nervous system. Peptides 6: 509-546, 1985. 
526. Smedh U, Hakansson ML, Meister B, and Uvnas-Moberg K. Leptin injected into the 
fourth ventricle inhibits gastric emptying. Neuroreport 9: 297-301, 1998. 
Page 95 of 119 Comprehensive Physiology
  96 
527. Smith JT, Acohido BV, Clifton DK, and Steiner RA. KiSS-1 neurones are direct targets 
for leptin in the ob/ob mouse. J Neuroendocrinol 18: 298-303, 2006. 
528. Smith PM, Chambers AP, Price CJ, Ho W, Hopf C, Sharkey KA, and Ferguson AV. 
The subfornical organ: a central nervous system site for actions of circulating leptin. Am J Physiol 
Regul Integr Comp Physiol 296: R512-520, 2009. 
529. Smith PM, and Ferguson AV. Cardiovascular actions of leptin in the subfornical organ 
are abolished by diet-induced obesity. J Neuroendocrinol 24: 504-510, 2012. 
530. Sohn JW, Elmquist JK, and Williams KW. Neuronal circuits that regulate feeding 
behavior and metabolism. Trends Neurosci 36: 504-512, 2013. 
531. Sohn JW, and Williams KW. Functional heterogeneity of arcuate nucleus pro-
opiomelanocortin neurons: implications for diverging melanocortin pathways. Mol Neurobiol 45: 
225-233, 2012. 
532. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M, and 
Fasshauer M. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel 
adipokine. Clin Sci (Lond) 115: 13-23, 2008. 
533. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, Han JY, Han SY, Han KH, 
Kim HK, and Cha DR. Visfatin: a new player in mesangial cell physiology and diabetic 
nephropathy. Am J Physiol Renal Physiol 295: F1485-1494, 2008. 
534. Sowers JR, Whitfield LA, Catania RA, Stern N, Tuck ML, Dornfeld L, and Maxwell M. 
Role of the sympathetic nervous system in blood pressure maintenance in obesity. J Clin 
Endocrinol Metab 54: 1181-1186, 1982. 
535. Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman 
SM, Tschöp M, and Banks WA. Adiponectin Does Not Cross the Blood-Brain Barrier but 
Modifies Cytokine Expression of Brain Endothelial Cells. Diabetes 55: 141-147, 2006. 
536. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, 
Alexander WS, Metcalf D, Nicola NA, and Hilton DJ. A family of cytokine-inducible inhibitors of 
signalling. Nature 387: 917-921, 1997. 
537. Steculorum SM, and Bouret SG. Maternal diabetes compromises the organization of 
hypothalamic feeding circuits and impairs leptin sensitivity in offspring. Endocrinology 152: 4171-
4179, 2011. 
538. Stejskal D, Adamovska S, Bartek J, Jurakova R, and Proskova J. Resistin - 
concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory 
disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147: 63-69, 2003. 
539. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale 
J, Hoffmann J, Hsiung HM, Kriauciunas A, and et al. The role of neuropeptide Y in the 
antiobesity action of the obese gene product. Nature 377: 530-532, 1995. 
540. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, 
Ahima RS, and Lazar MA. The hormone resistin links obesity to diabetes. Nature 409: 307-312, 
2001. 
541. Steppan CM, and Swick AG. A role for leptin in brain development. Biochem Biophys 
Res Commun 256: 600-602, 1999. 
Page 96 of 119Comprehensive Physiology
  97 
542. Sternson SM, Shepherd GM, and Friedman JM. Topographic mapping of VMH --> 
arcuate nucleus microcircuits and their reorganization by fasting. Nat Neurosci 8: 1356-1363, 
2005. 
543. Stoeckel LE, Arvanitakis Z, Gandy S, Small D, Kahn CR, Pascual-Leone A, Pawlyk 
A, Sherwin R, and Smith P. Complex mechanisms linking neurocognitive dysfunction to insulin 
resistance and other metabolic dysfunction. F1000Res 5: 353, 2016. 
544. Stranahan AM, Lee K, Martin B, Maudsley S, Golden E, Cutler RG, and Mattson MP. 
Voluntary exercise and caloric restriction enhance hippocampal dendritic spine density and BDNF 
levels in diabetic mice. Hippocampus 19: 951-961, 2009. 
545. Sun J, Gao Y, Yao T, Huang Y, He Z, Kong X, Yu KJ, Wang RT, Guo H, Yan J, Chang 
Y, Chen H, Scherer PE, Liu T, and Williams KW. Adiponectin potentiates the acute effects of 
leptin in arcuate Pomc neurons. Mol Metab 5: 882-891, 2016. 
546. Sunter D, Hewson AK, and Dickson SL. Intracerebroventricular injection of apelin-13 
reduces food intake in the rat. Neurosci Lett 353: 1-4, 2003. 
547. Sutton AK, Myers MG, Jr., and Olson DP. The Role of PVH Circuits in Leptin Action 
and Energy Balance. Annu Rev Physiol 78: 207-221, 2016. 
548. Suyama S, Maekawa F, Maejima Y, Kubota N, Kadowaki T, and Yada T. Glucose level 
determines excitatory or inhibitory effects of adiponectin on arcuate POMC neuron activity and 
feeding. Sci Rep 6: 30796, 2016. 
549. Swerdloff RS, Batt RA, and Bray GA. The pituitary-gonad response of genetically 
obese mice in parabiosis with thin and obese siblings. Endocrinology 65: 863-868, 1959. 
550. Swerdloff RS, Batt RA, and Bray GA. Reproductive hormonal function in the genetically 
obese (ob/ob) mouse. Endocrinology 98: 1359-1364, 1976. 
551. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, 
Ghatei M, and Bloom S. The effects of centrally administered apelin-13 on food intake, water 
intake and pituitary hormone release in rats. Biochem Biophys Res Commun 291: 1208-1212, 
2002. 
552. Takayama K, Iwazaki H, Hirabayashi M, Yakabi K, and Ro S. Distribution of c-Fos 
immunoreactive neurons in the brain after intraperitoneal injection of apelin-12 in Wistar rats. 
Neurosci Lett 431: 247-250, 2008. 
553. Takayanagi Y, Cascella NG, Santora D, Gregory PE, Sawa A, and Eaton WW. 
Relationships between serum leptin level and severity of positive symptoms in schizophrenia. 
Neurosci Res 77: 97-101, 2013. 
554. Tanida M, Yamamoto N, Shibamoto T, and Rahmouni K. Involvement of hypothalamic 
AMP-activated protein kinase in leptin-induced sympathetic nerve activation. PLoS One 8: 
e56660, 2013. 
555. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, 
Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, 
Mays GG, Wool EA, Monroe CA, and Tepper RI. Identification and expression cloning of a 
leptin receptor, OB-R. Cell 83: 1263-1271, 1995. 
Page 97 of 119 Comprehensive Physiology
  98 
556. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, 
Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, and Fujino M. Isolation and 
characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem 
Biophys Res Commun 251: 471-476, 1998. 
557. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, and Fujimiya M. 
The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul 
Pept 99: 87-92, 2001. 
558. Teixeira AL, Diniz BS, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, 
and Forlenza OV. Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and 
Alzheimer’s Disease. NeuroMolecular Medicine 15: 115-121, 2013. 
559. Telegdy G, and Jaszberenyi M. Transmitter mediation of the anxiolytic action of apelin-
13 in male mice. Behav Brain Res 263: 198-202, 2014. 
560. Teunissen CE, van der Flier WM, Scheltens P, Duits A, Wijnstok N, Nijpels G, 
Dekker JM, Blankenstein RM, and Heijboer AC. Serum leptin is not altered nor related to 
cognitive decline in Alzheimer's disease. J Alzheimers Dis 44: 809-813, 2015. 
561. Thaler JP, Yi CX, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, Zhao X, Sarruf 
DA, Izgur V, Maravilla KR, Nguyen HT, Fischer JD, Matsen ME, Wisse BE, Morton GJ, 
Horvath TL, Baskin DG, Tschop MH, and Schwartz MW. Obesity is associated with 
hypothalamic injury in rodents and humans. J Clin Invest 122: 153-162, 2012. 
562. Than A, He HL, Chua SH, Xu D, Sun L, Leow MK, and Chen P. Apelin Enhances 
Brown Adipogenesis and Browning of White Adipocytes. J Biol Chem 290: 14679-14691, 2015. 
563. Thompson JL, and Borgland SL. Presynaptic leptin action suppresses excitatory 
synaptic transmission onto ventral tegmental area dopamine neurons. Biol Psychiatry 73: 860-
868, 2013. 
564. Thon M, Hosoi T, and Ozawa K. Insulin enhanced leptin-induced STAT3 signaling by 
inducing GRP78. Sci Rep 6: 34312, 2016. 
565. Toda C, Shiuchi T, Kageyama H, Okamoto S, Coutinho EA, Sato T, Okamatsu-
Ogura Y, Yokota S, Takagi K, Tang L, Saito K, Shioda S, and Minokoshi Y. Extracellular 
signal-regulated kinase in the ventromedial hypothalamus mediates leptin-induced glucose 
uptake in red-type skeletal muscle. Diabetes 62: 2295-2307, 2013. 
566. Tong JQ, Zhang J, Hao M, Yang J, Han YF, Liu XJ, Shi H, Wu MN, Liu QS, and Qi 
JS. Leptin attenuates the detrimental effects of beta-amyloid on spatial memory and hippocampal 
later-phase long term potentiation in rats. Horm Behav 73: 125-130, 2015. 
567. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A, Williams LM, 
Dickson SL, and Dieguez C. Central administration of resistin promotes short-term satiety in 
rats. Eur J Endocrinol 153: R1-5, 2005. 
568. Trapp S, and Richards JE. The gut hormone glucagon-like peptide-1 produced in brain: 
is this physiologically relevant? Curr Opin Pharmacol 13: 964-969, 2013. 
569. Trayhurn P, Thomas ME, Duncan JS, and Rayner DV. Effects of fasting and refeeding 
on ob gene expression in white adipose tissue of lean and obese (oblob) mice. FEBS Lett 368: 
488-490, 1995. 
Page 98 of 119Comprehensive Physiology
  99 
570. Trayhurn P, Thurlby PL, and James WP. A defective response to cold in the obese 
(obob) mouse and the obese Zucker (fafa) rat [proceedings]. Proc Nutr Soc 35: 133A, 1976. 
571. Trayhurn P, Thurlby PL, and James WP. Thermogenic defect in pre-obese ob/ob mice. 
Nature 266: 60-62, 1977. 
572. Tsaousidou E, Paeger L, Belgardt BF, Pal M, Wunderlich CM, Bronneke H, 
Collienne U, Hampel B, Wunderlich FT, Schmidt-Supprian M, Kloppenburg P, and Bruning 
JC. Distinct Roles for JNK and IKK Activation in Agouti-Related Peptide Neurons in the 
Development of Obesity and Insulin Resistance. Cell Rep 9: 1495-1506, 2014. 
573. Tschop M, Smiley DL, and Heiman ML. Ghrelin induces adiposity in rodents. Nature 
407: 908-913, 2000. 
574. Tsiotra PC, Boutati E, Dimitriadis G, and Raptis SA. High insulin and leptin increase 
resistin and inflammatory cytokine production from human mononuclear cells. Biomed Res Int 
2013: 487081, 2013. 
575. Une K, Takei YA, Tomita N, Asamura T, Ohrui T, Furukawa K, and Arai H. 
Adiponectin in plasma and cerebrospinal fluid in MCI and Alzheimer’s disease. European Journal 
of Neurology 18: 1006-1009, 2011. 
576. Usher K, Park T, and Foster K. The experience of weight gain as a result of taking 
second-generation antipsychotic medications: the mental health consumer perspective. J 
Psychiatr Ment Health Nurs 20: 801-806, 2013. 
577. Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry 
JS, Retzlaff BM, Knopp RH, and Kahn SE. Resistin is not associated with insulin sensitivity or 
the metabolic syndrome in humans. Diabetologia 48: 2330-2333, 2005. 
578. Vachharajani V, Cunningham C, Yoza B, Carson J, Vachharajani TJ, and McCall C. 
Adiponectin-Deficiency Exaggerates Sepsis-Induced Microvascular Dysfunction in the Mouse 
Brain. Obesity 20: 498-504, 2012. 
579. Vaisse C, Halaas JL, Horvath CM, Darnell JE, Jr., Stoffel M, and Friedman JM. Leptin 
activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat 
Genet 14: 95-97, 1996. 
580. Valle A, Hoggard N, Adams AC, Roca P, and Speakman JR. Chronic central 
administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity 
and body temperature in C57BL/6 mice. J Neuroendocrinol 20: 79-84, 2008. 
581. van de Wall E, Leshan R, Xu AW, Balthasar N, Coppari R, Liu SM, Jo YH, 
MacKenzie RG, Allison DB, Dun NJ, Elmquist J, Lowell BB, Barsh GS, de Luca C, Myers 
MG, Jr., Schwartz GJ, and Chua SC, Jr. Collective and individual functions of leptin receptor 
modulated neurons controlling metabolism and ingestion. Endocrinology 149: 1773-1785, 2008. 
582. van Praag H, Kempermann G, and Gage FH. Running increases cell proliferation and 
neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 2: 266-270, 1999. 
583. Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, Capeau J, Fermon C, 
Valat AS, Lascols O, Hecart AC, Pigny P, Delemer B, Vigouroux C, and Wemeau JL. Fertility 
and obstetrical complications in women with LMNA-related familial partial lipodystrophy. J Clin 
Endocrinol Metab 93: 2223-2229, 2008. 
Page 99 of 119 Comprehensive Physiology
  100 
584. Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, Boutin P, 
Vaxillaire M, Leprêtre F, Dupont S, Hara K, Clément K, Bihain B, Kadowaki T, and Froguel 
P. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the 
APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the 
genetic risk for type 2 diabetes in French Caucasians. Human Molecular Genetics 11: 2607-2614, 
2002. 
585. Vazquez MJ, Gonzalez CR, Varela L, Lage R, Tovar S, Sangiao-Alvarellos S, 
Williams LM, Vidal-Puig A, Nogueiras R, Lopez M, and Dieguez C. Central resistin regulates 
hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 
149: 4534-4543, 2008. 
586. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, and Mickle DA. Resistin 
promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. 
Circulation 108: 736-740, 2003. 
587. Vong L, Ye C, Yang Z, Choi B, Chua S, Jr., and Lowell BB. Leptin action on 
GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons. Neuron 71: 
142-154, 2011. 
588. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, Vasseur F, 
Froguel P, Kimura S, Nagai R, and Kadowaki T. Impaired Multimerization of Human 
Adiponectin Mutants Associated with Diabetes: MOLECULAR STRUCTURE AND MULTIMER 
FORMATION OF ADIPONECTIN. Journal of Biological Chemistry 278: 40352-40363, 2003. 
589. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, 
Takekawa S, and Kadowaki T. Generation of globular fragment of adiponectin by leukocyte 
elastase secreted by monocytic cell line THP-1. Endocrinology 146: 790-796, 2005. 
590. Wan Z, Mah D, Simtchouk S, Klegeris A, and Little JP. Globular adiponectin induces a 
pro-inflammatory response in human astrocytic cells. Biochemical and Biophysical Research 
Communications 446: 37-42, 2014. 
591. Wang L, Martinez V, Barrachina MD, and Tache Y. Fos expression in the brain induced 
by peripheral injection of CCK or leptin plus CCK in fasted lean mice. Brain Res 791: 157-166, 
1998. 
592. Wang MY, Zhou YT, Newgard CB, and Unger RH. A novel leptin receptor isoform in rat. 
FEBS Lett 392: 87-90, 1996. 
593. Wang Q, Liu C, Uchida A, Chuang JC, Walker A, Liu T, Osborne-Lawrence S, Mason 
BL, Mosher C, Berglund ED, Elmquist JK, and Zigman JM. Arcuate AgRP neurons mediate 
orexigenic and glucoregulatory actions of ghrelin. Mol Metab 3: 64-72, 2014. 
594. Wang Y, Lam KSL, Chan L, Chan KW, Lam JBB, Lam MC, Hoo RCL, Mak WWN, 
Cooper GJS, and Xu A. Post-translational Modifications of the Four Conserved Lysine Residues 
within the Collagenous Domain of Adiponectin Are Required for the Formation of Its High 
Molecular Weight Oligomeric Complex. Journal of Biological Chemistry 281: 16391-16400, 2006. 
595. Watanabe M, Fukuda A, and Nabekura J. The role of GABA in the regulation of GnRH 
neurons. Front Neurosci 8: 387, 2014. 
596. Watanobe H, Schioth HB, Wikberg JE, and Suda T. The melanocortin 4 receptor 
mediates leptin stimulation of luteinizing hormone and prolactin surges in steroid-primed 
ovariectomized rats. Biochem Biophys Res Commun 257: 860-864, 1999. 
Page 100 of 119Comprehensive Physiology
  101 
597. Wayner MJ, Armstrong DL, Phelix CF, and Oomura Y. Orexin-A (Hypocretin-1) and 
leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides 25: 991-996, 2004. 
598. Wellen KE, and Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 115: 
1111-1119, 2005. 
599. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, and 
Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J 
Med 351: 987-997, 2004. 
600. Wen J-P, Liu C, Bi W-K, Hu Y-T, Chen Q, Huang H, Liang J-X, Li L-T, Lin L-X, and 
Chen G. Adiponectin inhibits KISS1 gene transcription through AMPK and specificity protein-1 in 
the hypothalamic GT1-7 neurons. Journal of Endocrinology 214: 177-189, 2012. 
601. Wen J-P, Lv W-S, Yang J, Nie A-F, Cheng X-B, Yang Y, Ge Y, Li X-Y, and Ning G. 
Globular adiponectin inhibits GnRH secretion from GT1-7 hypothalamic GnRH neurons by 
induction of hyperpolarization of membrane potential. Biochemical and Biophysical Research 
Communications 371: 756-761, 2008. 
602. Wilkinson M, Wilkinson D, Wiesner G, Morash B, and Ur E. Hypothalamic resistin 
immunoreactivity is reduced by obesity in the mouse: co-localization with alpha-
melanostimulating hormone. Neuroendocrinology 81: 19-30, 2005. 
603. Williams DL, Baskin DG, and Schwartz MW. Hindbrain leptin receptor stimulation 
enhances the anorexic response to cholecystokinin. Am J Physiol Regul Integr Comp Physiol 
297: R1238-1246, 2009. 
604. Williams KW, and Smith BN. Rapid inhibition of neural excitability in the nucleus tractus 
solitarii by leptin: implications for ingestive behaviour. J Physiol 573: 395-412, 2006. 
605. Williams MA, Qiu C, Muy-Rivera M, Vadachkoria S, Song T, and Luthy DA. Plasma 
Adiponectin Concentrations in Early Pregnancy and Subsequent Risk of Gestational Diabetes 
Mellitus. The Journal of Clinical Endocrinology & Metabolism 89: 2306-2311, 2004. 
606. Wise RA. Role of brain dopamine in food reward and reinforcement. Philos Trans R Soc 
Lond B Biol Sci 361: 1149-1158, 2006. 
607. Wittmann G, Hrabovszky E, and Lechan RM. Distinct glutamatergic and GABAergic 
subsets of hypothalamic pro-opiomelanocortin neurons revealed by in situ hybridization in male 
rats and mice. J Comp Neurol 521: 3287-3302, 2013. 
608. Won JC, Jang PG, Namkoong C, Koh EH, Kim SK, Park JY, Lee KU, and Kim MS. 
Central administration of an endoplasmic reticulum stress inducer inhibits the anorexigenic effects 
of leptin and insulin. Obesity (Silver Spring) 17: 1861-1865, 2009. 
609. Woods AJ, and Stock MJ. Leptin activation in hypothalamus. Nature 381: 745, 1996. 
610. Wu M-H, Chio C-C, Tsai K-J, Chang C-P, Lin N-K, Huang C-C, and Lin M-T. Obesity 
Exacerbates Rat Cerebral Ischemic Injury through Enhancing Ischemic Adiponectin-Containing 
Neuronal Apoptosis. Molecular Neurobiology 53: 3702-3713, 2016. 
611. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP, and Liao EY. 
Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210, 2007. 
Page 101 of 119 Comprehensive Physiology
  102 
612. Xin Q, Cheng B, Pan Y, Liu H, Yang C, Chen J, and Bai B. Neuroprotective effects of 
apelin-13 on experimental ischemic stroke through suppression of inflammation. Peptides 63: 55-
62, 2015. 
613. Xu Y, Hill JW, Fukuda M, Gautron L, Sohn JW, Kim KW, Lee CE, Choi MJ, Lauzon 
DA, Dhillon H, Lowell BB, Zigman JM, Zhao JJ, and Elmquist JK. PI3K signaling in the 
ventromedial hypothalamic nucleus is required for normal energy homeostasis. Cell Metab 12: 
88-95, 2010. 
614. Xue B, Thunhorst RL, Yu Y, Guo F, Beltz TG, Felder RB, and Johnson AK. Central 
Renin-Angiotensin System Activation and Inflammation Induced by High-Fat Diet Sensitize 
Angiotensin II-Elicited Hypertension. Hypertension 67: 163-170, 2016. 
615. Xue B, Yu Y, Zhang Z, Guo F, Beltz TG, Thunhorst RL, Felder RB, and Johnson AK. 
Leptin Mediates High-Fat Diet Sensitization of Angiotensin II-Elicited Hypertension by 
Upregulating the Brain Renin-Angiotensin System and Inflammation. Hypertension 67: 970-976, 
2016. 
616. Yamada N, Katsuura G, Ochi Y, Ebihara K, Kusakabe T, Hosoda K, and Nakao K. 
Impaired CNS leptin action is implicated in depression associated with obesity. Endocrinology 
152: 2634-2643, 2011. 
617. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, 
Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, 
Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, 
Shimizu T, Nagai R, and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic 
metabolic effects. Nature 423: 762-769, 2003. 
618. Yang L, Qi Y, and Yang Y. Astrocytes control food intake by inhibiting AGRP neuron 
activity via adenosine A1 receptors. Cell Rep 11: 798-807, 2015. 
619. Yang P, Maguire JJ, and Davenport AP. Apelin, Elabela/Toddler, and biased agonists 
as novel therapeutic agents in the cardiovascular system. Trends Pharmacol Sci 36: 560-567, 
2015. 
620. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai 
TY, and Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-
inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: 3815-3819, 2001. 
621. Yau SY, Li A, Hoo RLC, Ching YP, Christie BR, Lee TMC, Xu A, and So K-F. Physical 
exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the 
adipocyte hormone adiponectin. Proceedings of the National Academy of Sciences 111: 15810-
15815, 2014. 
622. Yoon MJ, Yoshida M, Johnson S, Takikawa A, Usui I, Tobe K, Nakagawa T, Yoshino 
J, and Imai S. SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates 
Hypothalamic NAD+ and Function in Mice. Cell Metab 21: 706-717, 2015. 
623. Yoshida K, Li X, Cano G, Lazarus M, and Saper CB. Parallel preoptic pathways for 
thermoregulation. J Neurosci 29: 11954-11964, 2009. 
624. Young JB, and Landsberg L. Diet-induced changes in sympathetic nervous system 
activity: possible implications for obesity and hypertension. J Chronic Dis 35: 879-886, 1982. 
Page 102 of 119Comprehensive Physiology
  103 
625. Yu S, Qualls-Creekmore E, Rezai-Zadeh K, Jiang Y, Berthoud HR, Morrison CD, 
Derbenev AV, Zsombok A, and Munzberg H. Glutamatergic Preoptic Area Neurons That 
Express Leptin Receptors Drive Temperature-Dependent Body Weight Homeostasis. J Neurosci 
36: 5034-5046, 2016. 
626. Yuan B, and Teng JF. Association between adiponectin receptor 2 gene polymorphisms 
and cerebral infarction. Genet Mol Res 13: 7808-7814, 2014. 
627. Yue L, Zhao L, Liu H, Li X, Wang B, Guo H, Gao L, Feng D, and Qu Y. Adiponectin 
Protects against Glutamate-Induced Excitotoxicity via Activating SIRT1-Dependent PGC-1alpha 
Expression in HT22 Hippocampal Neurons. Oxid Med Cell Longev 2016: 2957354, 2016. 
628. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi 
Y, Kim YB, Elmquist JK, Tartaglia LA, Kahn BB, and Neel BG. PTP1B regulates leptin signal 
transduction in vivo. Dev Cell 2: 489-495, 2002. 
629. Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, and Kahn BB. Protein-
tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem 283: 14230-
14241, 2008. 
630. Zamorano PL, Mahesh VB, De Sevilla LM, Chorich LP, Bhat GK, and Brann DW. 
Expression and localization of the leptin receptor in endocrine and neuroendocrine tissues of the 
rat. Neuroendocrinology 65: 223-228, 1997. 
631. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, and Tang CS. Apelin protects heart 
against ischemia/reperfusion injury in rat. Peptides 30: 1144-1152, 2009. 
632. Zhang D, Guo M, Zhang W, and Lu X-Y. Adiponectin Stimulates Proliferation of Adult 
Hippocampal Neural Stem/Progenitor Cells through Activation of p38 Mitogen-activated Protein 
Kinase (p38MAPK)/Glycogen Synthase Kinase 3β (GSK-3β)/β-Catenin Signaling Cascade. 
Journal of Biological Chemistry 286: 44913-44920, 2011. 
633. Zhang D, Wang X, and Lu X-Y. Adiponectin Exerts Neurotrophic Effects on Dendritic 
Arborization, Spinogenesis, and Neurogenesis of the Dentate Gyrus of Male Mice. Endocrinology 
157: 2853-2869, 2016. 
634. Zhang R, Dhillon H, Yin H, Yoshimura A, Lowell BB, Maratos-Flier E, and Flier JS. 
Selective inactivation of Socs3 in SF1 neurons improves glucose homeostasis without affecting 
body weight. Endocrinology 149: 5654-5661, 2008. 
635. Zhang X, Zhang G, Zhang H, Karin M, Bai H, and Cai D. Hypothalamic IKKbeta/NF-
kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell 135: 61-73, 2008. 
636. Zhang Y, Kerman IA, Laque A, Nguyen P, Faouzi M, Louis GW, Jones JC, Rhodes 
C, and Munzberg H. Leptin-receptor-expressing neurons in the dorsomedial hypothalamus and 
median preoptic area regulate sympathetic brown adipose tissue circuits. J Neurosci 31: 1873-
1884, 2011. 
637. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman JM. Positional 
cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994. 
638. Zhao AZ, Huan JN, Gupta S, Pal R, and Sahu A. A phosphatidylinositol 3-kinase 
phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat 
Neurosci 5: 727-728, 2002. 
Page 103 of 119 Comprehensive Physiology
  104 
639. Zhao S, Kanoski SE, Yan J, Grill HJ, and Hayes MR. Hindbrain leptin and glucagon-
like-peptide-1 receptor signaling interact to suppress food intake in an additive manner. Int J 
Obes (Lond) 36: 1522-1528, 2012. 
640. Zheng H, and Patel KP. Integration of renal sensory afferents at the level of the 
paraventricular nucleus dictating sympathetic outflow. Auton Neurosci 2016. 
  
Page 104 of 119Comprehensive Physiology
  105 
Tables 
 
Table 1: List of abbreviations 
Abbreviation Definition 
Aβ Amyloid beta 
ACC Anterior cingulate cortex  
ACE Angiotensin-converting enzyme  
ACTH Adrenocorticotropic hormone  
AD Alzheimer’s disease 
AgRP Agouti-related protein 
AHA Anterior hypothalamic area 
AMPK AMP-activated protein kinase  
α-MSH  Alpha melanocyte stimulating hormone 
AP Area postrema 
APP/PS1 Amyloid precursor protein/presenilin 1 
ARC Arcuate nucleus of the hypothalamus 
ATP Adenosine triphosphate 
AVP Arginine vasopressin  
BAT Brown adipose tissue 
BBB Blood brain barrier 
BMI Body mass index 
CamKII Calcium calmodulin-dependent protein kinase II 
CART Cocaine- and amphetamine-regulated transcript 
CCK Cholecystokinin 
CNS Central Nervous System 
CRH Corticotrophin releasing hormone  
CRR Counter-regulatory response 
CSF Cerebral-Spinal Fluid 
D2 Deiodinase type II  
DBP Diastolic blood pressure 
DMH Dorsomedial nucleus of the hypothalamus 
DMX Dorsomotor nucleus of the vagus  
DREADDs Designer Receptors Exclusively Activated by Designer Drugs 
DVC Dorsal vagal complex  
EGFP Engineered green fluorescent protein 
eNOS Endothelial nitric oxide synthase  
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinases 
FDA Food and Drug Administration  
FGF1 Fibroblast growth factor 1  
FGF21 Fibroblast growth factor 21 
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FOXO1 IRS-Akt-forkhead box protein 01  
FSH Follicle–stimulating hormone  
GABA Gamma-aminobutyric acid 
GFAP Glial-fibrillary acidic protein  
GH Growth Hormone 
GI Gastrointestinal 
GLP-1 Glucagon like peptide-1 
GAD67 Glutamic acid decarboxylase 67  
GnRH Gonadotrophin-releasing hormone  
HMW High molecular weight multimers 
HPA Hypothalamic-pituitary-adrenal  
HPG Hypothalamic-pituitary-gonadal 
HPT Hypothalamus pituitary thyroid 
ICV Intracerebroventricular 
IRS Insulin receptor substrate 
Jak Janus kinase 
JNK c-Jun N-terminal kinase  
KA Kainic Acid 
LH Luteinizing hormone 
LHA Lateral hypothalamic area 
lPB Lateral parabrachial nucleus  
IFN Interferon 
LTD Long-term depression  
LTP Long-term potentiation 
MAPK Mitogen-activated protein kinase 
MC3R Melanocortin-3 receptor 
MC4R Melanocortin-4 receptor 
MCAO Medial cerebral artery occlusion  
ME Median eminence 
MCH Melanin-concentrating hormone 
MCI Mild cognitive impairment  
NAMPT Nicotinamide phosphoribosyltransferase  
NAD Nicotinamide adenine dinucleotide  
mPOA Median preoptic area 
mTOR Mechanistic target of rapomycin 
NFkB Nuclear factor kappa B 
NMDA N-methyl-D-aspartate  
NPY Neuropeptide Y 
NTS Nucleus of the solitary tract 
ob Obese gene 
Ob-R Leptin receptor 
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OST-PTP Osteotesticular protein tyrosine phosphatase 
PACAP Pituitary adenylate cyclase-activating polypeptide 
PBA 4-phenyl butyrate  
PBEF pre-B-cell colony-enhancing factor 
PBN Parabrachial Nucleus 
PGC1α Peroxisome proliferator-activated receptor 1 alpha  
PI3K Phosphoinositide 3-kinase 
PIO Pioglitazone 
PKC Protein kinase C 
PLC Phospholipase C 
POA Preoptic area 
POMC Proopiomelanocortin 
PPAR Peroxisome proliferator-activated receptor 
PMv Ventral premammillary nucleus 
PrRP Prolactin-releasing peptide  
proTRH Pro-thyrotropin-releasing hormone  
pSTAT Phosphoylated signal transducer and activator of transcription 
PTP1B Protein-tyrosine phosphatase 1B 
PVH Paraventricular nucleus of the hypothalamus 
RAS Renin-angiotensin system  
RER Respiratory exchange ratio  
ROS Reactive oxygen species 
rPA Rostral raphe pallidus 
RVLM Rostral ventrolateral medulla 
scWAT Subcutaneous white adipose tissue 
SF-1 Steroidogenic factor 1 
SFO Subfornical organ  
SIRT1 Sirtuin-1  
SHP2 Src-homology 2 domain-containing phosphatase 2 
SHP2 Src-homology 2 domain-containing phosphatase 2 
SNP Single nucleotide polymorphisms  
SOCS Suppressor of cytokine signalling 
SON Supraoptic nucleus 
SREBP2 Sterol-regulatory element binding protein 2  
STAT Signal transducer and activator of transcription 
T1D Type-1 diabetes 
T2D Type-2 diabetes 
T3 Triiodothyronine 
T4 Thyroxine 
TH Tyrosine hydroxylase 
TLR4 Toll-like receptor 4  
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TNFα Tumor necrosis factor alpha 
TRH Thyrotropin-releasing hormone  
TSH Thyroid-stimulating hormone  
TUDCA Tauroursodeoxycholic acid  
Tyr Tyrosine 
TZD Thiazolidinedione 
UCP1 Uncoupling protein 1 
UCP2 Uncoupling protein 2 
VAD Vascular dementia  
VLM Ventrolateral medulla 
VMH Ventromedial nucleus of the hypothalamus 
VTA Ventral tegmental area  
WAT White adipose tissue 
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Table 2: Mammalian CNS Leptin Receptor Distribution 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus (ARC) 
-Dorsal Medial (DMH) 
- Lateral Hypothalamic area (LHA) 
-Median Eminence (ME) 
-Paraventricular Nucleus (PVH) 
-Ventromedial Nucleus (VMH) 
-Ventral Premammillary Nucleus (PMv) 
-Median preoptic area (mPOA) 
 
Mercer et al., 1996 (398) 
Schwartz et al., 1996 (507) 
Guan et al., 1997 (226) 
Elmquist et al., 1998 (180) 
Patternson et al.,  2011 (449) 
 
POMC neurons (108) 
NPY/AgRP neurons (397) 
Neurotensin neurons (353) 
CART neurons (176) 
Galanin neurons (339) 
TRH neurons (247) 
Astrocytes (272) 
Tanycytes (23) 
GABAergic neurons (587) 
Prolactin-releasing peptide neurons (PrRP) (155) 
Cortex Mercer et al., 1996 (398)  
Hippocampus Mercer et al., 1996 (398)  
Thalamus 
Mercer et al., 1996 (398) 
Emlquist et al., 1998 (180) 
 
Substantia Nigra 
Guan et al., 1997 (226) 
Figlewicz et al., 2003 (191) 
Tyrosine hydroxylase (TH) neurons (191) 
Ventral tegmental area (VTA) Figlewicz et al., 2003 (191) TH neurons (191) 
Cerebellum 
Guan et al 1997., (226) 
Emlquist et al., 1998 (180) 
 
Hindbrain 
- Area  postrema (AP) 
- Dorsal motor nucleus of the vagus (DMV) 
- Lateral parabrachial nucleus (lPB) 
- Nucleus of the solitary tract (NTS) 
-Spinal trigeminal tract 
- Spinal trigeminal nucleus 
Mercer et al., 1998 (400) 
 
CCK neurons (194, 209) 
GLP-1 (proglucagon) neurons (209) 
POMC neurons* (209) 
Choroid Plexus & Leptomeninges Mercer et al 1996 (398)  
*In POMC-EGFP mice  
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Table 3: Factors which influence leptin transport into the brain 
Increase Decrease 
Epinephrine (29) Obesity (77, 87) 
Glucose* (301) Fasting (300) 
Insulin* (301) Ovariectomy (302) 
Alcohol (441)  Triglycerides (30) 
CCK-8 (85) Lipopolysaccharide (425) 
Epidermal Growth Factor (23) c-reactive protein [CRP] (359) 
*Non-obese wild-type mice 
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Table 4: Mammalian CNS AdipoR1 Distribution. 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus 
- Lateral Hypothalamus 
-Paraventricular Nucleus 
- Supraoptic Nucleus 
- Preoptic area 
Guillod-Maximin et al., 2009(229) 
NPY/POMC neurons; astrocytes; ependymal 
cells (229) 
 
Warm sensitive neurons (316) 
Cortex Guillod-Maximin et al., 2009(229)  
Hippocampus Guillod-Maximin et al., 2009(229)  
Thalamus Guillod-Maximin et al., 2009(229)  
Striatum Guillod-Maximin et al., 2009(229)  
Pituitary Psilopanagioti et al., 2009 (462) GH, FSH, LH and TSH neurons 
Brainstem 
- Area  postrema 
- Nucleus of the solitary tract 
 
Fry et al., 2006 (200) 
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Table 5: Mammalian CNS AdipoR2 Distribution 
CNS expression site Reference Cell type 
Hypothalamus 
-Arcuate Nucleus 
- Lateral Hypothalamus 
-Paraventricular Nucleus 
- Supraoptic Nucleus 
- Preoptic area 
Perifornical region 
Guillod-Maximin et al., 2009 (229) 
 
Klein et al., 2011 (316) 
NPY/POMC neurons; astrocytes (229) 
 
Warm sensitive neurons (316) 
Cortex Guillod-Maximin et al., 2009 (229)  
Hippocampus Guillod-Maximin et al., 2009 (229)  
Thalamus Guillod-Maximin et al., 2009 (229)  
Striatum Guillod-Maximin et al., 2009 (229)  
Pituitary Psilopanagioti et al., 2009 (462) GH, FSH, LH and TSH neurons 
Brainstem 
- Area  postrema 
- Nucleus of the solitary tract 
 
Fry et al., 2006 (200) 
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Figure Legends 
Figure 1: Leptin-signaling in leptin-sensitive compared with leptin-resistant conditions 
Leptin-sensitive: Upon leptin binding to the extracellular domain of the receptor dimer, Janus 
kinase (JAK) 2 is activated resulting in phosphorylation of the intracellular domain of receptor at 
three tyrosine residues: 1) Phosphorylation of Tyr985 resulting in recruitment of Src-homology 2 
domain-containing phosphatase 2 (SHP2/PTPN1) leading to activation of the extracellular signal-
regulated kinases (ERK) signaling cascade (27, 89, 357); 2) Phosphorylation of Tyr1077 resulting 
in recruitment of the transcription factor Signal transducer and activator of transcription (STAT) 5 
(219) and 3) Phosphorylation of Tyr1138 resulting in recruitment of the transcription factor STAT3 
(27, 357, 579). Activation of Ob-Rb signaling also can result in activation of the 
phosphatidylinositol 3-kinase (PI3K) pathway via insulin receptor substrate (IRS) proteins (160, 
480). Negative feedback inhibition of Ob-Rb signaling is provided by suppressor of cytokine 
signaling (SOCS) 3 (53, 55, 164) binding at Try985 and PTP1B acting at Jak2 (106, 628). 
Leptin-resistant: Diet-induced obesity causes inflammation and ER stress in the brain (143, 438, 
561, 635). Obesity-associated inflammation and ER stress activate the nuclear factor-kappa B 
(NFκB) signaling pathway and c-Jun N-terminal kinase (JNK) in the brain (635). JNK inhibits IRS 
signaling. In the course of normal homeostatic leptin signaling, negative feedback inhibition of 
Ob-Rb signaling is provided by SOCS3 (53, 55, 164) and PTP1B binding (106, 628). Obesity is 
associated with elevated hypothalamic expression of both SOCS3 (53) and PTP1B (629). 
Expression of PTP1B is increased by inflammation (629) and ER stress (443) via the activation 
NFκB signaling suggesting providing a further link potential mechanistic link between 
inflammatory signaling and ER stress and the development of CNS leptin resistance.  
Solid blue arrows indicate activation; Dashed blue arrows indicate nuclear translocation; Red 
lines indicate an inhibitory action. 
 
Figure 1: Teaching Points 
Leptin signals through a tyrosine kinase linked receptor. The signaling mechanism is described in 
the formal figure legend. Phosphorylation of different tyrosine residues on the intracellular domain 
of the leptin receptor results in the activation of different downstream signaling pathways 
including kinases and transcription factors. These subsequently mediate a number of different 
downstream physiological events including modulation of neuroendocrine and autonomic 
pathways. Feedback inhibition of leptin receptor signaling is mediated via SOCS 3 and PTP1B. 
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When leptin levels are chronically elevated during obesity leptin signaling becomes less effective: 
a state known as leptin resistance. On a molecular level inflammation and ER stress associated 
with obesity lead to an enhancement of the inherent mechanisms inhibiting leptin signaling 
(SOCS3 and PTP1B) and also stimulation of JNK which inhibits leptin signaling via the IRS/PI3K 
pathway. 
 
Figure 2: Simplified diagram of CNS neurocircuits regulating energy and glucose 
homeostasis.  
A number of hypothalamic and extrahypothalamic sites have been implicated in the action of 
leptin in the regulation energy and glucose homeostasis. Due to the extensive neuronal 
interconnectivity between the brain nuclei in the diagram, for clarity, the neural projections 
between each site have not been indicated. The hypothalamic ARC contains neuropeptide Y and 
agouti-related peptide (NPY/AgRP) neurons that stimulate food intake and are inhibited by leptin, 
and proopiomelanocortin (POMC) neurons that reduce food intake and are stimulated by leptin. 
NPY/AgRP neurons also inhibit POMC neurons via synaptic release of the neurotransmitter 
GABA. POMC and AgRP neurons exert their effects on food intake via melanocortin 4 receptors 
(MC4R) expressed on downstream target neurons. 
ARC, arcuate nucleus; LepRb, leptin receptor; Mc3r/Mc4r, melanocortin-3/4 receptor; VMH, 
ventromedial hypothalamus; LHA, lateral hypothalamic area; PVN, paraventricular nucleus; DMH, 
dorsomedial hypothalamus; VTA, ventral tegmental area; NTS, nucleus of the solitary tract. 
Reprinted with permission from (410). 
 
Figure 2: Teaching points 
Leptin receptors are found in many different areas of the brain and important in regulating the 
regulation of food intake and body weight (energy homeostasis), and the control of blood glucose 
levels. This includes a number of areas within the hypothalamus but also non-hypothalamic areas 
of the brain including sites in the midbrain (VTA) and brainstem (NTS). The most well 
characterized and understood effects of leptin on glucose and energy homeostasis occur via its 
receptors expressed in the hypothalamus. In an area of the hypothalamus called the arcuate 
nucleus (ARC) neurons containing neuropeptide Y and agouti-related peptide [(NPY/AgRP) that 
stimulate food intake], and neurons containing proopiomelanocortin [(POMC) that reduce food 
intake]; both express leptin receptors. Leptin acts to decrease food intake by inhibiting the activity 
of NPY/AgRP neurons and increasing the activity of POMC neurons. Melanocortin 4 receptors 
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(MC4R) are important for mediating the downstream effects of POMC and NPY/AgRP neurons on 
food intake. In humans and animals, mutations in the POMC or MC4R gene cause profound 
obesity. 
 
Figure 3: Simplified schematic of adiponectin receptor signaling.  
AdipoR1/2 interacts with the adaptor protein APPL1 stimulating the insulin receptor substrate 1/2 
(IRS1/2) pathway leading to increased Akt (serine 473), Foxo1 (serine 256) and ERK (threonine 
202/tyrosine 204) phosphorylation. Activation of the receptor can also stimulate the JAK2-STAT3 
pathway, increasing STAT3 tyrosine 705 phosphorylation, translocation of dimerized STAT3 to 
the nucleus and activation of transcription. The adipokine can also activate the AMP-activated 
protein kinase (AMPK) via increasing intracellular calcium levels, leading to activation of 
calmodulin-dependent kinase kinase β (CamKKβ). Phosphorylation of AMPK (threonine 172) by 
CamKKβ, increases kinase activity and subsequent leads to phosphorylation of endothelial nitric 
oxide synthase (eNOS) at serine 1177 by AMPK. Adiponectin can also stimulate the stress 
activated MAP kinase pathway by stimulating phosphorylation of p38 MAPK. 
 
Figure 3: Teaching points 
Adiponectin receptors (AdipoR1/2) are seven transmembrane receptors but are not G-protein 
coupled. Activation of adiponectin receptors by adiponectin can lead to the activation of a number 
downstream signaling pathways, as described in the main figure legend. This includes kinases 
and transcription factors. AMPK, which is activated downstream of adiponectin receptors is a 
critical enzyme in the modulation of cellular energy levels regulating fatty acid uptake and β-
oxidation.  
Page 115 of 119 Comprehensive Physiology
  116 
Cross-References 
Adiponectin function and regulation 
Leptin function and regulation 
Autonomic nervous system and adipose tissue 
Hormonal influence on reward mechanisms 








Page 116 of 119Comprehensive Physiology
LEPTIN 









STAT5 P STAT3 P 
STAT3 























Page 117 of 119 Comprehensive Physiology
























Regulation of food intake, reproduction, neuroprotection 
P38 
MAPK 
Page 119 of 119 Comprehensive Physiology
